References

National Guideline Centre (UK)

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Guideline Centre (UK). Venous thromboembolism in over 16s: Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. London: National Institute for Health and Care Excellence (NICE); 2018 Mar. (NICE Guideline, No. 89.)

See Partial Update

December 2019: In recommendation 1.3.5 the British Standards for anti-embolism hosiery were updated because BS 6612 and BS 7672 have been withdrawn. August 2019: Recommendation 1.12.11 (1.5.30 in this document) was amended to clarify when anti-embolism stockings can be used for VTE prophylaxis for people with spinal injury.

December 2019: In recommendation 1.3.5 the British Standards for anti-embolism hosiery were updated because BS 6612 and BS 7672 have been withdrawn. August 2019: Recommendation 1.12.11 (1.5.30 in this document) was amended to clarify when anti-embolism stockings can be used for VTE prophylaxis for people with spinal injury.

Cover of Venous thromboembolism in over 16s

Venous thromboembolism in over 16s: Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism.

Show details

Contents

< PrevNext >

Appendix WReferences

1.: Abdel-Razeq HN, Hijjawi SB, Jallad SG, Ababneh BA. Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience. Journal of Thrombosis and Thrombolysis. 2010; 30(3):286–93 [PubMed: 20127272]
2.: Abdelkefi A, Ben Othman T, Kammoun L. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. Thrombosis and Haemostasis. 2004; 92(3):654–661 [PubMed: 15351864]
3.: Abdul SA, Tata LJ, Grainge MJ, West J. The incidence of first venous thromboembolism in and around pregnancy using linked primary and secondary care data: a population based cohort study from england and comparative meta-analysis. PloS One. 2013; 8(7):e70310 [PMC free article: PMC3726432] [PubMed: 23922975]
4.: Abdul Sultan A, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England. BMJ. 2013; 347:f6099 [PMC free article: PMC3898207] [PubMed: 24201164]
5.: Abernethy EA, Hartsuck JM. Postoperative pulmonary embolism. A prospective study utilizing low dose heparin. American Journal of Surgery. 1974; 128(6):739–742 [PubMed: 4432994]
6.: Abraham-Inpijn L. Critical evaluation of low-dose heparin in laryngectomy. Archivum Chirurgicum Neerlandicum. 1979; 31(1):9–15 [PubMed: 443830]
7.: Abraham-Inpijn L, Vreeken J. Effect of low-dose heparin on incidence of postoperative thrombosis in orthopaedic patients. Archivum Chirurgicum Neerlandicum. 1975; 27(1):63–68 [PubMed: 1098580]
8.: Abumuaileq RR, Abu-Assi E, Lopez-Lopez A, Raposeiras-Roubin S, Rodriguez-Manero M, Martinez-Sande L et al. Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. BMC Cardiovascular Disorders. 2015; 15:156 [PMC free article: PMC4653932] [PubMed: 26584938]
9.: Acuna DL, Berg GM, Harrison BL, Wray T, Dorsch D, Sook C. Assessing the use of venous thromboembolism risk assessment profiles in the trauma population: is it necessary? American Surgeon. 2011; 77(6):783–9 [PubMed: 21679651]
10.: Adam SS, McDuffie JR, Lachiewicz PF, Ortel TL, Williams JWJ. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. Annals of Internal Medicine. 2013; 159(4):275–284 [PubMed: 24026260]
11.: Adolf J, Knee H, Roder JD, van de Flierdt E, Siewert JR. Thromboembolism prophylaxis with low molecular weight heparin in abdominal surgery. Deutsche Medizinische Wochenschrift. 1989; 114(2):48–53 [PubMed: 2535983]
12.: Agarwal R, Hecht TEH, Lazo MC, Umscheid CA. Venous thromboembolism prophylaxis for patients undergoing bariatric surgery: a systematic review. Surgery for Obesity and Related Diseases. 2010; 6(2):213–220 [PubMed: 20176509]
13.: Agnelli G. Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine. 2013; 159(8):JC2 [PubMed: 24126663]
14.: Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. New England Journal of Medicine. 2012; 366(7):601–609 [PubMed: 22335737]
15.: Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. New England Journal of Medicine. 1998; 339(2):80–85 [PubMed: 9654538]
16.: Agnelli G, Prandoni P, Di Minno G, Cimminiello C, Scaglione F, Boracchi P et al. Thromboprophylaxis with low-molecular-weight heparins: an assessment of the methodological quality of studies. Seminars in Thrombosis and Hemostasis. 2015; 41(2):113–132 [PubMed: 25703242]
17.: Ahn S, Lim KS, Lee YS, Lee JL. Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score. Supportive Care in Cancer. 2013; 21(8):2309–13 [PubMed: 23525939]
18.: Akhtar N, Azhar M, Mir S, Ashraf MN, Kayani SB. Safety of low molecular weight heparin and unfractioned heparin in prevention of venous thromoboembolism (VTE). Pakistan Journal of Medical and Health Sciences. 2014; 8(4):896–899
19.: Akl EA, Kahale L, Sperati F, Neumann I, Labedi N, Terrenato I et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD009447. DOI: 10.1002/14651858.CD009447.pub2 [PubMed: 24966161] [CrossRef]
20.: Akl EA, Kahale L, Terrenato I, Neumann I, Yosuico VED, Barba M et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD006466. DOI: 10.1002/14651858.CD006466.pub4. [PubMed: 24897382] [CrossRef]
21.: Akl EA, Kamath G, Yosuico V, Kim SY, Barba M, Sperati F et al. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer. 2008; 112(11):2483–2492 [PubMed: 18404702]
22.: Akl EA, Ramly EP, Kahale LA, Yosuico VED, Barba M, Sperati F et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No.: CD006468. DOI: 10.1002/14651858.CD006468.pub5. [PubMed: 25318061] [CrossRef]
23.: Akl EA, Terrenato I, Barba M, Sperati F, Muti P, Schunemann HJ. Extended perioperative thromboprophylaxis in patients with cancer. A systematic review. Thrombosis and Haemostasis. 2008; 100(6):1176–1180 [PubMed: 19132245]
24.: Akl EA, Terrenato I, Barba M, Sperati F, Sempos EV, Muti P et al. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Archives of Internal Medicine. 2008; 168(12):1261–1269 [PubMed: 18574082]
25.: Al-Ani F, Shariff S, Siqueira L, Seyam A, Lazo-Langner A. Identifying venous thromboembolism and major bleeding in emergency room discharges using administrative data. Thrombosis Research. 2015; 136(6):1195–8 [PubMed: 26553020]
26.: Alalaf SK, Jawad AK, Jawad RK, Ali MS, Al Tawil NG. Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial. Journal of Thrombosis and Haemostasis. 2015; 13(12):2161–7 [PubMed: 26448633]
27.: Alalaf SK, Jawad RK, Muhammad PR, Ali MS, Al Tawil NG. Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial. BMC Pregnancy and Childbirth. 2015; 15:72 [PMC free article: PMC4377203] [PubMed: 25884460]
28.: Albertsen IE, Larsen TB, Rasmussen LH, Overvad TF, Lip GYH. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis. Drugs. 2012; 72(13):1755–1764 [PubMed: 22876779]
29.: Alfaro MJ, Paramo JA, Rocha E. Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine. Thrombosis and Haemostasis. 1986; 56(1):53–56 [PubMed: 3535158]
30.: Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Critical Care Medicine. 2013; 41(9):2088–2098 [PubMed: 23782973]
31.: Ali I, Shokri H, Elsayed HH. Prophylaxis against venous thromboembolism in thoracic surgery patients: Lack of guidelines or inappropriate implementation? Journal of the Egyptian Society of Cardio Thoracic Surgery. 2017; 01
32.: Alonso-Coello P, Ebrahim S, Guyatt GH, Tikkinen KA, Eckman MH, Neumann I et al. Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol. BMC Pregnancy and Childbirth. 2012; 12:40 [PMC free article: PMC3495041] [PubMed: 22646475]
33.: Alotaibi G, Alsaleh K, Wu C, Mcmurtry MS. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. International Angiology. 2014; 33(4):301–308 [PubMed: 25056161]
34.: Altinbas M, Coskun HS, Er O. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. Journal of Thrombosis and Haemostasis. 2004; 2(8):1266–1271 [PubMed: 15304029]
35.: Alvarenga YR. New anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries. A systematic review of randomized controlled trials. Jornal Vascular Brasileiro. 2012; 11(1):1–2
36.: American College of Obstetricians and Gynaecologists (ACOG). Thromboembolism in pregnancy. ACOG practice bulletin no. 123. Washington. American College of Obstetricians and Gynaecologists (ACOG), 2011. Available from: http://www.guideline.gov/content.aspx?id=34439&search=venous+thromboembolism+or+deep+vein+thrombosis+or+dvt+or+pulmonary+embolism+and+(prevention+or+prevent+or+prophylaxis)
37.: Amin AN, Lin J, Lenhart G, Schulman KL. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. Thrombosis and Haemostasis. 2009; 102(2):321–326 [PubMed: 19652883]
38.: Aminian A, Andalib A, Khorgami Z, Cetin D, Burguera B, Bartholomew J et al. Who Should Get Extended Thromboprophylaxis After Bariatric Surgery?: A Risk Assessment Tool to Guide Indications for Post-discharge Pharmacoprophylaxis. Annals of Surgery. 2017; 265(1):143–150 [PubMed: 28009739]
39.: Anderson DR. Aspirin after dalteparin was noninferior to continued dalteparin for preventing VTE after total hip arthroplasty. Annals of Internal Medicine. 2013; 159(6):JC12 [PubMed: 24042383]
40.: Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Annals of Internal Medicine. 2013; 158(11):800–806 [PubMed: 23732713]
41.: Annemans L, Minjoulat-Rey MC, De Knock M, Vranckx K, Czarka M, Gabriel S et al. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium. Acta Clinica Belgica. 2004; 59(6):346–357 [PubMed: 15819379]
42.: Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration. British Medical Journal. 1994; 308(6923):235–246 [PMC free article: PMC2539330] [PubMed: 8054013]
43.: Antolovic D, Rakow A, Contin P, Ulrich A, Rahbari NN, Buchler MW et al. A randomised controlled pilot trial to evaluate and optimize the use of anti-platelet agents in the perioperative management in patients undergoing general and abdominal surgery--the APAP trial (ISRCTN45810007). Langenbeck’s archives of surgery. 2012; 397(2):297–306 [PubMed: 22048442]
44.: Arabi YM, Alsolamy S, Al-Dawood A, Al-Omari A, Al-Hameed F, Burns KEA et al. Thromboprophylaxis using combined intermittent pneumatic compression and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients: Study protocol for a randomized controlled trial. Trials. 2016; 17:390 [PMC free article: PMC4972959] [PubMed: 27488380]
45.: Arabi YM, Khedr M, Dara SI, Dhar GS, Bhat SA, Tamim HM et al. Use of intermittent pneumatic compression and not graduated compression stockings is associated with lower incident VTE in critically ill patients: A multiple propensity scores adjusted analysis. Chest. 2013; 144(1):152–159 [PubMed: 23412593]
46.: Arcelus JI, Candocia S, Traverso CI, Fabrega F, Caprini JA, Hasty JH. Venous thromboembolism prophylaxis and risk assessment in medical patients. Seminars in Thrombosis and Hemostasis. 1991; 17 (Suppl 3):313–8 [PubMed: 1754887]
47.: Arnold JD, Dart BW, Barker DE, Maxwell RA, Burkholder HC, Mejia VA et al. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients. American Surgeon. 2010; 76(6):563–570 [PubMed: 20583509]
48.: Arrigo RT, Kalanithi P, Cheng I, Alamin T, Carragee EJ, Mindea SA et al. Charlson score is a robust predictor of 30-day complications following spinal metastasis surgery. Spine. 2011; 36(19):E1274–80 [PubMed: 21358481]
49.: Aryal MR, Pandit A, Ghimire S, Pathak R, Karmacharya P, Poudel DR et al. Thromboprophylaxis with apixaban and the risk of pulmonary embolism in patients undergoing knee replacement surgery. Journal of Community Hospital Internal Medicine Perspectives. 2015; 5(4):27889 [PMC free article: PMC4558285] [PubMed: 26333856]
50.: Aryal MR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR et al. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. American Journal of Cardiology. 2014; 114(4):577–582 [PubMed: 24998087]
51.: As-Sultany M, Pagkalos J, Yeganeh S, Craigs CL, Korres N, West RM et al. Use of oral direct factor Xa inhibiting anticoagulants in elective hip and knee arthroplasty: a meta-analysis of efficacy and safety profiles compared with those of low-molecular-weight heparins. Current Vascular Pharmacology. 2013; 11(3):366–375 [PubMed: 23140527]
52.: Assadian A, Knobl P, Hubl W, Senekowitsch C, Klingler A, Pfaffelmeyer N et al. Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial. Journal of Vascular Surgery. 2008; 47(3):537–542 [PubMed: 18234466]
53.: Atiq F, Van Den Bemt PMLA, Leebeek FWG, Van GT, Versmissen J. A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency. European Journal of Clinical Pharmacology. 2015; 71(8):921–929 [PMC free article: PMC4500846] [PubMed: 26071276]
54.: Attaran S, Somov P, Awad WI. Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo-elastography. European Journal of Cardio-Thoracic Surgery. 2010; 37(6):1384–1390 [PubMed: 20153216]
55.: Auer R, Scheer A, Wells PS, Boushey R, Asmis T, Jonker D et al. The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial. Blood Coagulation and Fibrinolysis. 2011; 22(8):760–762 [PubMed: 22198365]
56.: Avidan MS, Smith JR, Skrupky LP, Hill L, Jacobsohn E, Burnside B et al. The occurrence of antibodies to heparin-platelet factor 4 in cardiac and thoracic surgical patients receiving desirudin or heparin for postoperative venous thrombosis prophylaxis. Thrombosis Research. 2011; 128(6):524–529 [PubMed: 21794899]
57.: Avikainen V, von Bonsdorff H, Partio E, Kaira P, Hakkinen S, Usenius JP et al. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. Annales Chirurgiae et Gynaecologiae. 1995; 84(1):85–90 [PubMed: 7645915]
58.: Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology. 2011; 29(15):2099–103 [PubMed: 21464402]
59.: Ayhan H, Iyigun E, Ince S, Can MF, Hatipoglu S, Saglam M. Comparison of three different protocols in the prevention of postoperative deep vein thrombosis in patients at high-risk: Randomized clinical study. European Surgical Research. 2013; 50:64–65
60.: Ayhan H, Iyigun E, Ince S, Can MF, Hatipoglu S, Saglam M. A randomised clinical trial comparing the patient comfort and efficacy of three different graduated compression stockings in the prevention of postoperative deep vein thrombosis. Journal of Clinical Nursing. 2015; 24(15–16):2247–2257 [PubMed: 25960024]
61.: B G. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The heparin prophylaxis study group. Lancet. 1996; 347(9012):1357–1361 [PubMed: 8637340]
62.: Bachmann F, McKenna R, Meredith P, Carta S. Intermittent pneumatic compression of leg and thigh: a new successful method for the prevention of postoperative thrombosis. Schweizerische Medizinische Wochenschrift. 1976; 106(50):1819–1821 [PubMed: 1013707]
63.: Bagaria SJ, Bagaria VB. Strategies for diagnosis and prevention of venous thromboembolism during pregnancy. Journal of Pregnancy. 2011; 2011:206858 [PMC free article: PMC3159016] [PubMed: 21869932]
64.: Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews. 2014; (2) [PubMed: 24519568]
65.: Baker P, Petheram TG, Kurtz S, Konttinen YT, Gregg P, Deehan D. Patient reported outcome measures after revision of the infected TKR: comparison of single versus two-stage revision. Knee Surgery, Sports Traumatology, Arthroscopy. 2013; 21(12):2713–20 [PubMed: 22692517]
66.: Bakirhan K, Strakhan M. Pharmacologic prevention of venous thromboembolism in obese patients. Journal of Thrombosis and Thrombolysis. 2013; 36(3):247–257 [PubMed: 23180282]
67.: Balas PE. Efficiacy and safety of nadroparin (Fraxiparine) versus placebo in the prophylactic treatment of deep vein thrombosis in patients with high thrombo-embolic risk undergoing general surgery. Thrombosis Research. 1992; 65:(Suppl 1):S113
68.: Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AWA et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis. 2013; 110(4):732–741 [PubMed: 23846019]
69.: Bani-Hani M, Titi MA, Jaradat I, Al-Khaffaf H. Interventions for preventing venous thromboembolism following abdominal aortic surgery. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD005509. DOI: 10.1002/14651858.CD005509.pub2. [PMC free article: PMC9006878] [PubMed: 18254082] [CrossRef]
70.: Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. Journal of Thrombosis and Haemostasis. 2010; 8(11):2450–7 [PubMed: 20738765]
71.: Barber EL, Clarke-Pearson DL. The limited utility of currently available venous thromboembolism risk assessment tools in gynecological oncology patients. American Journal of Obstetrics and Gynecology. 2016; 215(4):445.e1–9 [PMC free article: PMC5045759] [PubMed: 27131583]
72.: Barbui T, Cassinelli G, Cortelazzo S, D’Alonzo U, Fantoni P, Lavorato F. Comparison of low molecular weight heparin CY 216 and unfractionated heparin in preventing post-operative venous thromboembolism in general surgery: a preliminary results of a cooperative study. Fibrinolysis. 1990; 4:(Suppl 1):79
73.: Barr DA, Irvine S, Ritchie ND, McCutcheon J, Seaton RA. Risk of venous thromboembolism in patients treated for bacterial infection in the community with outpatient parenteral antimicrobial therapy. QJM. 2014; 107(3):207–11 [PubMed: 24300160]
74.: Barrellier MT, Lebel B, Parienti JJ, Mismetti P, Dutheil JJ, Vielpeau C et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research. 2010; 126(4):e298–e304 [PubMed: 20797774]
75.: Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH. Thromboprophylaxis for trauma patients. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD008303. DOI: 10.1002/14651858.CD008303.pub2. [PubMed: 23543562] [CrossRef]
76.: Basta MN, Bauder AR, Kovach SJ, Fischer JP. Assessing the predictive accuracy of the American College of Surgeons National Surgical Quality Improvement Project Surgical Risk Calculator in open ventral hernia repair. American Journal of Surgery. 2016; 212(2):272–81 [PubMed: 27290635]
77.: Bath PMW, England TJ. Thigh-length compression stockings and DVT after stroke. Lancet. 2009; 373:1923–1924 [PubMed: 19477504]
78.: Bauer KA, Eriksson B, I, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. New England Journal of Medicine. 2001; 345(18):1305–1310 [PubMed: 11794149]
79.: Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach H-E, Abletshauser C et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis. 2011; 105(6):981–988 [PubMed: 21505722]
80.: Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thrombosis and Haemostasis. 2007; 98(6):1237–45 [PubMed: 18064320]
81.: Baumgartner A, Jacot N, Moser G, Krahenbuhl B. Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine. Vasa. 1989; 18(2):152–156 [PubMed: 2545054]
82.: Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes. Value in Health. 2014; 17(4):462–70 [PubMed: 24969008]
83.: Becattini C, Agnelli G, Manina G, Noya G, Rondelli F. Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surgery for Obesity and Related Diseases. 2012; 8(1):108–115 [PubMed: 22014482]
84.: Beghi C, Fragnito C, Antonelli A, Reverberi C, Ferrari P, Saccani S et al. Prevention of deep venous thrombosis by a new low molecular weight heparin (Fluxum) in cardiac surgery. International Angiology. 1993; 12(4):383–386 [PubMed: 8207317]
85.: Beitland S, Sandven I, Kjaervik LK, Sandset PM, Sunde K, Eken T. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Medicine. 2015; 41(7):1209–1219 [PubMed: 25971389]
86.: Bekelis K, Desai A, Bakhoum SF, Missios S. A predictive model of complications after spine surgery: the National Surgical Quality Improvement Program (NSQIP) 2005–2010. Spine Journal: Official Journal of the North American Spine Society. 2014; 14(7):1247–55 [PubMed: 24211097]
87.: Bekelis K, Kalakoti P, Nanda A, Missios S. A predictive model of unfavorable outcomes after benign intracranial tumor resection. World Neurosurgery. 2015; 84(1):82–9 [PubMed: 25748477]
88.: Bekelis K, Missios S, Mackenzie TA, Fischer A, Labropoulos N, Eskey C. A predictive model of outcomes during cerebral aneurysm coiling. Journal of Neurointerventional Surgery. 2014; 6(5):342–8 [PubMed: 23828326]
89.: Belch JJ, Lowe GDO, Ward AG. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scottish Medical Journal. 1981; 26(2):115–117 [PubMed: 7291971]
90.: Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis. Acta Oncologica. 2014; 53(9):1230–1237 [PubMed: 25162954]
91.: Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for acute medical illness. Thrombosis and Haemostasis. 1996; 76(4):529–534 [PubMed: 8902991]
92.: Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. New England Journal of Medicine. 1996; 335(10):696–700 [PubMed: 8703168]
93.: Bergqvist D, Efsing HO, Hallbook T, Hedlund T. Thromboembolism after elective and post-traumatic hip surgery--a controlled prophylactic trial with dextran 70 and low-dose heparin. Acta Chirurgica Scandinavica. 1979; 145(4):213–218 [PubMed: 386676]
94.: Berkin JA, Lee C, Landsberger E, Chazotte C, Bernstein PS, Goffman D. Scorecard implementation improves identification of postpartum patients at risk for venous thromboembolism. Journal of Healthcare Risk Management. 2016; 36(1):8–13 [PubMed: 27400171]
95.: Bern MM, Bierbaum B, Wetzner S, Brennan W, McAlister S. Very low dose warfarin as prophylaxis against ultrasound detected deep vein thrombosis following primary hip replacement. American Journal of Hematology. 2002; 71(2):69–74 [PubMed: 12353302]
96.: Bern MM, Ward D, Miley G, Spitz D, Spigelman Z, Mattingly D et al. Prospective randomized study of thromboembolic disease (TED) prophylaxis after knee or hip replacement: Fixed low dose warfarin vs. variable dose warfarin vs. fondaparinux, each given for 4 weeks. Pathophysiology of Haemostasis and Thrombosis. 2010; 37:(Suppl 1):A145
97.: Beyer-Westendorf J, Donath L, Lutzner J, Werth S, Radke O, Guenther K-P et al. Efficacy and safety of VTE prophylaxis with oral rivaroxaban compared to fondaparinux or low-molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery. Blood. 2011; 118(21) [PMC free article: PMC3522808] [PubMed: 22515679]
98.: Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. American Journal of Medicine. 1998; 105(2):91–99 [PubMed: 9727814]
99.: Bikdeli B, Sharif-Kashani B, Shahabi P, Raeissi S, Shahrivari M, Shoraka AR et al. Comparison of three risk assessment methods for venous thromboembolism prophylaxis. Blood Coagulation and Fibrinolysis. 2013; 24(2):157–63 [PubMed: 23314387]
100.: Bilgi K, Muthusamy A, Subair M, Srinivasan S, Kumar A, Ravi R et al. Assessing the risk for development of Venous Thromboembolism (VTE) in surgical patients using Adapted Caprini scoring system. International Journal Of Surgery. 2016; 30:68–73 [PubMed: 27109201]
101.: Bin Abdulhak AA, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwalt KE et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology. 2013; 15(10):1412–1420 [PubMed: 23954918]
102.: Bircan A, Karadeniz N, Ozden A, Cakir M, Varol E, Oyar O et al. A simple clinical model composed of ECG, shock index, and arterial blood gas analysis for predicting severe pulmonary embolism. Clinical and Applied Thrombosis/Hemostasis. 2011; 17(2):188–96 [PubMed: 19959488]
103.: Bischof M, Leuppi JD, Sendi P. Cost-effectiveness of extended venous thromboembolism prophylaxis with fondaparinux in hip surgery patients. Expert Review of Pharmacoeconomics and Outcomes Research. 2006; 6(2):171–180 [PubMed: 20528553]
104.: Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: A cost-effectiveness analysis. American Journal of Cardiovascular Drugs. 2005; 5(2):121–130 [PubMed: 15725043]
105.: Blackshear WM, Jr., Prescott C, LePain F, Benoit S, Dickstein R, Seifert KB. Influence of sequential pneumatic compression on postoperative venous function. Journal of Vascular Surgery. 1987; 5(3):432–436 [PubMed: 3509596]
106.: Blanchard J, Meuwly JY, Leyvraz PF, Miron MJ, Bounameaux H, Hoffmeyer P et al. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. Journal of Bone and Joint Surgery (British Volume). 1999; 81(4):654–659 [PubMed: 10463739]
107.: Blondon M, Hugon-Rodin J. A clinical risk score to predict the incidence of postpartum venous thromboembolism. Evidence Based Medicine. 2017; 22(3):98 [PubMed: 28377376]
108.: Bloom BJ, Filion KB, Atallah R, Eisenberg MJ. Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. American Journal of Cardiology. 2014; 113(6):1066–1074 [PubMed: 24440332]
109.: Board NE. National Joint Registry 13th Annual Report. 2016. Available from: http://www.njrreports.org.uk/Portals/0/PDFdownloads/NJR%2013th%20Annual%20Report%202016.pdf
110.: Bockheim HM, McAllen KJ, Baker R, Barletta JF. Mechanical prophylaxis to prevent venous thromboembolism in surgical patients: a prospective trial evaluating compliance. Journal of Critical Care. 2009; 24(2):192–196 [PubMed: 19327952]
111.: Boehringer Ingelheim. Asantin DVT nach myokardinfarkt (internal report). Bracknell. Boehringer Ingelheim, 1981.
112.: Boehringer Ingelheim. Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement. NCT00152971. 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT00152971 Last accessed: 28/06/17.
113.: Boese CK, Weis M, Phillips T, Lawton-Peters S, Gallo T, Centeno L. The efficacy of continuous passive motion after total knee arthroplasty: A comparison of three protocols. Journal of Arthroplasty. 2014; 29(6):1158–1162 [PubMed: 24412145]
114.: Bogari H, Patanwala AE, Cosgrove R, Katz M. Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease. Thrombosis Research. 2014; 134(6):1220–3 [PubMed: 25294587]
115.: Bohl DD, Maltenfort MG, Huang R, Parvizi J, Lieberman JR, Della Valle CJ. Development and Validation of a Risk Stratification System for Pulmonary Embolism After Elective Primary Total Joint Arthroplasty. Journal of Arthroplasty. 2016; 31:(9 Suppl):187–91 [PubMed: 27067463]
116.: Boneu B. An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the international clivarin Assessment Group. Blood Coagulation and Fibrinolysis. 1993; 4:(Suppl 1):S21–S22 [PubMed: 8180325]
117.: Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics. 2014; 17(10):691–695 [PubMed: 25065536]
118.: Borgstrom S, Greitz T, Van der Linden W, Molin J, Rudics I. Anticoagulation prophylaxis of venous thrombosis in patients with fractured neck of the femur. Acta Chirurgica Scandinavica. 1965; 129:500–508 [PubMed: 14296582]
119.: Borris L. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement: The RECORD study programme. Pathophysiology of Haemostasis and Thrombosis. 2010; 37:(Suppl 1):105
120.: Bottaro FJ, Elizondo MC, Doti C, Bruetman JE, Perez Moreno PD, Bullorsky EO et al. Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis. Thrombosis and Haemostasis. 2008; 99(6):1104–1111 [PubMed: 18521515]
121.: Botteman MF, Caprini J, Stephens JM, Nadipelli V, Bell CF, Pashos CL et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clinical Therapeutics. 2002; 24(11):1960–1986 [PubMed: 12501885]
122.: Bouman AC, Ten Cate-Hoek AJ, Dirksen CD, Joore MA. Eliciting patients’ preferences for elastic compression stocking therapy after deep vein thrombosis: potential for improving compliance. Journal of Thrombosis and Haemostasis. 2016; 14(3):510–7 [PubMed: 26670129]
123.: Boutros IR, Landham PR, Brown RR, Gosali HS. The use of graduated compression stockings in association with fondaparinux in surgery of the hip: A multicentre, multinational, randomised, open-label, parallel-group comparative study. Journal of Bone and Joint Surgery - Series B. 2008; 90(11):1535–1536 [PubMed: 18978279]
124.: Bozas G, Muazzam IA, Ilyas W, Maraveyas A. PO-39 - Primary thromboprophylaxis for ambulatory patients with advanced metastatic pancreatic cancer. A practical implementation of lessons from published experience. Thrombosis Research. 2016; 140: Suppl 1:S191 [PubMed: 27161727]
125.: Braidy N, Bui K, Bajorek B. Evaluating the impact of new anticoagulants in the hospital setting. Pharmacy Practice. 2011; 9(1):1–10 [PMC free article: PMC4132966] [PubMed: 25132883]
126.: Bramlage P, Michaelis HC, Melzer N. Comparison of 3,000 and 5,000 IU aXa/day certoparin in the prevention of deep-vein thrombosis after total hip replacement. Thrombosis Journal. 2012; 10(1):10 [PMC free article: PMC3441324] [PubMed: 22713698]
127.: Brekelmans MP, Kappelhof M, Nieuwkerk PT, Nierman M, Buller HR, Coppens M. Preference for direct oral anticoagulants in patients treated with vitamin K antagonists for venous thromboembolism. Netherlands Journal of Medicine. 2017; 75(2):50–55 [PubMed: 28276323]
128.: Breuer L, Ringwald J, Schwab S, Kohrmann M. Ischemic stroke in an obese patient receiving dabigatran. New England Journal of Medicine. 2013; 368(25):2440–2 [PubMed: 23782198]
129.: Briel RC, Doller P, Hermann CP. [Prevention of thromboembolism in hysterectomies with low molecular weight heparin Fragmin]. Geburtshilfe und Frauenheilkunde. 1988; 48(3):160–164 [PubMed: 2836259]
130.: Brismar B, Hardstedt C, Jacobson S, Kager L, Malmborg AS. Reduction of catheter-associated thrombosis in parenteral nutrition by intravenous heparin therapy. Archives of Surgery. 1982; 117(9):1196–1199 [PubMed: 6810843]
131.: Brockbank J, Wolowacz S. Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review. Pharmacoeconomics. 2017; 35(5):517–535 [PubMed: 28185212]
132.: Brotman DJ, Shihab HM, Prakasa KR, Kebede S, Haut ER, Sharma R et al. Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. JAMA surgery. 2013; 148(7):675–686 [PubMed: 23754086]
133.: Brown GA. Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooled analysis of randomized controlled trials. Journal of Arthroplasty. 2009; 24:(6 Suppl):77–83 [PubMed: 19628366]
134.: Brown R, Lip GY, Gallego P. Dabigatran etexilate for venous thromboembolism: a safety evaluation. Expert opinion on drug safety. 2014; 13(5):639–647 [PubMed: 24598005]
135.: Bruins Slot KMH, Berge E. Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation. JAMA - Journal of the American Medical Association. 2014; 311(11):1150–1151 [PubMed: 24643605]
136.: Bruun-Olsen V, Heiberg KE, Mengshoel AM. Continuous passive motion as an adjunct to active exercises in early rehabilitation following total knee arthroplasty - a randomized controlled trial. Disability and Rehabilitation. 2009; 31(4):277–83 [PubMed: 18608367]
137.: Bump GM, Dandu M, Kaufman SR, Shojania KG, Flanders SA. How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials. Journal of Hospital Medicine. 2009; 4(5):289–297 [PubMed: 19504490]
138.: Bushwitz J, Leclaire A, He J, Mozingo D. Venous thromboembolic complications in burn patients receiving heparin or enoxaparin as prophylaxis. Value in Health. 2010; 13(3):A152
139.: Bynke O, Hillman J, Lassvik C. Does peroperative external pneumatic leg muscle compression prevent post-operative venous thrombosis in neurosurgery? Acta Neurochirurgica. 1987; 88(1–2):46–48 [PubMed: 3425413]
140.: CADTH. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness. Toronto. Canadian Agency for Drugs and Technologies in Health (CADTH), 2013. Available from: https://www.cadth.ca/media/pdf/htis/jun-2013/RC0455%20-%20LMWH%20for%20DVT%20or%20PE%20Final%20%20ABS.pdf
141.: CADTH. Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety. Toronto. Canadian Agency for Drugs and Technologies in Health (CADTH), 2013. Available from: https://www.cadth.ca/media/pdf/htis/jul-2013/RC0460%20LMWH%20vs%20UFH%20final.pdf
142.: CADTH. Timing of enoxaparin administration for the prophylaxis of venous thromboembolism: clinical evidence and guidelines. Toronto. Canadian Agency for Drugs and Technologies in Health (CADTH), 2013. Available from: https://www.cadth.ca/media/pdf/htis/jun-2013/RB0587%20VTE%20Prophylaxis%20Final.pdf
143.: Calisir C, Yavas US, Ozkan IR, Alatas F, Cevik A, Ergun N et al. Performance of the Wells and revised Geneva scores for predicting pulmonary embolism. European Journal of Emergency Medicine. 2009; 16(1):49–52 [PubMed: 18931619]
144.: Caloghera C, Bordos D, Miculit F, Aboubakr W, Teodorescu C, Vancea D. Prevention of postoperative thromboembolism with small doses of heparin. Revista de Chirurgie, Oncologie, Radiologie, ORL, Oftalmologie, Stomatologie Chirurgie. 1984; 33(3):161–167 [PubMed: 6238351]
145.: Campbell MJ. Full audit cycle assessing how current antenatal inpatients are risk assessed for venous thromboembolic (VTE) disease as an inpatient and antenatally at Ninewells Hospital, Dundee, Scotland, October 2012. BJOG: An International Journal of Obstetrics and Gynaecology. 2013; 120:472
146.: Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Cordova R et al. Graduated compression stockings versus low molecular-weight heparin for prevention of deep vein thrombosis after knee arthroscopy. a randomized trial. Pathophysiology of Haemostasis and Thrombosis. 2008; 36:(Suppl 1):A21
147.: Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. European Heart Journal. 2014; 35(47):3346–3355 [PubMed: 25182247]
148.: Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. European Heart Journal. 2015; 36(28):1805–1811 [PMC free article: PMC4508487] [PubMed: 25975659]
149.: Capri S, Ageno W, Imberti D, Palareti G, Piovella F, Scannapieco G et al. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. Internal and Emergency Medicine. 2010; 5(1):33–40 [PubMed: 19890611]
150.: Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Disease-a-Month. 2005; 51(2–3):70–8 [PubMed: 15900257]
151.: Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Seminars in Thrombosis and Hemostasis. 1991; 17 (Suppl 3):304–12 [PubMed: 1754886]
152.: Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Seminars in Hematology. 2001; 38(2 Suppl 5):12–9 [PubMed: 11449339]
153.: Caprini JA, Botteman MF, Stephens JM, Nadipelli V, Ewing MM, Brandt S et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value in Health. 2003; 6(1):59–74 [PubMed: 12535239]
154.: Carpenter CR, Keim SM, Seupaul RA, Pines JM. Differentiating low-risk and Nn-risk PE patients: The PERC Score. Journal of Emergency Medicine. 2009; 36(3):317–322 [PubMed: 19097732]
155.: Carrier M, Le GG, Tay J, Wu CM, Lee AY. Thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide and lenalidomide: A systematic review and meta-analysis. Blood. 2010; 116(21)
156.: Carson W, Schilling B, Simons WR, Parks C, Choe Y, Faria C et al. Comparative effectiveness of dalteparin and enoxaparin in a hospital setting. Journal of Pharmacy Practice. 2012; 25(2):180–189 [PubMed: 21987527]
157.: Casele H, Haney EI, James A, Rosene-Montella K, Carson M. Bone density changes in women who receive thromboprophylaxis in pregnancy. American Journal of Obstetrics and Gynecology. 2006; 195(4):1109–13 [PubMed: 17000242]
158.: Casella IB, Puech-Leao P. Generic versus branded enoxaparin in prophylaxis and treatment of vein thrombosis. Revista da Associacao Medica Brasileira. 2015; 61(1):44–50 [PubMed: 25909208]
159.: Castellano JJ, Rojas AM, Karia R, Hunter T, Slover J, Moroz A. A randomized, double-blind, placebo-controlled study of neuromuscular electrical stimulation (NMES) use for recovery after elective total hip replacement surgery. Bulletin of the Hospital for Joint Diseases. 2016; 74(4):275–281 [PubMed: 27815950]
160.: Catania G, Salanitri G. Prevention of postoperative deep vein thrombosis by two different heparin types. International Journal of Clinical Pharmacology, Therapy and Toxicology. 1988; 26(6):304–309 [PubMed: 2842266]
161.: Cavallo F, Raimondo F, Harda I, Lupo B, Romano A, Catalano L et al. A phase III study of enoxaparin vs aspirin as thromboprophylaxis for newly diagnosed myeloma patients treated with lenalidomide-based regimen. Blood. 2010; 116(21)
162.: Cavazza S, Rainaldi MP, Adduci A, Palareti G. Thromboprophylaxis following cesarean delivery: one site prospective pilot study to evaluate the application of a risk score model. Thrombosis Research. 2012; 129(1):28–31 [PubMed: 21840574]
163.: Chagnon I, Bounameaux H, Aujesky D, Roy PM, Gourdier AL, Cornuz J et al. Comparison of two clinical prediction rules and implicit assessment among patients with suspected pulmonary embolism. American Journal of Medicine. 2002; 113(4):269–75 [PubMed: 12361811]
164.: Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in Extensive small-cell lung cancer by the Cancer and Leukemia Group B. Journal of Clinical Oncology. 1989; 7(8):993–1002 [PubMed: 2547030]
165.: Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. Thrombosis Research. 2016; 145:119–125 [PubMed: 27536894]
166.: Chan NC, Siegal D, Lauw MN, Ginsberg JS, Eikelboom JW, Guyatt GH et al. A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. Journal of Thrombosis and Thrombolysis. 2015; 40(2):231–239 [PubMed: 25403952]
167.: Chapelle C, Rosencher N, Jacques Zufferey P, Mismetti P, Cucherat M, Laporte S et al. Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials. Arthroscopy. 2014; 30(8):987–996 [PubMed: 24813323]
168.: Chatterjee S, Weinberg I, Yeh RW, Chakraborty A, Sardar P, Weinberg MD et al. Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. Thrombosis and Haemostasis. 2017; 117(2):246–251 [PubMed: 27882375]
169.: Chauleur C, Quenet S, Varlet MN, Seffert P, Laporte S, Decousus H et al. Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women. Thrombosis Research. 2008; 122(4):478–84 [PubMed: 18280547]
170.: Che DH, Cao JY, Shang LH, Man YC, Yu Y. The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. European Journal of Internal Medicine. 2013; 24(5):433–439 [PubMed: 23385011]
171.: Chelladurai Y, Stevens KA, Haut ER, Brotman DJ, Sharma R, Shermock KM et al. Venous thromboembolism prophylaxis in patients with traumatic brain injury: a systematic review. F1000Research. 2013; 2:132 [PMC free article: PMC4184319] [PubMed: 25309725]
172.: Chen JY, Chao TH, Guo YL, Hsu CH, Huang YY, Chen JH et al. A simplified clinical model to predict pulmonary embolism in patients with acute dyspnea. International Heart Journal. 2006; 47(2):259–71 [PubMed: 16607053]
173.: Chen K-P, Huang C-X, Huang D-J, Cao K-J, Ma C-S, Wang F-Z et al. Anticoagulation therapy in Chinese patients with non-valvular atrial fibrillation: A prospective, multi-center, randomized, controlled study. Chinese Medical Journal. 2012; 125(24):4355–4360 [PubMed: 23253701]
174.: Cheng SS, Nordenholz K, Matero D, Pearlman N, McCarter M, Gajdos C et al. Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. Intensive Care Medicine. 2012; 38(4):642–648 [PubMed: 22231174]
175.: Chiasson TC, Manns BJ, Stelfox HT. An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding. PLoS Medicine. 2009; 6(6) [PMC free article: PMC2695771] [PubMed: 19554085]
176.: Child S, Sheaff R, Boiko O, Bateman A, Gericke CA. Has incentive payment improved venous thrombo-embolism risk assessment and treatment of hospital in-patients? F1000Research. 2013; 2:41 [PMC free article: PMC3790600] [PubMed: 24358864]
177.: Chin PL, Amin MS, Yang KY, Yeo SJ, Lo NN. Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial. Journal of Orthopaedic Surgery. 2009; 17(1):1–5 [PubMed: 19398783]
178.: Cho KY, Kim KI, Khurana S, Bae DK, Jin W. Is routine chemoprophylaxis necessary for prevention of venous thromboembolism following knee arthroplasty in a low incidence population? Archives of Orthopaedic and Trauma Surgery. 2013; 133(4):551–559 [PubMed: 23381297]
179.: Choi SH, Shim JH, Park CH, Song KY. Low molecular-weight heparin for thromboprophylaxis in patients undergoing gastric cancer surgery: an experience from one Korean institute. Annals of surgical treatment and research. 2014; 86(1):22–27 [PMC free article: PMC3994607] [PubMed: 24761403]
180.: Christensen TD, Vad H, Pedersen S, Hornbech K, Zois NE, Licht PB et al. Coagulation profile in patients undergoing video-assisted thoracoscopic lobectomy: A randomized, controlled trial. PloS One. 2017; 12 (2) (no pagination)(e0171809) [PMC free article: PMC5310875] [PubMed: 28199364]
181.: Clark WB, MacGregor AB, Prescott RJ, Ruckley CV. Pneumatic compression of the calf and postoperative deep-vein thrombosis. Lancet. 1974; 2(7871):5–7 [PubMed: 4134404]
182.: Clemens A, van Ryn J, Sennewald R, Yamamura N, Stangier J, Feuring M et al. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. European Journal of Clinical Pharmacology. 2012; 68(5):607–616 [PMC free article: PMC3332339] [PubMed: 22252796]
183.: CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: a randomized trial. Annals of Internal Medicine. 2010; 153(9):553–562 [PubMed: 20855784]
184.: CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration. Effect of intermittent pneumatic compression on disability, living circumstances, quality of life, and hospital costs after stroke: secondary analyses from CLOTS 3, a randomised trial. Lancet Neurology. 2014; 13(12):1186–1192 [PubMed: 25453458]
185.: CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration, Dennis M, Sandercock P, Reid J, Graham C, Forbes J et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet. 2013; 382(9891):516–524 [PubMed: 23727163]
186.: CLOTS Trials Collaboration, Dennis M, Sandercock P, Reid J, Graham C, Murray G et al. The effect of graduated compression stockings on long-term outcomes after stroke: the CLOTS trials 1 and 2. Stroke. 2013; 44(4):1075–1079 [PubMed: 23482600]
187.: CLOTS Trials Collaboration, Dennis M, Sandercock PAG, Reid J, Graham C, Murray G et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet. 2009; 373(9679):1958–1965 [PMC free article: PMC2692021] [PubMed: 19477503]
188.: Cohen A, Drost P, Marchant N, Mitchell S, Orme M, Rublee D et al. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. Clinical and Applied Thrombosis/Hemostasis. 2012; 18(6):611–627 [PubMed: 22387582]
189.: Cohen A, Stellbrink C, Le Heuzey JY, Faber T, Aliot E, Banik N et al. SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: a pilot study. Archives of Cardiovascular Diseases. 2015; 108(2):122–131 [PubMed: 25684570]
190.: Cohen AT, Alikhan R, Arcelus JI, Bergmann JF, Haas S, Merli GJ et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thrombosis and Haemostasis. 2005; 94(4):750–9 [PubMed: 16270626]
191.: Cohen AT, Batson S, Hamilton M, Masseria C, Mitchell S, Phatak H. Comparison of apixaban, dabigatran, rivaroxaban, and edoxaban in the acute treatment and prevention of venous thromboembolism: Systematic review and network meta-analysis. Value in Health. 2015; 18(3):A132
192.: Cohen AT, Bauersachs R, Gitt AK, Mismetti P, Monreal M, Willich SN et al. Health state in patients with venous thromboembolism on conventional and Non-VKA oral anticoagulants as assessed with the EQ-5D-5L questionnaire: Prefer in VTE registry. Value in Health. 2014; 17(7):A493–A494 [PubMed: 27201471]
193.: Cohen AT, Granziera S. Excellence, quality and limitations of the NICE venous thromboembolism score tool: how can it be improved? British Journal of Haematology. 2014; 167(5):702–4 [PubMed: 25041053]
194.: Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS ONE [Electronic Resource]. 2015; 10(12):e0144856 [PMC free article: PMC4696796] [PubMed: 26716830]
195.: Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. Journal of Thrombosis and Thrombolysis. 2011; 31(4):407–416 [PMC free article: PMC3090572] [PubMed: 21359646]
196.: Cohen AT, Spiro TE, Burton P, Buller HR, Haskell L, Hu D-Y et al. The MAGELLAN study: An analysis of outcomes utilizing d-dimer. Blood. 2011; 118(21)
197.: Cohen H, Dore CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M et al. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus. 2015; 24(10):1087–1094 [PMC free article: PMC4527976] [PubMed: 25940537]
198.: Cohen ME, Bilimoria KY, Ko CY, Hall BL. Development of an American college of surgeons national surgery quality improvement program: morbidity and mortality risk calculator for colorectal surgery. Journal of the American College of Surgeons. 2009; 208(6):1009–16 [PubMed: 19476884]
199.: Cohn SM, Moller BA, Feinstein AJ, Burns GA, Ginzburg E, Hammers LW. Prospective trial of low-molecular-weight heparin versus unfractionated heparin in moderately injured patients. Vascular Surgery. 1999; 33(2):219–223
200.: Coleman CI, Peacock WF, Fermann GJ, Crivera C, Weeda ER, Hull M et al. External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications. BMC Health Services Research. 2016; 16(1):610 [PMC free article: PMC5075157] [PubMed: 27770814]
201.: Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. British Medical Journal. 1994; 308(6921):81–106 [PMC free article: PMC2539220] [PubMed: 8298418]
202.: Collen JF, Jackson JL, Shorr AF, Moores LK. Prevention of venous thromboembolism in neurosurgery: a metaanalysis. Chest. 2008; 134(2):237–249 [PubMed: 18641095]
203.: Colwell CW, Jr., Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. Journal of Bone and Joint Surgery (American Volume). 1999; 81(7):932–940 [PubMed: 10428124]
204.: Colwell CW, Jr., Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. Journal of Bone and Joint Surgery. 1994; 76(1):3–14 [PubMed: 8288662]
205.: Colwell CW, Spiro TE, Trowbridge AA, Stephens JW, Gardiner GA, Ritter MA. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clinical Orthopaedics and Related Research. 1995; 321:19–27 [PubMed: 7497668]
206.: Colwell Jr CW, Froimson MI, Anseth SD, Giori NJ, Hamilton WG, Barrack RL et al. A mobile compression device for thrombosis prevention in hip and knee arthroplasty. Journal of Bone and Joint Surgery - American Volume. 2014; 96(3):177–183 [PubMed: 24500578]
207.: Commercial Medicines Unit (CMU), Department of Health. Electronic market information tool (EMIT). 2015. Available from: http://cmu.dh.gov.uk/electronic-market-information-tool-emit/ Last accessed: 22/08/2017.
208.: Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA, Jr. et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Journal of Bone and Joint Surgery (American Volume). 2001; 83(3):336–345 [PubMed: 11263636]
209.: Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA, Jr. et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. Journal of Bone and Joint Surgery (American Volume). 2001; 83-a(3):336–45 [PubMed: 11263636]
210.: Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009; 361(12):1139–51 [PubMed: 19717844]
211.: Constans J, Boutinet C, Salmi LR, Saby JC, Nelzy ML, Baudouin P et al. Comparison of four clinical prediction scores for the diagnosis of lower limb deep venous thrombosis in outpatients. American Journal of Medicine. 2003; 115(6):436–40 [PubMed: 14563499]
212.: Cook D. Dalteparin did not differ from unfractionated heparin for reducing proximal DVT in critically ill patients. Annals of Internal Medicine. 2011; 155(2):JC1–JC7 [PubMed: 21768573]
213.: Cornette J, Jacquemyn Y, Vercauteren M, Buytaert P. A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. Phlebology. 2002; 17(2):67–69
214.: Cornuz J, Ghali WA, Hayoz D, Stoianov R, Depairon M, Yersin B. Clinical prediction of deep venous thrombosis using two risk assessment methods in combination with rapid quantitative D-dimer testing. American Journal of Medicine. 2002; 112(3):198–203 [PubMed: 11893346]
215.: Correia LC, Goes C, Ribeiro H, Cunha M, Paula R, Esteves JP. Prevalence and predictors of pulmonary embolism in patients with acutely decompensated heart failure. Arquivos Brasileiros de Cardiologia. 2012; 98(2):120–5 [PubMed: 22231917]
216.: Cosmi B, Filippini M, Tonti D, Avruscio G, Ghirarduzzi A, Bucherini E et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis. 2012; 10(6):1026–1035 [PubMed: 22487001]
217.: Costa ML, Griffin XL, Achten J, Metcalfe D, Judge A, Pinedo-Villanueva R et al. World Hip Trauma Evaluation (WHiTE): framework for embedded comprehensive cohort studies. BMJ Open. 2016; 6(10):e011679 [PMC free article: PMC5093367] [PubMed: 27797994]
218.: Costa R, Da Silva KR, Rached R, Martinelli Filho M, Carnevale FC, Moreira LFP et al. Prevention of venous thrombosis by warfarin after permanent transvenous leads implantation in high-risk patients. Pacing and Clinical Electrophysiology. 2009; 32 (Suppl 1):S247–S251 [PubMed: 19250106]
219.: Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. Journal of Clinical Oncology. 2005; 23(18):4063–4069 [PubMed: 15767639]
220.: Couture E, Cerantola M, Farand P, Berube S, Dalery K, Gervais A et al. Risk profile and impact of pharmacological thromboprophylaxis on bleeding event and outcome: Insights from a contemporary STEMI prospective registry. Canadian Journal of Cardiology. 2016; 32 (10 Supplement 1):S254–S255
221.: Crane S, Jaconelli T, Eragat M. Retrospective validation of the pulmonary embolism rule-out criteria rule in ‘PE unlikely’ patients with suspected pulmonary embolism. European Journal of Emergency Medicine. 2016; 19:19 [PubMed: 28002070]
222.: Creagh MD, Dehnel A, Rider L, McSorley A, Carson P, Asri R. Does systematic risk assessment in pregnancy identify women at risk for venous thromboembolism and so avoid thrombosis? Experience of an 18 month programme based on national guidance. Journal of Thrombosis and Haemostasis. 2013; 11:867
223.: Cui J, Wu B, Liu C, Li Z. A systematic review and adjusted indirect comparison of oral anticoagulants. Orthopedics. 2014; 37(11):763–771 [PubMed: 25361361]
224.: Curtis L, Burns A. Unit costs of health and social care 2016. Canterbury. Personal Social Services Research Unit University of Kent, 2016. Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2016/
225.: Cushman M, O’Meara ES, Heckbert SR, Zakai NA, Rosamond W, Folsom AR. Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology. Thrombosis Research. 2016; 144:127–32 [PMC free article: PMC4980192] [PubMed: 27328432]
226.: Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S et al. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis. 1997; 77(1):26–31 [PubMed: 9031444]
227.: Dahl OE, Andreassen G, Aspelin T, Müller C, Mathiesen P, Nyhus S et al. Prolonged thromboprophylaxis following hip replacement surgery -- results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis. 1997; 77(1):26–31 [PubMed: 9031444]
228.: Dahl OE, Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement. Journal of Thrombosis and Haemostasis. 2003; 1(5):896–906 [PubMed: 12871354]
229.: Dal AM, Allara E, Montani D, Milani S, Frassati C, Cossu S et al. Flushing the central venous catheter: Is heparin necessary? Journal of Vascular Access. 2014; 15(4):241–248 [PubMed: 24811598]
230.: Dar TI, Wani K, Ashraf M, Malik A, Ahmad S, Gojwari T et al. Low molecular weight heparin in prophylaxis of deep vein thrombosis in Asian general surgical patients: A Kashmir experience. Indian Journal of Critical Care Medicine. 2012; 16(2):71–74 [PMC free article: PMC3439781] [PubMed: 22988360]
231.: Dargaud Y, Rugeri L, Ninet J, Negrier C, Trzeciak MC. Management of pregnant women with increased risk of venous thrombosis. International Journal of Gynaecology and Obstetrics. 2005; 90(3):203–7 [PubMed: 15964002]
232.: Dargaud Y, Rugeri L, Vergnes MC, Arnuti B, Miranda P, Negrier C et al. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. British Journal of Haematology. 2009; 145(6):825–35 [PubMed: 19388925]
233.: Datta I, Ball CG, Rudmik L, Hameed SM, Kortbeek JB. Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature. Journal of Trauma Management and Outcomes. 2010; 4:1 [PMC free article: PMC2823661] [PubMed: 20205800]
234.: Davies LM, Richardson GA, Cohen AT. Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery. Value in Health. 2000; 3(6):397–406 [PubMed: 16464199]
235.: Davies MG, Hart JP, El-Sayed HF. Efficacy of prophylactic inferior vena caval filters in prevention of pulmonary embolism in the absence of deep venous thrombosis. Journal of Vascular Surgery. 2016; 4(1):127–130.e1 [PubMed: 26946909]
236.: De A, Roy P, Garg VK, Pandey NK. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. Blood Coagulation and Fibrinolysis. 2010; 21(1):57–61 [PubMed: 19844176]
237.: de Bastos M, Barreto SM, Caiafa JS, Boguchi T, Silva JL, Rezende SM. Derivation of a risk assessment model for hospital-acquired venous thrombosis: the NAVAL score. Journal of Thrombosis and Thrombolysis. 2016; 41(4):628–35 [PubMed: 26446587]
238.: De Veciana M, Trail P, Dattel B. Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy. American Journal of Obstetrics and Gynecology. 2001; 185(6):S182
239.: Dechavanne M, Saudin F, Viala JJ, Kher A, Bertrix L, de Mourgues G. Prevention of venous thrombosis. Success of high doses of heparin during total hip replacement for osteoarthritis. La Nouvelle Presse Médicale. 1974; 3(20):1317–1319 [PubMed: 4843085]
240.: Dechavanne M, Ville D, Berruyer M, Trepo F, Dalery F, Clermont N et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis. 1989; 19(1):5–12 [PubMed: 2537787]
241.: Dechavanne M, Ville D, Viala JJ, Kher A, Faivre J, Pousset MB et al. Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients. Haemostasis. 1975; 4(2):94–100 [PubMed: 1205340]
242.: Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis: interruption cave study group. New England Journal of Medicine. 1998; 338(7):409–415 [PubMed: 9459643]
243.: Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011; 139(1):69–79 [PubMed: 20453069]
244.: Deeks ED. Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery. Drugs. 2012; 72(9):1271–1291 [PubMed: 22686618]
245.: Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D’Armini AM, Snijder R et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation. 2016; 133(9):859–71 [PubMed: 26826181]
246.: den Ottolander GJH, vad der Mass APC, Veen MR. The preventive value against venous thrombosis by treatment with ASA and RA-233 in patients with decompensated heart disease. Washington. Proceedings of III congress of International Society for Thrombosis and Haemostasis, 1972.
247.: Dennis M, Graham C, Smith J, Forbes J, Sandercock P. Which stroke patients gain most from intermittent pneumatic compression: Further analyses of the CLOTS 3 trial. International Journal of Stroke. 2015; 10(A100):103–107 [PubMed: 26307376]
248.: Dennis M, Sandercock P, Graham C, Forbes J, Smith J. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. Health Technology Assessment. 2015; 19(76):1–90 [PMC free article: PMC4782814] [PubMed: 26418530]
249.: Department of Health. NHS Outcomes Framework: at-a-glance: List of outcomes and indicators in the NHS Outcomes Framework for 2016–17. 2016. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/513157/NHSOF_at_a_glance.pdf
250.: Department of Health. NHS reference costs 2015–16. 2016. Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016 Last accessed: 09/08/2017.
251.: Desai AK, Pang J, Aparnath M, Ilowite J. Utility of Inferior Vena Cava Filters in Severe Pulmonary Embolism, Catheter-directed Therapy in Massive and Submassive Pulmonary Embolism, and HAS-BLED Score to Determine Risk of Major Hemorrhage in Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine. 2016; 193(11):1301–3 [PubMed: 26991597]
252.: Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation. 2014; 129(25):2638–2644 [PubMed: 24744272]
253.: Di Marca S, Cilia C, Campagna A, D’Arrigo G, Abd ElHafeez S, Tripepi G et al. Comparison of Wells and revised Geneva rule to assess pretest probability of pulmonary embolism in high-risk hospitalized elderly adults. Journal of the American Geriatrics Society. 2015; 63(6):1091–7 [PubMed: 26032745]
254.: Di Nisio M, Peinemann F, Porreca E, Rutjes AW. Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery. Cochrane Database of Systematic Reviews 2015, Issue 6. Art. No.: CD009658. DOI: 10.1002/14651858.CD009658.pub2. [PubMed: 26091835] [CrossRef]
255.: Di Nisio M, Porreca E, Otten HM, Rutjes AWS. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database of Systematic Reviews 2014, Issue 8. Art. No.: CD008500. DOI: 10.1002/14651858.CD008500.pub3. [PubMed: 25171736] [CrossRef]
256.: Di Nisio M, Raskob G, Buller HR, Grosso MA, Zhang G, Winters SM et al. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thrombosis and Haemostasis. 2017; 02:02 [PubMed: 28151543]
257.: Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thrombosis and Haemostasis. 2010; 104(4):760–770 [PubMed: 20806107]
258.: Diaz JP, Soto MH, Marquez M, Escobar JY. Cost-minimization analysis of tinzaparin sodium compared to other low-molecular-weight heparins for patients with deep venous thrombosis. Value in Health. 2015; 18(3):A143
259.: Dietch ZC, Petroze RT, Thames M, Willis R, Sawyer RG, Williams MD. The “high-risk” deep venous thrombosis screening protocol for trauma patients: Is it practical? The Journal of Trauma and Acute Care Surgery. 2015; 79(6):970–5 [PMC free article: PMC4684967] [PubMed: 26488317]
260.: DiSerio FJ, Sasahara AA. United States trial of dihydroergotamine and heparin prophylaxis of deep vein thrombosis. American Journal of Surgery. 1985; 150(4A):25–32 [PubMed: 3901790]
261.: Dong MF, Ma ZS, Ma SJ, Chai SD, Tang PZ, Yao DK et al. Anticoagulation therapy with combined low dose aspirin and warfarin following mechanical heart valve replacement. Thrombosis Research. 2011; 128(5):e91–e94 [PubMed: 21813162]
262.: Dong WJ, Qian HJ, Qian Y, Zhou L, Hu SL. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism after total hip replacement: A meta-analysis. Experimental and Therapeutic Medicine. 2016; 12(2):969–974 [PMC free article: PMC4950621] [PubMed: 27446305]
263.: Dooley C, Kaur R, Sobieraj DM. Comparison of the efficacy and safety of low molecular weight heparins for venous thromboembolism prophylaxis in medically ill patients. Current Medical Research and Opinion. 2014; 30(3):367–380 [PubMed: 23971722]
264.: Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Archives of Internal Medicine. 2008; 168(16):1805–1812 [PubMed: 18779469]
265.: Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. New England Journal of Medicine. 2015; 373(9):823–33 [PMC free article: PMC4931686] [PubMed: 26095867]
266.: Dranitsaris G, Jelincic V, Choe Y. Meta-regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events. Clinical and Applied Thrombosis/Hemostasis. 2012; 18(3):233–242 [PubMed: 22387576]
267.: Dranitsaris G, Kahn SR, Stumpo C, Paton TW, Martineau J, Smith R et al. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. American Journal of Cardiovascular Drugs. 2004; 4(5):325–333 [PubMed: 15449974]
268.: Dranitsaris G, Shane LG, Crowther M, Feugere G, Woodruff S. Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis. Clinicoeconomics & Outcomes Research. 2017; 9:65–73 [PMC free article: PMC5237592] [PubMed: 28138260]
269.: Dranitsaris G, Stumpo C, Smith R, Bartle W. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery. American Journal of Cardiovascular Drugs. 2009; 9(1):45–58 [PubMed: 19178131]
270.: Drescher FS, Sirovich BE, Lee A, Morrison DH, Chiang WH, Larson RJ. Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. Journal of Hospital Medicine. 2014; 9(9):579–585 [PubMed: 25045166]
271.: Dronkers CE, Tan M, Mol GC, Iglesias Del Sol A, van de Ree MA, Huisman MV et al. Evaluation of the new simple and objective clinical decision rule “I-DVT” in patients with clinically suspected acute deep vein thrombosis. Thrombosis Research. 2016; 141:112–8 [PubMed: 27002413]
272.: Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective. Journal of Medical Economics. 2011; 14(6):824–834 [PubMed: 22023098]
273.: Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer’s perspective. Pharmacoeconomics. 2012; 30(2):87–101 [PubMed: 22187932]
274.: Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. Annals of Internal Medicine. 2003; 138(3):W15–24 [PubMed: 12558384]
275.: Edwards JZ, Pulido PA, Ezzet KA, Copp SN, Walker RH, Colwell CWJ. Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty. Journal of Arthroplasty. 2008; 23(8):1122–1127 [PubMed: 18534421]
276.: Effect of aspirin on postoperative venous thrombosis. Report of the Steering Committee of a trial sponsored by the Medical Research Council. Lancet. 1972; 2(7775):441–445 [PubMed: 4115340]
277.: Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010; 121(14):1630–6 [PubMed: 20351233]
278.: Eichinger S, Heinze G, Kyrle PA. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. Journal of the American Heart Association. 2014; 3(1):e000467 [PMC free article: PMC3959721] [PubMed: 24385451]
279.: Eikelboom JW, Kearon C, Guyatt G, Sessler DI, Yusuf S, Cook D et al. Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials. Anesthesiology. 2016; 125(6):1121–1129 [PubMed: 27627817]
280.: Eikelboom JW, Quinlan DJ, O’Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation. 2009; 120(20):2006–2011 [PubMed: 19884469]
281.: Elbadawi A, Saad M, Nairooz R. Aspirin Use Prior to Coronary Artery Bypass Grafting Surgery: a Systematic Review. Current Cardiology Reports. 2017; 19 (2) (no pagination)(18) [PubMed: 28213669]
282.: Elf JL, Strandberg K, Nilsson C, Svensson PJ. Clinical probability assessment and D-dimer determination in patients with suspected deep vein thrombosis, a prospective multicenter management study. Thrombosis Research. 2009; 123(4):612–6 [PubMed: 18514263]
283.: Elit LM, Lee AY, Parpia S, Swystun LL, Liaw PC, Hoskins P et al. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thrombosis Research. 2012; 130(6):894–900 [PubMed: 23046525]
284.: Elsasser GN, Goodman MD, Destache CJ, Frey DR, Hadi Z. Preprinted risk assessment and prophylaxis order form for venous thromboembolism. American Journal of Health-System Pharmacy. 2007; 64(12):1294–8 [PubMed: 17563053]
285.: Elton L, Lamb F, Marsden P. The risk assessment and management of venous thrombo-embolism in pregnancy: An audit against current newcastle-upon-tyne hospitals and RCOG guidelines. International Journal of Gynecology and Obstetrics. 2015; 131:E236
286.: Encke A, Stock C, Dumke HO. Doppelblindstudie zur postoperativen thromboseprophylaxe mit dipyridamol/acetylsalicysaure. Der Chirurg. 1976; 47(12):670–673 [PubMed: 1001131]
287.: Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mairuhu AT et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. European Respiratory Journal. 2017; 49(2) [PubMed: 28232411]
288.: Eriksson B, Dahl OE, Rosencher N, Kurth A, Niek van Dijk C, Frostick S et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591):949–956 [PubMed: 17869635]
289.: Eriksson B, I, Kälebo P, Anthymyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. Journal of Bone and Joint Surgery. 1991; 73(4):484–493 [PubMed: 2013587]
290.: Eriksson B, I., Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK et al. Oral, direct factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. Journal of Thrombosis and Haemostasis. 2006; 4(1):121–128 [PubMed: 16409461]
291.: Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine. 2008; 358(26):2765–2775 [PubMed: 18579811]
292.: Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thrombosis and Haemostasis. 2011; 105(4):721–729 [PubMed: 21225098]
293.: Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al. Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis and Haemostasis. 2007; 5(11):2178–2185 [PubMed: 17764540]
294.: Eriksson BI, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery (British Volume). 2009; 91(5):636–644 [PubMed: 19407299]
295.: Eriksson BI, Turpie AGG, Lassen MR, Prins MH, Agnelli G, Kalebo P et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). Journal of Thrombosis and Haemostasis. 2010; 8(4):714–721 [PubMed: 20088935]
296.: Erkens PM, Gandara E, Wells PS, Shen AY, Bose G, Le Gal G et al. Does the pulmonary embolism severity Index accurately identify low risk patients eligible for outpatient treatment? Thrombosis Research. 2012; 129(6):710–4 [PubMed: 21906787]
297.: Eskander MB, Limb D, Stone MH, Furlong AJ, Shardlow D, Stead D et al. Sequential mechanical and pharmacological thromboprophylaxis in the surgery of hip fractures. A pilot study. International Orthopaedics. 1997; 21(4):259–261 [PMC free article: PMC3617695] [PubMed: 9349964]
298.: Evans RS, Linford LH, Sharp JH, White G, Lloyd JF, Weaver LK. Computer identification of symptomatic deep venous thrombosis associated with peripherally inserted venous catheters. AMIA Annual Symposium Proceedings/AMIA Symposium. 2007:226–30 [PMC free article: PMC2655799] [PubMed: 18693831]
299.: Evans RS, Lloyd JF, Aston VT, Woller SC, Tripp JS, Elliott CG et al. Computer surveillance of patients at high risk for and with venous thromboembolism. AMIA Annual Symposium Proceedings/AMIA Symposium. 2010; 2010:217–21 [PMC free article: PMC3041332] [PubMed: 21346972]
300.: Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. Journal of the American College of Cardiology. 2011; 58(4):395–401 [PMC free article: PMC3175766] [PubMed: 21757117]
301.: Faunø P, Suomalainen O, Rehnberg V, Hansen TB, Krøner K, Soimakallio S et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. Journal of Bone and Joint Surgery. 1994; 76(12):1814–1818 [PubMed: 7989386]
302.: Feller JA, Parkin JD, Phillips GW, Hannon PJ, Hennessy O, Huggins RM. Prophylaxis against venous thrombosis after total hip arthroplasty. Australian and New Zealand Journal of Surgery. 1992; 62(8):606–610 [PubMed: 1642580]
303.: Feng W, Wu K, Liu Z, Kong G, Deng Z, Chen S et al. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis. Thrombosis Research. 2015; 136(6):1133–44 [PubMed: 26498222]
304.: Finks JF, English WJ, Carlin AM, Krause KR, Share DA, Banerjee M et al. Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. Annals of Surgery. 2012; 255(6):1100–4 [PubMed: 22566018]
305.: Finnish Medical Society Duodecim. Deep vein thrombosis. EBM guidelines. Duodecim Medical Publication Ltd, 2013. Available from: http://www.ebm-guidelines.com/ebmg/ltk.free?p_artikkeli=ebm00108
306.: Finnish Medical Society Duodecim. Prevention of venous thromembolism. EBM guidelines. Duodecim Medical Publication Ltd, 2014. Available from: http://www.ebm-guidelines.com/ebmg/ltk.free?p_artikkeli=ebm00109
307.: Fisher WD, Agnelli G, George DJ, Kakkar AK, Lassen MR, Mismetti P et al. Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study. Bone and Joint Journal. 2013; 95-B(4):459–466 [PubMed: 23539696]
308.: Fitzgerald RH, Jr., Spiro TE, Trowbridge AA, Gardiner GA, Jr., Whitsett TL, O’Connell MB et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. Journal of Bone and Joint Surgery. 2001; 83-A(6):900–906 [PubMed: 11407799]
309.: Flanders SA, Greene MT, Grant P, Kaatz S, Paje D, Lee B et al. Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism: a cohort study. JAMA Internal Medicine. 2014; 174(10):1577–84 [PubMed: 25133488]
310.: Flicoteaux H, Kher A, Jean N, Blery M, Judet T, Honnart F et al. Comparision of low dose heparin and low dose heparin combined with aspirin in prevention of deep vein thrombosis after total hip replacement. Pathologie Biologie. 1977; 25(Suppl):55–58 [PubMed: 353659]
311.: Fordyce MJ, Baker AS, Staddon GE. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. British Medical Journal. 1991; 303(6796):219–220 [PMC free article: PMC1670497] [PubMed: 1884058]
312.: Fordyce MJ, Ling RS. A venous foot pump reduces thrombosis after total hip replacement. Journal of Bone and Joint Surgery (British Volume). 1992; 74(1):45–49 [PubMed: 1732264]
313.: Fraisse F, Holzapfel L, Couland JM. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory and Critical Care Medicine. 2000; 161(4):1109–1114 [PubMed: 10764298]
314.: Francis CW, Pellegrini VD, Leibert KM, Totterman S, Azodo MV, Harris CM et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thrombosis and Haemostasis. 1996; 75(5):706–711 [PubMed: 8725709]
315.: Francis CW, Pellegrini VD, Totterman S, Boyd AD, Marder VJ, Liebert KM et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. Journal of Bone and Joint Surgery (American Volume). 1997; 79(9):1365–1372 [PubMed: 9314399]
316.: Franco Moreno AI, Garcia Navarro MJ, Ortiz Sanchez J, Martin Diaz RM, Madronal Cerezo E, de Ancos Aracil CL et al. A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES). European Journal of Internal Medicine. 2016; 29:59–64 [PubMed: 26775136]
317.: Freeman A, Horner T, Pendleton RC, Rondina MT. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. American Journal of Hematology. 2012; 87(7):740–743 [PMC free article: PMC3385867] [PubMed: 22565589]
318.: Freick H, Haas S. Prevention of deep vein thrombosis by low-molecular-weight heparin and dihydroergotamine in patients undergoing total hip replacement. Thrombosis Research. 1991; 63(1):133–143 [PubMed: 1658962]
319.: Friedman RJ, Davidson BL, Heit J, Kessler C, Elliott CG. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group. Journal of Bone and Joint Surgery (American Volume). 1994; 76(8):1174–1185 [PubMed: 8056798]
320.: Fuji T, Fuijita S, Ujihira T, Sato T. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo. Journal of Arthroplasty. 2010; 25(8):1267–74 [PubMed: 19854610]
321.: Fuji T, Fujita S, Kawai Y, Abe Y, Kimura T, Fukuzawa M et al. A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. Thrombosis Journal. 2015; 13(1) [PMC free article: PMC4316611] [PubMed: 25653574]
322.: Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Fukuzawa M et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thrombosis Journal. 2015; 13:27 [PMC free article: PMC4534125] [PubMed: 26269694]
323.: Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Kiuchi Y et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thrombosis Research. 2014; 133(6):1016–1022 [PubMed: 24680549]
324.: Fuji T, Fujita S, Kimura T, Ibusuki K, Abe K, Tachibana S et al. Clinical benefit of graduated compression stockings for prevention of venous thromboembolism after total knee arthroplasty: post hoc analysis of a phase 3 clinical study of edoxaban. Thrombosis Journal [Electronic Resource]. 2016; 14:13 [PMC free article: PMC4899917] [PubMed: 27284271]
325.: Fuji T, Fujita S, Ochi T. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. International Orthopaedics. 2008; 32(4):443–451 [PMC free article: PMC2532275] [PubMed: 17468868]
326.: Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. Journal of Thrombosis and Haemostasis. 2010; 8(11):2458–2468 [PubMed: 20723033]
327.: Fuji T, Nakamura M, Takeuchi M. Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: results from 2 randomized, placebo-controlled, double-blind studies. Clinical and Applied Thrombosis/Hemostasis. 2014; 20(2):199–211 [PubMed: 22952213]
328.: Fuji T, Ochi T, Niwa S, Fujita S. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: Two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. Journal of Orthopaedic Science. 2008; 13(5):442–451 [PubMed: 18843459]
329.: Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thrombosis Research. 2014; 134(6):1198–1204 [PubMed: 25294589]
330.: Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). American Heart Journal. 2006; 151(3):713–9 [PubMed: 16504638]
331.: Galanter WL, Thambi M, Rosencranz H, Shah B, Falck S, Lin FJ et al. Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. American Journal of Health-System Pharmacy. 2010; 67(15):1265–73 [PubMed: 20651317]
332.: Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2016; 37:67–119 [PubMed: 26320113]
333.: Gallagher M, Oliver K, Hurwitz M. Improving the use of venous thromboembolism prophylaxis in an Australian teaching hospital. Quality & Safety in Health Care. 2009; 18(5):408–12 [PubMed: 19812106]
334.: Gallus A, Raman K, Darby T. Venous thrombosis after elective hip replacement--the influence of preventive intermittent calf compression and of surgical technique. British Journal of Surgery. 1983; 70(1):17–19 [PubMed: 6337668]
335.: Garcea D, Martuzzi F, Santelmo N, Savoia M, Casertano MG, Furno A et al. Post-surgical deep vein thrombosis prevention: evaluation of the risk/benefit ratio of fractionated and unfractionated heparin. Current Medical Research and Opinion. 1992; 12(9):572–583 [PubMed: 1316258]
336.: Gates S, Brocklehurst P, Ayers S, Bowler U, Group. TiPA. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. American Journal of Obstetrics and Gynecology. 2004; 191(4):1296–1303 [PubMed: 15507957]
337.: Gates S, Brocklehurst P, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD001689. DOI: 10.1002/14651858.CD001689 [PubMed: 12076417] [CrossRef]
338.: Gazzaniga GM, Angelini G, Pastorino G, Santoro E, Lucchini M, Dal Pra ML. Enoxaparin in the prevention of deep venous thrombosis after major surgery: multicentric study. The Italian Study Group. International Surgery. 1993; 78(3):271–275 [PubMed: 8276557]
339.: Gearhart MM, Luchette FA, Proctor MC, Lutomski DM, Witsken C, James L et al. The risk assessment profile score identifies trauma patients at risk for deep vein thrombosis. Surgery. 2000; 128(4):631–40 [PubMed: 11015097]
340.: Geerts WH, Jay RM, Code KI. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. New England Journal of Medicine. 1996; 335(10):701–707 [PubMed: 8703169]
341.: Gerhart TN, Yett HS, Robertson LK, Lee MA, Smith M, Salzman EW. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial. Journal of Bone and Joint Surgery (American Volume). 1991; 73(4):494–502 [PubMed: 1707413]
342.: Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017; 26:26 [PMC free article: PMC5634762] [PubMed: 28550032]
343.: Gibson H, Thamban S. Improving venous thromboprophylaxis in London maternity unit. BJOG: An International Journal of Obstetrics and Gynaecology. 2014; 121:127
344.: Gibson JL, Ekevall K, Walker I, Greer IA. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. British Journal of Obstetrics and Gynaecology. 1998; 105(7):795–797 [PubMed: 9692422]
345.: Gibson NS, Sohne M, Kruip MJ, Tick LW, Gerdes VE, Bossuyt PM et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thrombosis and Haemostasis. 2008; 99(1):229–34 [PubMed: 18217159]
346.: Godwin JE, Comp P, Davidson B, Rossi M, Group NCCT. Comparison of the efficacy and safety of subcutaneous RD heparin vs subcutaneous unfractionated heparin for the prevention of deep-vein thrombosis in patients undergoing abdominal or pelvic surgery for cancer. Thrombosis and Haemostasis. 1993; 69(6):647
347.: Goel DP, Buckley R, deVries G, Abelseth G, Ni A, Gray R. Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial. Journal of Bone and Joint Surgery (British Volume). 2009; 91(3):388–394 [PubMed: 19258618]
348.: Goergen SK, Chan T, de Campo JF, Wolfe R, Gan E, Wheeler M et al. Reducing the use of diagnostic imaging in patients with suspected pulmonary embolism: validation of a risk assessment strategy. Emergency Medicine Australasia. 2005; 17(1):16–23 [PubMed: 15675900]
349.: Goffman D, Fisher N, Kowenski J, Ngai I, Lee S, Chazotte C et al. Utilization of a checklist to evaluate risk for postpartum venous thromboembolism. American Journal of Obstetrics and Gynecology. 2009; 1:S297
350.: Gomes M, Ramacciotti E, Henriques AC, Araujo GR, Szultan LA, Miranda FJ et al. Generic versus branded enoxaparin in the prevention of venous thromboembolism following major abdominal surgery: report of an exploratory clinical trial. Clinical and Applied Thrombosis/Hemostasis. 2011; 17(6):633–639 [PubMed: 21949036]
351.: Gomez-Cerezo JF, Gomez-Arrayas I, Suarez-Fernandez C, Betegon-Nicolas L, Salas-Cansado M, Rubio-Terres C. Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement. Revista Espanola de Cirugia Ortopedica y Traumatologia. 2013; 56(6):459–470 [PubMed: 23594943]
352.: Gomez-Outes A, Avendano-Sola C, Terleira-Fernandez AI, Vargas-Castrillon E. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain. Pharmacoeconomics. 2014; 32(9):919–936 [PubMed: 24895235]
353.: Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S et al. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health TechnolAssess. 2006; 10(15) [PubMed: 16707072]
354.: Gordois A, Posnett J, Borris L, Bossuyt P, Jonsson B, Levy E et al. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; 1(10):2167–2174 [PubMed: 14521600]
355.: Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Annals of Internal Medicine. 1999; 130(10):789–99 [PubMed: 10366368]
356.: Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:(2 Suppl):e227S–77S [PMC free article: PMC3278061] [PubMed: 22315263]
357.: Gozzard D, Hutchinson J, Lloyd A, Hutchings A. Economic evaluation of extended and conventional prophylaxis with enoxaparin against venous thromboembolism in patients undergoing surgery for abdominal cancer. Journal of Medical Economics. 2004; 7:53–65
358.: Grant GH, Merriman JB, Hoffman MK. Implementation and efficacy of a formalized venous thromboembolism prevention strategy in the peripartum population. American Journal of Obstetrics and Gynecology. 2016; 1):S227–S228
359.: Green D, Rossi EC, Yao JS. Deep vein thrombosis in spinal cord injury : effect of prophylaxis with calf compression, aspirin and dipyridamole. Paraplegia. 1982; 20:227–234 [PubMed: 6813814]
360.: Green L, Lawrie AS, Patel S, Hossain F, Chitolie A, Mackie IJ et al. The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. British Journal of Haematology. 2010; 151(5):469–476 [PubMed: 20950405]
361.: Greenfield LJ, Proctor MC, Rodriguez JL, Luchette FA, Cipolle MD, Cho J. Posttrauma thromboembolism prophylaxis. Journal of Trauma-Injury Infection & Critical Care. 1997; 42(1):100–3 [PubMed: 9003265]
362.: Grille S, Castro V, Turcatti P, Mussio D, Laporte G, Medici F et al. Prophylaxis for venous thromboembolic disease in pregnancy and postpartum period. Haematologica. 2015; 100:626
363.: Gronberg T, Hartikainen JE, Nuotio I, Biancari F, Ylitalo A, Airaksinen KE. Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study). American Journal of Cardiology. 2016; 117(8):1294–8 [PubMed: 26892448]
364.: Groote Schuur Hospital Thromboembolus Study Group. Failure of low-dose heparin to prevent significant thromboembolic complications in high-risk surgical patients: interim report of prospective trial. British Medical Journal. 1979; 1(6176):1447–1450 [PMC free article: PMC1599102] [PubMed: 380742]
365.: Gruettner J, Walter T, Lang S, Meyer M, Apfaltrer P, Henzler T et al. Importance of Wells score and Geneva score for the evaluation of patients suspected of pulmonary embolism. In Vivo. 2015; 29(2):269–72 [PubMed: 25792656]
366.: Haas S, Hohmann V, Bramlage P. Prevention of venous thromboembolism using enoxaparin in day surgery: results of the SMART noninterventional study. Clinical and Applied Thrombosis/Hemostasis. 2012; 18(3):265–271 [PubMed: 22084412]
367.: Haas S, Stemberger A, Fritsche HM, Welzel D, Wolf H, Lechner F et al. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Arzneimittel-Forschung. 1987; 37(7):839–843 [PubMed: 2823840]
368.: Haas SB, Insall JN, Scuderi GR, Windsor RE, Ghelman B. Pneumatic sequential-compression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. Journal of Bone and Joint Surgery. 1990; 72(1):27–31 [PubMed: 2404020]
369.: Haas SK, Hach-Wunderle V, Mader FH, Paar WD. Venous thromboembolic risk and thromboprophylaxis in acutely ill medical outpatients: Summarized data from the AT-HOME study. Phlebologie. 2006; 35(6):286–288
370.: Haas SK, Hach-Wunderle V, Mader FH, Ruster K, Paar WD. An evaluation of venous thromboembolic risk in acutely ill medical patients immobilized at home: the AT-HOME Study. Clinical and Applied Thrombosis/Hemostasis. 2007; 13(1):7–13 [PubMed: 17164492]
371.: Haas SK, Wolf H, Encke A, Fareed J. Prevention of fatal postoperative pulmonary embolism by low molecular weight heparin. A double blind comparison of certoparin and unfractionated heparin. Thrombosis and Haemostasis. 1999; 82(5):1548
372.: Hachey KJ, Sterbling H, Choi DS, Pinjic E, Hewes PD, Munoz J et al. Prevention of Postoperative Venous Thromboembolism in Thoracic Surgical Patients: Implementation and Evaluation of a Caprini Risk Assessment Protocol. Journal of the American College of Surgeons. 2016; 222(6):1019–27 [PubMed: 26775163]
373.: Hack V, Schwarz E, Rumpelein C, Stein EL, Pachmann U. Risk of thrombosis during the course of pregnancy mechanism and individual therapeutic consequences. Transfusion Medicine and Hemotherapy. 2012; 39:57
374.: Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Archives of Orthopaedic and Trauma Surgery. 2004; 124(8):507–517 [PubMed: 15365714]
375.: Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. American Journal of Hematology. 2016; 91(4):390–394 [PubMed: 26799697]
376.: Hairon N. New risk assessment tool aims to help nurses prevent VTE. Nursing Times. 2008; 104(39):23–5 [PubMed: 19051543]
377.: Hajibandeh S, Hajibandeh S, Antoniou GA, Scurr James RH, Torella F. Neuromuscular electrical stimulation for the prevention of venous thromboembolism. Cochrane Database of Systematic Reviews 2015, Issue 6. Art. No.: CD011764. DOI: 10.1002/14651858.CD011764. [PMC free article: PMC6486105] [PubMed: 29161465] [CrossRef]
378.: Hamel-Desnos CM, Gillet JL, Desnos PR, Allaert FA. Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phlebology. 2009; 24(4):176–182 [PubMed: 19620700]
379.: Hamersley S, Landy H. Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin. American Journal of Obstetrics and Gynecology. 1998; 178:S66
380.: Hamidi S, Riazi M. Incidence of venous thromboembolic complications in instrumental spinal surgeries with preoperative chemoprophylaxis. Journal of Korean Neurosurgical Society. 2015; 57(2):114–118 [PMC free article: PMC4345188] [PubMed: 25733992]
381.: Hamidi V, Ringerike T, Hagen G, Reikvam A, Klemp M. New anticoagulants as thromboprophylaxis after total hip or knee replacement. International Journal of Technology Assessment in Health Care. 2013; 29(3):234–243 [PubMed: 23768996]
382.: Hampson WG, Harris FC, Lucas HK, Roberts PH, McCall IW, Jackson PC et al. Failure of low-dose heparin to prevent deep-vein thrombosis after hip-replacement arthroplasty. Lancet. 1974; 2(7884):795–797 [PubMed: 4138905]
383.: Hamulyak K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thrombosis and Haemostasis. 1995; 74(6):1428–1431 [PubMed: 8772214]
384.: Handley AJ. Low-dose heparin after myocardial infarction. Lancet. 1972; 300(7778):623–624 [PubMed: 4116776]
385.: Handley AJ, Emerson PA, Fleming PR. Heparin in the prevention of deep vein thrombosis after myocardial infarction. British Medical Journal. 1972; 2(5811):436–438 [PMC free article: PMC1788022] [PubMed: 4555651]
386.: Hanison E, Corbett K. Non-pharmacological interventions for the prevention of venous thromboembolism: a literature review. Nursing Standard. 2016; 31(8):48–57 [PubMed: 27808636]
387.: Hansberry KL, Thompson IM, Jr., Bauman J, Deppe S, Rodriguez FR. A prospective comparison of thromboembolic stockings, external sequential pneumatic compression stockings and heparin sodium /dihydroergotamine mesylate for the prevention of thromboembolic complications in urological surgery. Journal of Urology. 1991; 145(6):1205–1208 [PubMed: 2033693]
388.: Haque S, Bishnoi A, Khairandish H, Menon D. Thromboprophylaxis in Ambulatory Trauma Patients With Foot and Ankle Fractures: Prospective Study Using a Risk Scoring System. Foot & Ankle Specialist. 2016; 9(5):388–93 [PubMed: 27044599]
389.: Hardwick ME, Pulido PA, Colwell CWJ. A mobile compression device compared with low-molecular-weight heparin for prevention of venous thromboembolism in total hip arthroplasty. Orthopaedic Nursing. 2011; 30(5):312–316 [PubMed: 21934585]
390.: Harenberg J, Roebruck P, Heene DL. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thrombosis Research. 1990; 59(3):639–650 [PubMed: 2173168]
391.: Harenberg J, Schneider D, Heilmann L, Wolf H. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis. 1993; 23(6):314–320 [PubMed: 8034237]
392.: Harinath G, St John PH. Use of a thromboembolic risk score to improve thromboprophylaxis in surgical patients. Annals of the Royal College of Surgeons of England. 1998; 80(5):347–349 [PMC free article: PMC2503127] [PubMed: 9849337]
393.: Harris C, Sulmers C, Groesch K, Wilson T, Delfino K, Taylor F. Venous thromboembolism: Padua prediction score in the obstetric patient. Obstetrics and Gynecology. 2016; 127:88S
394.: Harris WH, Athanasoulis CA, Waltman AC, Salzman EW. Prophylaxis of deep-vein thrombosis after total hip replacement. Dextran and external pneumatic compression compared with 1.2 or 0.3 gram of aspirin daily. Journal of Bone and Joint Surgery. 1985; 67(1):57–62 [PubMed: 2578469]
395.: Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. New England Journal of Medicine. 1977; 297(23):1246–1249 [PubMed: 335247]
396.: Hata T, Yasui M, Murata K, Okuyama M, Ohue M, Ikeda M et al. Safety of fondaparinux to prevent venous thromboembolism in Japanese patients undergoing colorectal cancer surgery: a multicenter study. Surgery Today. 2014; 44(11):2116–2123 [PMC free article: PMC4194009] [PubMed: 24840400]
397.: Haut ER, Garcia LJ, Shihab HM, Brotman DJ, Stevens KA, Sharma R et al. The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis. JAMA Surg. 2014; 149(2):194–202 [PubMed: 24195920]
398.: Haxaire C, Tromeur C, Couturaud F, Leroyer C. A Qualitative Study to Appraise Patients and Family Members Perceptions, Knowledge, and Attitudes towards Venous Thromboembolism Risk. PloS One. 2015; 10(11):e0142070 [PMC free article: PMC4633063] [PubMed: 26536460]
399.: Haywood KL, Griffin XL, Achten J, Costa ML. Developing a core outcome set for hip fracture trials. Bone Joint J. 2014; 96-b(8):1016–23 [PubMed: 25086115]
400.: Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation. 2012; 126(3):343–348 [PubMed: 22700854]
401.: Health and Social Care Information Centre. Statistics on Obesity, Physical Activity and Diet. 2016. Available from: http://content.digital.nhs.uk/catalogue/PUB20562/obes-phys-acti-diet-eng-2016-rep.pdf
402.: Heath S, Goodfellow A. Maternal venous thromboembolism (VTE) risk assessment. Journal of Paediatrics and Child Health. 2016; 52:69
403.: Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Internal Medicine Journal. 2002; 32(3):84–88 [PubMed: 11885848]
404.: Hedlund PO, Blombäck M. The effect of prophylaxis with low dose heparin on blood coagulation parameters. A double blind study in connection with transvesical prostatectomy. Thrombosis and Haemostasis. 1979; 41(2):337–345 [PubMed: 382433]
405.: Hedlund PO, Blombäck M. The effects of low-dose heparin treatment on patients undergoing transvesical prostatectomy. Urological Research. 1981; 9(3):147–152 [PubMed: 7257029]
406.: Heilmann L, Heitz R, Koch FU, Ose C. Perioperative prevention of thrombosis in cesarean section: results of a randomized prospective comparative study with 6% hydroxyethyl starch and 0.62 low dose heparin. Zeitschrift für Geburtshilfe und Perinatologie. 1991; 195(1):10–15 [PubMed: 1711261]
407.: Heilmann L, Kruck M, Schindler AE. (Prevention of thrombosis in gynecology: double-blind comparison of low molecular weight heparin and unfractionated heparin). Geburtshilfe und Frauenheilkunde. 1989; 49(9):803–807 [PubMed: 2553528]
408.: Heilmann L, von Tempelhoff GF, Kirkpatrick C, Schneider DM, Hommel G, Pollow K. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast cancer surgery: efficacy, safety, and follow-up. Clinical and Applied Thrombosis/Hemostasis. 1998; 4(4):268–273
409.: Heinemann LAJ, DoMinh T, Assmann A, Schramm W, Scurmann R, Hilpert J et al. VTE risk assessment - A prognostic model: BATER cohort study of young women. Thrombosis Journal. 2005; 3(5) [PMC free article: PMC1087887] [PubMed: 15836797]
410.: Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 2000; 132(11):853–861 [PubMed: 10836911]
411.: Heit JA, Scott D, Berkowitz SD, Bona R, Cabanas V, Corson JD et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: A double-blind dose-ranging study. Thrombosis and Haemostasis. 1997; 77(1):32–38 [PubMed: 9031445]
412.: Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O’Fallon WM et al. The epidemiology of venous thromboembolism in the community. ThrombHaemost. 2001; 86(1):452–463 [PubMed: 11487036]
413.: Helviz Y, Dzigivker I, Raveh-Brawer D, Hersch M, Zevin S, Einav S. Anti-Factor Xa Activity of Prophylactic Enoxaparin Regimens in Critically Ill Patients. Israel Medical Association Journal: Imaj. 2016; 18(2):108–13 [PubMed: 26979004]
414.: Hendriksen JM, Geersing GJ, Lucassen WA, Erkens PM, Stoffers HE, van Weert HC et al. Diagnostic prediction models for suspected pulmonary embolism: systematic review and independent external validation in primary care. BMJ. 2015; 351:h4438 [PMC free article: PMC4561760] [PubMed: 26349907]
415.: Hewes PD, Hachey KJ, Zhang XW, Tripodis Y, Rosenkranz P, Ebright MI et al. Evaluation of the Caprini model for venothromboembolism in esophagectomy patients. Annals of Thoracic Surgery. 2015; 100(6):2072–8 [PubMed: 26279363]
416.: Hill NC, Hill JG, Sargent JM, Taylor CG, Bush PV. Effect of low dose heparin on blood loss at caesarean section. British Medical Journal. 1988; 296(6635):1505–1506 [PMC free article: PMC2546022] [PubMed: 3134089]
417.: Hills NH, Pflug JJ, Jeyasingh K, Boardman L, Calnan JS. Prevention of deep vein thrombosis by intermittent pneumatic compression of calf. British Medical Journal. 1972; 1(793):131–135 [PMC free article: PMC1787116] [PubMed: 5007837]
418.: Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ. 2011; 343:d4656 [PMC free article: PMC3156826] [PubMed: 21846713]
419.: Hippisley-Cox J, Coupland C, Brindle P. The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study. BMJ Open. 2014; 4(8):e005809 [PMC free article: PMC4156807] [PubMed: 25168040]
420.: Hirschl M, Kundi M. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons. Zeitschrift fur Gefasskrankheiten. 2014; 43(5):353–364 [PubMed: 25147012]
421.: Ho KM, Bham E, Pavey W. Incidence of Venous Thromboembolism and Benefits and Risks of Thromboprophylaxis After Cardiac Surgery: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2015; 4(10):e002652 [PMC free article: PMC4845147] [PubMed: 26504150]
422.: Ho KM, Tan JA. Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation. 2013; 128(9):1003–1020 [PubMed: 23852609]
423.: Ho YK, Seow-Choen F, Leong A, Eu KW, Nyam D, Teoh MK. Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients. Diseases of the Colon and Rectum. 1999; 42(2):196–203 [PubMed: 10211496]
424.: Hochhegger B, Alves GR, Chaves M, Moreira AL, Kist R, Watte G et al. Interobserver agreement between radiologists and radiology residents and emergency physicians in the detection of PE using CTPA. Clinical Imaging. 2014; 38(4):445–7 [PubMed: 24667043]
425.: Hoffman R, Largiadèr F, Brütsch HP. Perioperative thromboembolic prophylaxis with low molecular weight heparin and postoperative bleeding complications. Langenbecks Archiv für Chirurgie. 1990; 375(Suppl II):1179–1184 [PubMed: 1983509]
426.: Hoffmann R, Largiader F. Perioperative prevention of thromboembolism with standard heparin and low molecular weight heparin, evaluation of postoperative hemorrhage. A double-blind, prospective, randomized and mono-center study. Langenbecks Archiv für Chirurgie. 1992; 377(5):258–261 [PubMed: 1328784]
427.: Hoffmeyer P, Simmen H, Jakob M, Sommer C, Platz A, Ilchmann T et al. Rivaroxaban for Thromboprophylaxis After Nonelective Orthopedic Trauma Surgery in Switzerland. Orthopedics. 2017; 40(2):109–116 [PubMed: 27874908]
428.: Hohl Moinat C, Periard D, Grueber A, Hayoz D, Magnin JL, Andre P et al. Predictors of venous thromboembolic events associated with central venous port insertion in cancer patients. Journal of Oncology Print. 2014; 2014:743181 [PMC free article: PMC3934091] [PubMed: 24665264]
429.: Holley A, King C, Moores L, Jackson JL, Shorr A. The role of twice versus three times daily heparin dosing for thromboembolism prophylaxis in general medical patients admitted to the hospital. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD007382. DOI: DOI: 10.1002/14651858.CD007382. [CrossRef]
430.: Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal. Pharmacoeconomics. 2012; 30(2):137–146 [PubMed: 22185183]
431.: Hossain Shahcheraghi G, Javid M, Arasteh MM. Thromboembolic disease after knee arthroplasty is rare in Southern Iran. Journal of orthopaedics. 2015; 12(2):86–91 [PMC free article: PMC4421096] [PubMed: 25972699]
432.: Howard A, Zaccagnini D, Ellis M, Williams A, Davies AH, Greenhalgh RM. Randomized clinical trial of low molecular weight heparin with thigh-length or knee-length antiembolism stockings for patients undergoing surgery. British Journal of Surgery. 2004; 91(7):842–847 [PubMed: 15227689]
433.: Howell R, Fidler J, Letsky E, De Swiet M. The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics and Gynaecology. 1983; 90(12):1124–1128 [PubMed: 6360198]
434.: Huang W, Anderson FA, Spencer FA, Gallus A, Goldberg RJ. Risk-assessment models for predicting venous thromboembolism among hospitalized non-surgical patients: a systematic review. Journal of Thrombosis and Thrombolysis. 2013; 35(1):67–80 [PubMed: 22826096]
435.: Hui AC, Heras-Palou C, Dunn I, Triffitt PD, Crozier A, Imeson J et al. Graded compression stockings for prevention of deep-vein thrombosis after hip and knee replacement. Journal of Bone and Joint Surgery (British Volume). 1996; 78(4):550–554 [PubMed: 8682818]
436.: Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circulation Cardiovascular Quality and Outcomes. 2010; 3(6):652–660 [PubMed: 20923996]
437.: Hull R, Delmore TJ, Hirsch J, Gent M, Armstrong P, Lofthouse R et al. Effectiveness of intermittent pulsative elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. Thrombosis Research. 1979; 16(1–2):37–45 [PubMed: 505427]
438.: Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. New England Journal of Medicine. 1993; 329(19):1370–1376 [PubMed: 8413432]
439.: Hull RD, Gersh MH. The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants. Current Medical Research and Opinion. 2015; 31(2):197–210 [PubMed: 25299352]
440.: Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Archives of Internal Medicine. 2000; 160(14):2199–2207 [PubMed: 10904464]
441.: Hull RD, Raskob GE, Gent M, McLoughlin D, Julian D, Smith FC et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA. 1990; 263(17):2313–2317 [PubMed: 2182917]
442.: Hume M, Kuriakose TX, Zuch L, Turner RH. 125I fibrinogen and the prevention of venous thrombosis. Archives of Surgery. 1973; 107(5):803–806 [PubMed: 4744294]
443.: Hunter R, Lewis S, Noble S, Rance J, Bennett PD. “Post-thrombotic panic syndrome”: A thematic analysis of the experience of venous thromboembolism. British Journal of Health Psychology. 2016; 9:9 [PubMed: 27611117]
444.: Ibrahim M, Ahmed A, Mohamed WY, El-Sayed Abu Abduo S. Effect of compression devices on preventing deep vein thrombosis among adult trauma patients: A systematic review. Dimensions of Critical Care Nursing. 2015; 34(5):289–300 [PubMed: 26244245]
445.: Ikesaka R, Delluc A, Le Gal G, Carrier M. Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. Thrombosis Research. 2014; 133(4):682–687 [PubMed: 24508449]
446.: Imberti D, Legnani C, Baldini E, Cini M, Nicolini A, Guerra M et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thrombosis Research. 2009; 124(6):667–671 [PubMed: 19482341]
447.: Ismail SK, Norris L, Khashan A, Myers J, Simpson N, Dekker G et al. Can calibrated automated thrombogram assay predict venous thrombosis in pregnancy? Thrombosis Research. 2015; 135:S67
448.: Izadpanah M, Khalili H, Dashti-Khavidaki S, Mohammadi M. Heparin and related drugs for venous thromboembolism prophylaxis: subcutaneous or intravenous continuous infusion? Journal of comparative effectiveness research. 2015; 4(2):167–184 [PubMed: 25825845]
449.: Jacobso BF, Louw S, Riback WJ. The use of vte prophylaxis in relation to patient risk profiling (TUNE-IN) wave 2 study. South African Medical Journal. 2014; 104(12):880–884 [PubMed: 28375075]
450.: Jameson SS, Baker PN, Charman SC, Deehan DJ, Reed MR, Gregg PJ et al. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using national joint registry data. Journal of Bone and Joint Surgery (British Volume). 2012; 94(7):914–8 [PubMed: 22733945]
451.: Jameson SS, Charman SC, Gregg PJ, Reed MR, Van Der Meulen JH. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: A non-randomised comparison from information in the National Joint Registry. Journal of Bone and Joint Surgery - Series B. 2011; 93 B(11):1465–1470 [PubMed: 22058295]
452.: Jameson SS, Rymaszewska M, Hui AC, James P, Serrano-Pedraza I, Muller SD. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. Journal of Bone and Joint Surgery (American Volume). 2012; 94(17):1554–8 [PubMed: 22832942]
453.: Jamula E, Woods K, Verhovsek M, Douketis JD. Comparison of pain and ecchymosis with low-molecular-weight heparin vs. unfractionated heparin in patients requiring bridging anticoagulation after warfarin interruption: A randomized trial. Journal of Thrombosis and Thrombolysis. 2009; 28(3):266–268 [PubMed: 19219405]
454.: Janssen KJ, Siccama I, Vergouwe Y, Koffijberg H, Debray TP, Keijzer M et al. Development and validation of clinical prediction models: marginal differences between logistic regression, penalized maximum likelihood estimation, and genetic programming. Journal of Clinical Epidemiology. 2012; 65(4):404–12 [PubMed: 22214734]
455.: Janvrin SB, Davies G, Greenhalgh RM. Postoperative deep vein thrombosis caused by intravenous fluids during surgery. British Journal of Surgery. 1980; 67(10):690–693 [PubMed: 7000224]
456.: Jiang Y, Du H, Liu J, Zhou Y. Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. Chinese Medical Journal. 2014; 127(12):2201–2205 [PubMed: 24931228]
457.: Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clinical Oncology. 1999; 11(2):105–10 [PubMed: 10378636]
458.: Joint Formulary Committee. British National Formulary (BNF) July 2016 update. 2016. Available from: http://www.bnf.org.uk Last accessed: 09/08/2017.
459.: Jourdan M, McColl I. The use of prophylactic subcutaneous heparin in patients undergoing hernia repairs. British Journal of Clinical Practice. 1984; 38(9):298–300 [PubMed: 6477809]
460.: Junqueira Daniela RG, Perini E, Penholati Raphael RM, Carvalho MG. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD007557. DOI: 10.1002/14651858.CD007557.pub2. [PubMed: 22972111] [CrossRef]
461.: Kabrhel C, McAfee AT, Goldhaber SZ. The contribution of the subjective component of the Canadian Pulmonary Embolism Score to the overall score in emergency department patients. Academic Emergency Medicine. 2005; 12(10):915–20 [PubMed: 16204134]
462.: Kafeza M, Shalhoub J, Salooja N, Bingham L, Spagou K, Davies AH. A systematic review of clinical prediction scores for deep vein thrombosis. Phlebology. 2016; 24:24
463.: Kahn SR, Galanaud JP, Vedantham S, Ginsberg JS. Guidance for the prevention and treatment of the post-thrombotic syndrome. Journal of Thrombosis and Thrombolysis. 2016; 41(1):144–53 [PMC free article: PMC4715836] [PubMed: 26780743]
464.: Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet. 2014; 383(9920):880–888 [PubMed: 24315521]
465.: Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson RD. A multicenter randomized placebo controlled trial of compression stockings to prevent the post-thrombotic syndrome after proximal deep venous thrombosis: The S.O.X. trial. Blood. 2012; 120(21)
466.: Kakkar AK, Agnelli G, Fisher W, George D, Lassen MR, Mismetti P et al. Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. Annals of Surgery. 2014; 259(6):1073–1079 [PubMed: 24374549]
467.: Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372(9632):31–39 [PubMed: 18582928]
468.: Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Thrombosis and Haemostasis. 2000; 83(4):523–529 [PubMed: 10780310]
469.: Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. British Journal of Surgery. 1985; 72(10):786–91 [PubMed: 3899240]
470.: Kakkar VV, Stringer MD, Hedges AR, Parker CJ, Welzel D, Ward VP et al. Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis. American Journal of Surgery. 1989; 157(4):413–418 [PubMed: 2539025]
471.: Kakkos SK, Warwick D, Nicolaides AN, Stansby GP, Tsolakis IA. Combined (mechanical and pharmacological) modalities for the prevention of venous thromboembolism in joint replacement surgery. Journal of Bone and Joint Surgery (British Volume). 2012; 94(6):729–734 [PubMed: 22628585]
472.: Kalodiki EP, Hoppensteadt DA, Nicolaides AN, Fareed J, Gill K, Regan F et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. International Angiology. 1996; 15(2):162–168 [PubMed: 8803642]
473.: Kang N, Sobieraj DM. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thrombosis Research. 2014; 133(6):1145–1151 [PubMed: 24713109]
474.: Kapoor A, Chuang W, Radhakrishnan N, Smith KJ, Berlowitz D, Segal JB et al. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics. 2010; 28(7):521–538 [PMC free article: PMC3916183] [PubMed: 20550220]
475.: Karamat A, Awan S, Hussain MG, Al Hameed F, Butt F, Wahla AS. Usefulness of Clinical Prediction Rules, D-dimer, and Arterial Blood Gas Analysis to Predict Pulmonary Embolism in Cancer Patients. Oman Medical Journal. 2017; 32(2):148–153 [PMC free article: PMC5397075] [PubMed: 28439386]
476.: Katsios C, Donadini M, Meade M, Mehta S, Hall R, Granton J et al. Prediction scores do not correlate with clinically adjudicated categories of pulmonary embolism in critically ill patients. Canadian Respiratory Journal. 2014; 21(1):36–42 [PMC free article: PMC3938238] [PubMed: 24083302]
477.: Katz DF, Maddox TM, Turakhia M, Gehi A, O’Brien EC, Lubitz SA et al. Analysis from the national cardiovascular data registry’s outpatient practice innovation and clinical excellence atrial fibrillation registry. Circulation: Cardiovascular Quality and Outcomes. 2017; 10 (5) (no pagination)(e003476) [PubMed: 28506981]
478.: Kawaguchi T, Kumabe T, Kanamori M, Saito R, Yamashita Y, Sonoda Y et al. Risk assessment for venous thromboembolism in patients with neuroepithelial tumors: pretreatment score to identify high risk patients. Neurologia Medico-Chirurgica. 2013; 53(7):467–73 [PubMed: 23883557]
479.: Kawaji H, Ishii M, Tamaki Y, Hamasaki M, Ishikawa H, Sasaki K. Postoperative prophylactic effect of fondaparinux for prevention of deep venous thrombosis after cemented total hip replacement: a comparative study. Modern rheumatology. 2012; 22:216–222 [PubMed: 21761228]
480.: Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. New England Journal of Medicine. 2003; 349(7):631–9 [PubMed: 12917299]
481.: Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. British Journal of Haematology. 2006; 133(3):259–269 [PubMed: 16643427]
482.: Kessler P, Pour L, Gregora E, Zemanova M, Penka M, Brejcha M et al. Low molecular weight heparins for thromboprophylaxis during induction chemotherapy in patients with multiple myeloma. Klinika Onkologie. 2011; 24(4):281–6 [PubMed: 21905619]
483.: Kettunen K, Poikolainen E, Karjalainen P, Oksala I, Alhava E, Rehnberg V et al. (Prevention of postoperative deep vein thrombosis with small doses of heparin). Duodecim. 1974; 90(11):834–838 [PubMed: 4426267]
484.: Khairy P, Aboulhosn J, Broberg CS, Cohen S, Cook S, Dore A et al. Thromboprophylaxis for atrial arrhythmias in congenital heart disease: A multicenter study. International Journal of Cardiology. 2016; 223:729–735 [PubMed: 27573597]
485.: Khokhar A, Chari A, Murray D, McNally M, Pandit H. Venous thromboembolism and its prophylaxis in elective knee arthroplasty: an international perspective. Knee. 2013; 20(3):170–176 [PubMed: 22858314]
486.: Khorana AA, Francis CW, Kuderer N, Carrier M, Ortel TL, Wun T et al. Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial. Blood. 2015; 126:427–427 [PubMed: 28139259]
487.: Kierkegaard A, Norgren L. Graduated compression stockings in the prevention of deep vein thrombosis in patients with acute myocardial infarction. European Heart Journal. 1993; 14(10):1365–1368 [PubMed: 8262083]
488.: Kiil J, Jensen FT. The incidence of postoperative pulmonary embolism and the influence of heparin in low dosages on this as assessed by ventilation-perfusion scintigraphy. Ugeskrift for Laeger. 1978; 140(21):1215–1217 [PubMed: 351903]
489.: Kiil J, Kiil J, Axelsen F. Heparin in low dosage as prophylaxis of postoperative pulmonary embolism and deep venous thrombosis. Ugeskrift for Laeger. 1978; 140(21):1224–1230 [PubMed: 351904]
490.: Kiil J, Kiil J, Axelsen F, Andersen D. Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin. Lancet. 1978; 1(8074):1115–1116 [PubMed: 77413]
491.: Kiil J, Moller JC. Postoperative deep thrombosis in the lower limbs and the prophylactic value of heparin in low dosage as assessed by phlebography. Ugeskrift for Laeger. 1978; 140(21):1221–1224 [PubMed: 664072]
492.: Kiil J, Møoller JC. Postoperative deep vein thrombosis of the lower limb and prophylactic value of heparin evaluated by phlebography. Acta Radiologica: Diagnosis. 1979; 20(3):507–512 [PubMed: 393078]
493.: Killewich LA, Aswad MA, Sandager GP, Lilly MP, Flinn WR. A randomized, prospective trial of deep venous thrombosis prophylaxis in aortic surgery. Archives of Surgery. 1997; 132(5):499–504 [PubMed: 9161392]
494.: Kim SM, Moon YW, Lim SJ, Kim DW, Park YS. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. Thrombosis and Haemostasis. 2016; 115(3):600–7 [PubMed: 26790579]
495.: Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. British Medical Journal. 1998; 316(7133):736–741 [PMC free article: PMC28477] [PubMed: 9529408]
496.: Kiudelis M, Gerbutavicius R, Gerbutaviciene R, Griniute R, Mickevicius A, Endzinas Z et al. A combinative effect of low-molecular-weight heparin and intermittent pneumatic compression device for thrombosis prevention during laparoscopic fundoplication. Medicina. 2010; 46(1):18–23 [PubMed: 20234158]
497.: Klerk CPW, Smorenburg SM, Otten HM. The effect of low molecular weight heparin on survival in patients with advanced malignancy. Journal of Clinical Oncology. 2005; 23(10):2130–2135 [PubMed: 15699479]
498.: Klok FA, Kruisman E, Spaan J, Nijkeuter M, Righini M, Aujesky D et al. Comparison of the revised Geneva score with the Wells rule for assessing clinical probability of pulmonary embolism. Journal of Thrombosis and Haemostasis. 2008; 6(1):40–4 [PubMed: 17973649]
499.: Klok FA, Niemann C, Dellas C, Hasenfus G, Konstantinides S, Lankeit M. Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. Journal of Thrombosis and Thrombolysis. 2016; 41(2):312–20 [PubMed: 26091712]
500.: Knudson MM. Thromboembolism following multiple trauma. Journal of Trauma. 1992; 32(1):2–11 [PubMed: 1732568]
501.: Koo KH, Choi JS, Ahn JH, Kwon JH, Cho KT. Comparison of clinical and physiological efficacies of different intermittent sequential pneumatic compression devices in preventing deep vein thrombosis: a prospective randomized study. Clinics in Orthopedic Surgery. 2014; 6(4):468–475 [PMC free article: PMC4233228] [PubMed: 25436073]
502.: Kooiman J, van Hagen N, Iglesias Del Sol A, Planken EV, Lip GY, van der Meer FJ et al. The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PloS One. 2015; 10(4):e0122520 [PMC free article: PMC4407886] [PubMed: 25905638]
503.: Koppenhagen K, Adolf J, Matthes M, Troster E, Roder JD, Hass S et al. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thrombosis and Haemostasis. 1992; 67(6):627–630 [PubMed: 1324534]
504.: Koppenhagen K, Matthes M. Heparin-dihydergot or heparin alone in thrombosis prophylaxis? Medizinische Welt. 1982; 33(6):216–223 [PubMed: 7070283]
505.: Koppenhagen K, Matthes M, Haering R, Troester E, Wolf H, Welzel D. Prophylaxis of thromboembolism in elective abdominal surgery: comparison of efficiacy and safety of low molecular weight heparin and unfractionated heparin. Munchener Medizinische Wochenschrift. 1990; 132(43):677–680
506.: Kosir MA, Schmittinger L, Barno WL, Duddella P, Pone M, Perales A et al. Prospective double-arm study of fibrinolysis in surgical patients. Journal of Surgical Research. 1998; 74(1):96–101 [PubMed: 9536981]
507.: Kourlaba G, Relakis J, Mylonas C, Kapaki V, Kontodimas S, Holm MV et al. The humanistic and economic burden of venous thromboembolism in cancer patients: A systematic review. Blood Coagulation and Fibrinolysis. 2015; 26(1):13–31 [PubMed: 25202884]
508.: Krasinski Z, Szpurek D, Staniszewski R, Dzieciuchowicz L, Pawlaczyk K, Krasinska B et al. The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment. International Angiology. 2014; 33(4):365–371 [PubMed: 25056168]
509.: Krauss T, Rath W, Dittmer U, Kuhn W. Prevention of thromboembolism with low molecular weight heparin (Fragmin) in obstetrics. Zeitschrift für Geburtshilfe und Perinatologie. 1994; 198(4):120–125 [PubMed: 7975797]
510.: Kraytman M, Kutnowski M, Ansay J, Fastrez R. Prophylaxis of postoperative deep vein thromboses by means of weak doses of subcutaneous heparin. Acta Chirurgica Belgica. 1976; 75(5):519–529 [PubMed: 1015181]
511.: Kresec O, Lebaudy C, Laborde C, Paludetto MN, Fleuriant C, Barkate A et al. Elderly patients and oral anticoagulants: Evaluation of patient’s knowledge and the case for a pharmaceutical interview. International Journal of Clinical Pharmacy. 2011; 33 (4):704–705
512.: Kruse-Blinkenberg HO, Gormsen J. The influence of low dose heparin in elective surgery on blood coagulation, fibrinolysis, platelet function, antithrombin III and antiplasmin. Acta Chirurgica Scandinavica. 1980; 146(6):375–382 [PubMed: 7008475]
513.: Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. New England Journal of Medicine. 2005; 352(10):969–977 [PubMed: 15758007]
514.: Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA. A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. Oncologist. 2016; 21(7):861–7 [PMC free article: PMC4943384] [PubMed: 27125754]
515.: Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Archives of Internal Medicine. 1999; 159(5):457–60 [PubMed: 10074953]
516.: Kujath P, Hoffmann M. Physical prophylaxis for thromboembolism: Current state of knowledge on use of medical thromboprophylaxis stockings. Chirurg. 2013; 84(12):1057–1061 [PubMed: 24068203]
517.: Kurtoglu M, Group RS. An observational study for venous thromboembolism risk assessment among hospitalized patients in general surgery clinics across Turkey. Phlebology. 2011; 26(8):344–52 [PubMed: 21821721]
518.: Kutnowski M, Vandendris M, Steinberger R, Kraytman M. Prevention of postoperative deep-vein thrombosis by low-dose heparin in urological surgery. A double-blind, randomised study. Urological Research. 1977; 5(3):123–125 [PubMed: 919112]
519.: Kwok CS, Pradhan S, Yeong JK-y, Loke YK. Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison. Chest. 2013; 144(2):593–600 [PubMed: 23519234]
520.: La Regina M, Orlandini F, Marchini F, Marinaro A, Bonacci R, Bonanni P et al. Combined assessment of thrombotic and haemorrhagic risk in acute medical patients. Thrombosis and Haemostasis. 2016; 115(2):392–8 [PubMed: 26403152]
521.: Lahnborg G, Lagergren H, Hedenstierna G. Effect of low-dose heparin prophylaxis on arterial oxygen tension after high laparotomy. Lancet. 1976; 1(7950):54–56 [PubMed: 54579]
522.: Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. American Journal of Medicine. 1989; 87(2):144–52 [PubMed: 2787958]
523.: Lankeit M, Friesen D, Schafer K, Hasenfus G, Konstantinides S, Dellas C. A simple score for rapid risk assessment of non-high-risk pulmonary embolism. Clinical Research in Cardiology. 2013; 102(1):73–80 [PMC free article: PMC3536952] [PubMed: 23011575]
524.: Laporte S, Chapelle C, Bertoletti L, Lega JC, Cucherat M, Zufferey PJ et al. Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs. Thrombosis and Haemostasis. 2014; 112(3):503–510 [PubMed: 24965841]
525.: Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. New England Journal of Medicine. 2008; 358(26):2776–2786 [PubMed: 18579812]
526.: Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hipreplacement surgery: a randomised double-blind comparison. Lancet. 2002; 359(9319):1715–1720 [PubMed: 12049858]
527.: Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejø Bro HP, Andersen G et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research. 1998; 89(6):281–287 [PubMed: 9669750]
528.: Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro HP, Andersen G et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research. 1998; 89(6):281–7 [PubMed: 9669750]
529.: Lassen MR, Borris LC, Christiansen HM, Boll KL, Eiskjaer SP, Nielsen BW et al. Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. Acta Orthopaedica Scandinavica. 1991; 62(1):33–38 [PubMed: 1848385]
530.: Lassen MR, Borris LC, Christiansen HM, Møller-Larsen F, Knudsen VE, Boris P et al. Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery. British Journal of Surgery. 1988; 75(7):686–689 [PubMed: 2843255]
531.: Lassen MR, Borris LC, Christiansen HM, Møller-Larsen F, Knudsen VE, Boris P et al. Prevention of thromboembolism in hip-fracture patients. Comparison of low-dose heparin and low-molecular-weight heparin combined with dihydroergotamine. Archives of Orthopaedic and Trauma Surgery. 1989; 108(1):10–13 [PubMed: 2913977]
532.: Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. Journal of Thrombosis and Haemostasis. 2007; 5(12):2368–75 [PubMed: 17868430]
533.: Lassen MR, Fisher W, Mouret P, Agnelli G, George D, Kakkar A et al. Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE. Journal of Thrombosis and Haemostasis. 2012; 10(5):822–832 [PubMed: 22429800]
534.: Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine. 2010; 363(26):2487–2498 [PubMed: 21175312]
535.: Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375(9717):807–815 [PubMed: 20206776]
536.: Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. New England Journal of Medicine. 2009; 361(6):594–604 [PubMed: 19657123]
537.: Lavitola P, Sampaio RO, Oliveira W, Boer BN, Tarasoutchi F, Spina GS et al. Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation. Arquivos Brasileiros de Cardiologia. 2010; 95(6):749–755 [PubMed: 20976374]
538.: Lawrence JC, Xabregas A, Gray L, Ham JM. Seasonal variation in the incidence of deep vein thrombosis. British Journal of Surgery. 1977; 64(11):777–780 [PubMed: 338089]
539.: Lawton R. Graduated compression as an adjunct to pharmacoprophylaxis in surgery (GAPS): the issues of recruiting to a multicenter trial in venous thromboembolism prevention. Journal of vascular surgery: venous and lymphatic disorders Conference: 2017 american venous forum annual meeting United states Conference start: 20170214 Conference end: 20170217. 2017; 5(1):165
540.: Le Gagneux F, Steg A, Le Guillou M. Subcutaneous enoxaparine (Lovenox) versus placebo for preventing deep vein thrombosis (DVT) after transurethral prostatectomy (TUP). Thrombosis and Haemostasis. 1987; 58:116
541.: Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Annals of Internal Medicine. 2006; 144(3):165–71 [PubMed: 16461960]
542.: Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer. 1994; 74(1):38–45 [PubMed: 8004580]
543.: Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F et al. Prevention of deep vein thrombosis after major knee surgery -- a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thrombosis and Haemostasis. 1992; 67(4):417–423 [PubMed: 1321509]
544.: Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L’Espérance B, Demers C et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Annals of Internal Medicine. 1996; 124(7):619–626 [PubMed: 8607589]
545.: Lecumberri R, Lopez VG, Font A, Gonzalez BE, Gurpide A, Gomez CJ et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study. Thrombosis Research. 2013; 132(6):666–670 [PubMed: 24491267]
546.: Lecumberri R, Panizo E, Gomez-Guiu A, Varea S, Garcia-Quetglas E, Serrano M et al. Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients. Journal of Thrombosis and Haemostasis. 2011; 9(6):1108–1115 [PubMed: 21481177]
547.: Legnani C, Maccaferri M, Palareti G, Ludovici S, Guazzaloca G, Marabini A et al. Perioperative prophylaxis with a low molecular weight heparin reduces late PAI-1 levels after gynaecological surgery. Fibrinolysis. 1990; 4(4):241–245
548.: Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. Journal of the American Medical Informatics Association. 1997; 4(1):49–56 [PMC free article: PMC61198] [PubMed: 8988474]
549.: Lenssen TA, van Steyn MJ, Crijns YH, Waltje EM, Roox GM, Geesink RJ et al. Effectiveness of prolonged use of continuous passive motion (CPM), as an adjunct to physiotherapy, after total knee arthroplasty. BMC Musculoskeletal Disorders. 2008; 9:60 [PMC free article: PMC2386789] [PubMed: 18442423]
550.: Levine MN, Gent M, Hirsh J, Weitz J, Turpie AG, Powers P et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Archives of Internal Medicine. 1996; 156(8):851–856 [PubMed: 8774203]
551.: Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Annals of Internal Medicine. 1991; 114(7):545–551 [PubMed: 1848054]
552.: Levitan B, Yuan Z, Turpie AGG, Friedman RJ, Homering M, Berlin JA et al. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vascular Health and Risk Management. 2014; 10:157–167 [PMC free article: PMC3971939] [PubMed: 24707185]
553.: Li B, Wang K, Zhao X, Lin C, Sun H. Comparison of fondaparinux sodium and low molecular weight heparin in the treatment of hypercoagulability secondary to traumatic infection. Chinese Journal of Traumatology. 2015; 18(3):147–9 [PubMed: 26643240]
554.: Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017; 390(10093):490–499 [PMC free article: PMC5537194] [PubMed: 28622955]
555.: Li S, Liu B, Xu D, Xu Y. Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials. PloS One. 2014; 9(4):e95354 [PMC free article: PMC3988190] [PubMed: 24736694]
556.: Li X-Y, Fan J, Cheng Y-Q, Wang Y, Yao C, Zhong N-S. Incidence and prevention of venous thromboembolism in acutely ill hospitalized elderly Chinese. Chinese Medical Journal. 2011; 124(3):335–340 [PubMed: 21362329]
557.: Lieberman JR, Huo MM, Hanway J, Salvati EA, Sculco TP, Sharrock NE. The prevalence of deep venous thrombosis after total hip arthroplasty with hypotensive epidural anesthesia. Journal of Bone and Joint Surgery. 1994; 76(3):341–348 [PubMed: 8126039]
558.: Lieberman JR, Pensak MJ. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. Journal of Bone and Joint Surgery (American Volume). 2013; 95(19):1801–1811 [PubMed: 24088973]
559.: Liew A, Douketis J. 4 risk assessment models had good calibration but poor discrimination for VTE in hospitalized medical patients. Annals of Internal Medicine. 2016; 165(6):JC35 [PubMed: 27653732]
560.: Liew AY, Piran S, Eikelboom JW, Douketis JD. Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials. Journal of Thrombosis and Thrombolysis. 2016; 30:30 [PubMed: 27900627]
561.: Lim W, Meade M, Lauzier F, Zarychanski R, Mehta S, Lamontagne F et al. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients. Critical Care Medicine. 2015; 43(2):401–410 [PubMed: 25474533]
562.: Limmer J, Ellbruck D, Muller H, Eisele E, Rist J, Schutze F et al. Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis. Clinical Investigator. 1994; 72(11):913–919 [PubMed: 7894222]
563.: Lin FF, Lin CH, Chen B, Zheng K. Combination prophylaxis versus pharmacologic prophylaxis alone for preventing deep vein thrombosis in hip surgery. Hip International. 2016; 26(6):561–566 [PubMed: 27739569]
564.: Lindqvist PG, Bremme K, Hellgren M. Efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of venous thromboembolism. Acta Obstetricia et Gynecologica Scandinavica. 2011; 90(6):648–653 [PubMed: 21314819]
565.: Lindqvist PG, Hellgren M. Obstetric thromboprophylaxis: the Swedish guidelines. Advances in Hematology. 2011; 2011:157483 [PMC free article: PMC3226316] [PubMed: 22162688]
566.: Lindqvist PG, Kublikas M, Dahlback B. Individual risk assessment of thrombosis in pregnancy. Acta Obstetricia et Gynecologica Scandinavica. 2002; 81(5):412–6 [PubMed: 12027814]
567.: Lindqvist PG, Torsson J, Almqvist A, Bjorgell O. Postpartum thromboembolism: severe events might be preventable using a new risk score model. Vascular Health and Risk Management. 2008; 4(5):1081–1087 [PMC free article: PMC2605344] [PubMed: 19183756]
568.: Lip GYH, Merino J, Ezekowitz M, Ellenbogen K, Zamoryakhin D, Lanz H et al. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The edoxaban vs. warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) study. American Heart Journal. 2015; 169(5):597–604 [PubMed: 25965706]
569.: Liu F, Chu X, Huang J, Tian K, Hua J, Tong P. Administration of enoxaparin 24 h after total knee arthroplasty: safer for bleeding and equally effective for deep venous thrombosis prevention. Archives of Orthopaedic and Trauma Surgery. 2014; 134(5):679–683 [PubMed: 24535621]
570.: Liu X, Liu C, Chen X, Wu W, Lu G. Comparison between Caprini and Padua risk assessment models for hospitalized medical patients at risk for venous thromboembolism: a retrospective study. Interactive Cardiovascular and Thoracic Surgery. 2016; 23(4):538–43 [PubMed: 27297558]
571.: Liu X, O’Rourke F, Van Nguyen H. Venous thromboembolism in psychogeriatric in-patients--a study of risk assessment, incidence, and current prophylaxis prescribing. International Psychogeriatrics. 2013; 25(6):913–7 [PubMed: 23425864]
572.: Lobastov K, Barinov V, Laberko L, Obolensky V, Boyarintsev V, Rodoman G. Electrical calf muscle stimulation with Veinoplus device in postoperative venous thromboembolism prevention. International Angiology. 2014; 33(1):42–49 [PubMed: 24452085]
573.: Locadia M, Bossuyt PM, Stalmeier PF, Sprangers MA, van Dongen CJ, Middeldorp S et al. Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences. Thrombosis and Haemostasis. 2004; 92(6):1336–41 [PubMed: 15583742]
574.: Loew D, Bruecke P, Simma W. Acetylsalicylic acid, low dose heparin, and a combination of both substances in the prevention of postoperative thromboembolism: a double blind study. Thrombosis Research. 1977; 11(1):81–86 [PubMed: 329468]
575.: Loew D, Wellmer HK, Baer U, Merguet H, Rumpf P, Petersen H et al. Postoperative thromboembolie-prophylaxe mit acetylsalicylsaure. Deutsche Medizinische Wochenschrift. 1974; 99(12):565–572 [PubMed: 4835526]
576.: Loffredo L, Perri L, Catasca E, Del BM, Angelico F, Violi F. Antithrombotic drugs in acutely ill medical patients: Review and meta-analysis of interventional trials with low-molecular-weight heparin and fondaparinux. Clinical Practice. 2013; 10(5):615–627
577.: Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. Journal of Clinical Pharmacy and Therapeutics. 2011; 36(1):111–124 [PubMed: 21198726]
578.: Lou J, Zhou YF, Wu MH, Huang JH. Effect of low-molecular heparin on therapeutic effect and renal function in patients with gastric cancer. World chinese journal of digestology. 2017; 25(3):276–280
579.: Louis SG, Van PY, Riha GM, Barton JS, Kunio NR, Underwood SJ et al. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial. Journal of Trauma and Acute Care Surgery. 2014; 76(4):937–3 [PubMed: 24662855]
580.: Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation. 2012; 126(4):448–54 [PubMed: 22679142]
581.: Low-molecular-weight heparin better than unfractionated heparin for preventing DVT in medical patients. Journal of the National Medical Association. 2008; 100(1):151
582.: Lowe LW. The role of anticoagulants in hip surgery. ‘In:’ McKibbin B, editor. Recent advances in orthopaedics No 3. Edinburgh: Churchill Livingstone. 1979. p. 31–55.
583.: Lowe LW. Venous thrombosis and embolism. Journal of Bone and Joint Surgery (British Volume). 1981; 63(2):155–167 [PubMed: 6163785]
584.: Lu J-P, Knudson MM, Bir N, Kallet R, Atkinson K. Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: A pilot study. Journal of the American College of Surgeons. 2009; 209(5):589–594 [PubMed: 19854398]
585.: Lubenow N, Hinz P, Thomaschewski S, Lietz T, Vogler M, Ladwig A et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood. 2010; 115(9):1797–1803 [PubMed: 19965682]
586.: Lunde L. Can EQ-5D and 15D be used interchangeably in economic evaluations? Assessing quality of life in post-stroke patients. Eur J Health Econ. 2013; 14(3):539–50 [PubMed: 22678657]
587.: Lundkvist J, Bergqvist D, Jonsson B. Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden. European Journal of Health Economics. 2003; 4(4):254–262 [PubMed: 15609193]
588.: Lyle B, Landercasper J, Johnson JM, Al-Hamadani M, Vang CA, Groshek J et al. Is the American College of Surgeons National Surgical Quality Improvement Program surgical risk calculator applicable for breast cancer patients undergoing breast-conserving surgery? American Journal of Surgery. 2016; 211(4):820–823 [PubMed: 26489987]
589.: Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. Journal of Clinical Oncology. 2015; 33(6):654–656 [PMC free article: PMC4881372] [PubMed: 25605844]
590.: Lynd LD, Goeree R, Crowther MA, O’Brien BJ. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma. Canadian Journal of Clinical Pharmacology. 2007; 14(2):e215–e226 [PubMed: 17652767]
591.: M.D. Anderson Cancer Center. Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients. NCT00966277. 2013. Available from: https://clinicaltrials.gov/show/NCT00966277 Last accessed: 28/06/17.
592.: Ma G, Zhang R, Wu X, Wang D, Ying K. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. Thrombosis Research. 2015; 135(5):816–822 [PubMed: 25728496]
593.: Macatangay C, Todd SR, Tyroch AH. Thromboembolic prophylaxis with intermittent pneumatic compression devices in trauma patients: a false sense of security? Journal of Trauma Nursing. 2008; 15(1):12–15 [PubMed: 18467942]
594.: Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K et al. Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. Journal of Clinical Oncology. 2016; 34(5):488–94 [PubMed: 26700124]
595.: MacCallum PK, Thomson JM, Poller L. Effects of fixed minidose warfarin on coagulation and fibrinolysis following major gynaecological surgery. Thrombosis and Haemostasis. 1990; 64(4):511–515 [PubMed: 2084936]
596.: Macht R, Gardner I, Talutis S, Rosenkranz P, Doherty G, McAneny D. Evaluation of a Standardized Risk-Based Venous Thromboembolism Prophylaxis Protocol in the Setting of Thyroid and Parathyroid Surgery. Journal of the American College of Surgeons. 2017; 01:01 [PubMed: 28161482]
597.: MacIntyre IMC, Vasilescu C, Jones DRB. Heparin versus dextran in the prevention of deep-vein thrombosis. A multi-unit controlled trial. Lancet. 1974; 2(7873):118–120 [PubMed: 4135556]
598.: Macoviak JA, Melnik G, McLean G. The effect of the low-dose heparin on the prevention of venous thrombosis in patients receiving short-term parenteral nutrition. Current Surgery. 1984; 41:98–100 [PubMed: 6426864]
599.: Maestre A, Trujillo-Santos J, Riera-Mestre A, Jimenez D, Di Micco P, Bascunana J et al. Identification of low-risk patients with acute symptomatic pulmonary embolism for outpatient therapy. Annals of the American Thoracic Society. 2015; 12(8):1122–9 [PubMed: 26114586]
600.: Mahan CE, Liu Y, Turpie AG, Vu JT, Heddle N, Cook RJ et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thrombosis and Haemostasis. 2014; 112(4):692–9 [PubMed: 24990708]
601.: Manganelli D, Pazzagli M, Mazzantini D, Punzi G, Manca M, Vignali C et al. Prolonged prophylaxis with unfractioned heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. Respiration. 1998; 65(5):369–374 [PubMed: 9782219]
602.: Maniscalco P, Caforio M, Imberti D, Porcellini G, Benedetti R. Apixaban versus enoxaparin in elective major orthopedic surgery: A clinical review. Clinical and Applied Thrombosis/Hemostasis. 2015; 21(2):115–119 [PubMed: 25125051]
603.: Manns BJ, Scott-Douglas N, Tonelli M, Ravani P, LeBlanc M, Dorval M et al. An economic evaluation of rt-PA locking solution in dialysis catheters. Journal of the American Society of Nephrology. 2014; 25(12):2887–95 [PMC free article: PMC4243340] [PubMed: 25012176]
604.: Mannucci PM, Citterio LE, Panajotopoulos N. Low-dose heparin and deep-vein thrombosis after total hip replacement. Thrombosis and Haemostasis. 1976; 36(1):157–164 [PubMed: 1036806]
605.: Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. Journal of Thrombosis and Haemostasis. 2016; 14(9):1773–8 [PMC free article: PMC5035574] [PubMed: 27273134]
606.: Manson JE. Current recommendations: what is the clinician to do? Fertility and Sterility. 2014; 101(4):916–21 [PubMed: 24680650]
607.: Maraveyas A, Ettelaie C, Echrish H, Li C, Gardiner E, Greenman J et al. Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. Blood Coagulation and Fibrinolysis. 2010; 21(5):452–458 [PubMed: 20386431]
608.: Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer. 2012; 48(9):1283–1292 [PubMed: 22100906]
609.: Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. American Journal of Medicine. 2001; 111(2):130–139 [PubMed: 11498067]
610.: Marchetti V, Beati C, Pogliani EM, Vincre G. Low-dose calcium-heparin prophylaxis in thoracic surgery. Bleeding, changes in coagulation and fibrinolysis. Minerva Medica. 1983; 74(28–29):1745–1748 [PubMed: 6866306]
611.: Marcy TR, Truong T, Rai A. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves. Consultant Pharmacist. 2015; 30(11):644–56 [PubMed: 26629800]
612.: Mariani F, Marone EM, Gasbarro V, Bucalossi M, Spelta S, Amsler F et al. Multicenter randomized trial comparing compression with elastic stocking versus bandage after surgery for varicose veins. Journal of Vascular Surgery. 2011; 53(1):115–122 [PubMed: 21050700]
613.: Maurer LH, Herndon IJ, Hollis DR, Aisner J, Carey RW, Skarin AT. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. Journal of Clinical Oncology. 1997; 15(11):3378–3387 [PubMed: 9363869]
614.: Maynard GA, Morris TA, Jenkins IH, Stone S, Lee J, Renvall M et al. Optimizing prevention of hospital-acquired venous thromboembolism (VTE): prospective validation of a VTE risk assessment model. Journal of Hospital Medicine (Online). 2010; 5(1):10–8 [PubMed: 19753640]
615.: Mayor S. Older patients should take PPIs to cut risk of bleed from aspirin, study says. BMJ. 2017; 357:j2865
616.: McAlister FA, Wiebe N, Jun M, Sandhu R, James MT, McMurtry MS et al. Are existing risk scores for nonvalvular atrial fibrillation useful for prediction or risk adjustment in patients with chronic kidney disease? Canadian Journal of Cardiology. 2017; 33(2):243–252 [PubMed: 27956042]
617.: McAlpine K, Breau RH, Mallick R, Cnossen S, Cagiannos I, Morash C et al. Current guidelines do not sufficiently discriminate venous thromboembolism risk in urology. Urologic Oncology. 2017; 14:14 [PubMed: 28214280]
618.: McBride JA, Turpie AG, Kraus V, Hilz C. Failure of aspirin and dipyridamole to influence the incidence of leg scan detected venous thrombosis after elective hip surgery. Thrombosis et Diathesis Haemorrhagica. 1975; 34(2):564 [PubMed: 1105877]
619.: McCaffrey R, Bishop M, Adonis-Rizzo M, Williamson E, McPherson M, Cruikshank A et al. Development and testing of a DVT risk assessment tool: providing evidence of validity and reliability. Worldviews on Evidence-Based Nursing. 2007; 4(1):14–20 [PubMed: 17355406]
620.: McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics. 2009; 27(10):829–846 [PubMed: 19803538]
621.: McCullagh L, Walsh C, Barry M. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting. Pharmacoeconomics. 2012; 30(10):941–959 [PubMed: 22667458]
622.: McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F et al. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: a Canadian analysis using the Ontario Ministry of Health perspective. Journal of Medical Economics. 2012; 15(5):817–828 [PubMed: 22494267]
623.: McGoldrick DM, Redmond HP. Venous thromboembolism prophylaxis risk assessment in a general surgery cohort: a closed-loop audit. Irish Journal of Medical Science. 2016:1–3 [PubMed: 27830442]
624.: McKenna R, Galante J, Bachmann F, Wallace DL, Kaushal PS, Meredith P. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. British Medical Journal. 1980; 280(6213):514–517 [PMC free article: PMC1601413] [PubMed: 6989432]
625.: McLean S, Ryan K, O’Donnell JS. Primary thromboprophylaxis in the palliative care setting: a qualitative systematic review. Palliative Medicine. 2010; 24(4):386–395 [PubMed: 20360427]
626.: McLintock C, Brighton T, Chunilal S, Dekker G, McDonnell N, McRae S et al. Recommendations for the prevention of pregnancy-associated venous thromboembolism. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2012; 52(1):3–13 [PubMed: 21950269]
627.: Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J et al. The responsiveness and validity of the CAMPHOR Utility Index. European Respiratory Journal. 2008; 32(6):1513–9 [PubMed: 18768576]
628.: Mearns BM. Thrombosis: a new scoring system for simple risk prediction in patients with unprovoked venous thromboembolism. Nature Reviews Cardiology. 2010; 7(6):299 [PubMed: 20521364]
629.: Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009; 374(9683):29–38 [PubMed: 19539361]
630.: Meizoso JP, Karcutskie CAt, Ray JJ, Ruiz X, Ginzburg E, Namias N et al. A simplified stratification system for venous thromboembolism risk in severely injured trauma patients. Journal of Surgical Research. 2017; 207:138–144 [PubMed: 27979470]
631.: Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis C. Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. Annals of Pharmacotherapy. 2010; 44(6):1061–1071 [PubMed: 20424181]
632.: Mellbring G, Palmér K. Prophylaxis of deep vein thrombosis after major abdominal surgery. Comparison between dihydroergotamine-heparin and intermittent pneumatic calf compression and evaluation of added graduated static compression. Acta Chirurgica Scandinavica. 1986; 152:597–600 [PubMed: 3544626]
633.: Melon E, Keravel Y, Gaston A, Huet Y, Combes S, Group N. Deep venous thrombosis prophylaxis by low molecular weight heparin in neurosurgical patients. Anesthesiology. 1991; 75:A214
634.: Messori A, Fadda V, Maratea D, Trippoli S, Marinai C. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation. International Journal of Clinical Pharmacology and Therapeutics. 2015; 53(3):211–219 [PubMed: 25295718]
635.: Metzger A, Nagaraj T. New oral anticoagulants: clinical parameters and uses in practice. Consultant Pharmacist. 2015; 30(6):329–345 [PubMed: 26048464]
636.: Meyer G, Sanchez O, Jimenez D. Risk assessment and management of high and intermediate risk pulmonary embolism. Presse Medicale. 2015; 44(12 Pt 2):e401–8 [PubMed: 26585742]
637.: Michot M, Conen D, Holtz D, Erni D, Zumstein MD, Ruflin GB et al. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low-molecular weight heparin. Arthroscopy. 2002; 18(3):257–263 [PubMed: 11877611]
638.: Migliaccio-Walle K, Rublee D, Simon TA. Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach. Postgraduate Medicine. 2012; 124(1):41–49 [PubMed: 22314113]
639.: Mihaljevic Z, Dimnjakovic D, Tripkovic B, Buljan M, Aljinovic A, Delimar D et al. Influence of fondaparinux versus nadroparin calcium thromboprophylaxis on clinical parameters following total knee arthroplasty. Acta Clinica Croatica. 2016; 55(3):414–420 [PubMed: 29045105]
640.: Millar JA, Gee AL. Estimation of clinical and economic effects of prophylaxis against venous thromboembolism in medical patients, including the effect of targeting patients at high-risk. Internal Medicine Journal. 2016; 46(3):315–24 [PubMed: 26749038]
641.: Mirdamadi A, Dashtkar S, Kaji M, Pazhang F, Haghpanah B, Gharipour M. Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial. ARYA Atherosclerosis. 2014; 10(6):292–297 [PMC free article: PMC4354081] [PubMed: 25815018]
642.: Mirhosseini SJ, Forouzannia SK, Mostafavi Pour Manshadi SMY, Ali-Hassan-Sayegh S, Naderi N, Sanatkar M. Comparison of aspirin plus heparin with heparin alone on asymptomatic perioperative deep vein thrombosis in candidates for elective off-pump coronary artery bypass graft: a randomized clinical trial. Cardiology Journal. 2013; 20(2):139–143 [PubMed: 23558871]
643.: Miron MJ, Perrier A, Bounameaux H. Clinical assessment of suspected deep vein thrombosis: comparison between a score and empirical assessment. Journal of Internal Medicine. 2000; 247(2):249–54 [PubMed: 10692088]
644.: Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmüller A, Juillard-Delsart D et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thrombosis and Haemostasis. 2000; 83(1):14–19 [PubMed: 10669147]
645.: Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. British Journal of Surgery. 2001; 88(7):913–930 [PubMed: 11442521]
646.: Mismetti P, Laporte S, Zufferey P, Epinat M, Decousus H, Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. Journal of Thrombosis and Haemostasis : JTH. 2004; 2(7):1058–1070 [PubMed: 15219187]
647.: Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thrombosis and Haemostasis. 2003; 90(2):235–44 [PubMed: 12888870]
648.: Mockler A, O’Brien B, Emed J, Ciccotosto G. The experience of patients with cancer who develop venous thromboembolism: an exploratory study. Oncology Nursing Forum. 2012; 39(3):E233–40 [PubMed: 22543394]
649.: Modi S, Deisler R, Gozel K, Reicks P, Irwin E, Brunsvold M et al. Wells criteria for DVT is a reliable clinical tool to assess the risk of deep venous thrombosis in trauma patients. World Journal of Emergency Surgery. 2016; 11:24 [PMC free article: PMC4898382] [PubMed: 27279896]
650.: Mokhtari M, Attarian H, Norouzi M, Kouchek M, Kashani BS, Sirati F et al. Venous thromboembolism risk assessment, prophylaxis practices and interventions for its improvement (AVAIL-ME Extension Project, Iran). Thrombosis Research. 2014; 133(4):567–73 [PubMed: 24507872]
651.: Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. Thrombosis and Haemostasis. 2013; 110(5) [PubMed: 23965805]
652.: Monreal M, Lafoz E, Roca J, Granero X, Soler J, Salazar X et al. Platelet count, antiplatelet therapy and pulmonary embolism -- a prospective study in patients with hip surgery. Thrombosis and Haemostasis. 1995; 73(3):380–385 [PubMed: 7667819]
653.: Morgan ES, Wilson E, Watkins T, Gao F, Hunt BJ. Maternal obesity and venous thromboembolism. International Journal of Obstetric Anesthesia. 2012; 21(3):253–63 [PubMed: 22647590]
654.: Morimoto A, Ueda Y, Yokoi T, Tokizawa Y, Yoshino K, Fujita M et al. Perioperative venous thromboembolism in patients with gynecological malignancies: a lesson from four years of recent clinical experience. Anticancer Research. 2014; 34(7):3589–3595 [PubMed: 24982374]
655.: Morris GK, Mitchell JR. Preventing venous thromboembolism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen. British Medical Journal. 1977; 1(6060):535–537 [PMC free article: PMC1605162] [PubMed: 843794]
656.: Morris RJ, Woodcock JP. Intermittent pneumatic compression or graduated compression stockings for deep vein thrombosis prophylaxis? A systematic review of direct clinical comparisons. Annals of Surgery. 2010; 251(3):393–396 [PubMed: 20083996]
657.: Moskovitz PA, Ellenberg SS, Feffer HL, Kenmore P, I, Neviaser RJ, Rubin BE et al. Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. Journal of Bone and Joint Surgery. 1978; 60(8):1065–1070 [PubMed: 363722]
658.: Mozafar M, Samsami M, Sobhiyeh MR, Jabbehdari S, Fallah Zavareh M. Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourol Mon. 2013; 5(2):762–5 [PMC free article: PMC3703136] [PubMed: 23841041]
659.: Mueller K, Bernaitis N, Badrick T, Anoopkumar-Dukie S. HAS-BLED Predicts Warfarin Control in Australian Patients treated for Deep Vein Thrombosis. Basic & Clinical Pharmacology & Toxicology. 2016; 08:08 [PubMed: 27718518]
660.: Muir KW. The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism. Stroke. 2008; 39(7):2174–2176 [PubMed: 18436873]
661.: Murugesan A, Srivastava DN, Ballehaninna UK, Chumber S, Dhar A, Misra MC et al. Detection and prevention of post-operative deep vein thrombosis [DVT] using nadroparin among patients undergoing major abdominal operations in India; a randomised controlled trial. Indian Journal of Surgery. 2010; 72(4):312–317 [PMC free article: PMC3002774] [PubMed: 21938194]
662.: Myhre HO, Holen A. Thrombosis prophylaxis. Dextran or warfarin-sodium? A controlled clinical study. Nordisk Medicin. 1969; 82(49):1534–1538 [PubMed: 5372427]
663.: Naccarato M, Chiodo GF, Dennis M, Sandercock Peter AG. Physical methods for preventing deep vein thrombosis in stroke. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD001922. DOI: 10.1002/14651858.CD001922.pub3. [PMC free article: PMC9896018] [PubMed: 20687069] [CrossRef]
664.: Nakase J, Toribatake Y, Mouri Y, Seki H, Kitaoka K, Tomita K. Heparin versus danaproid for prevention of venous thromboembolism after hip surgery. Journal of Orthopaedic Surgery. 2009; 17(1):6–9 [PubMed: 19398784]
665.: Nam D, Nunley RM, Johnson SR, Keeney JA, Clohisy JC, Barrack RL. The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty. Journal of Arthroplasty. 2016; 31(6):1299–306 [PubMed: 26777547]
666.: National Clinical Guideline Centre. Venous thromoembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) inpatients admitted to hospital. NICE clinical guideline 92. London. National Clinical Guideline Centre, 2010. Available from: http://www.nice.org.uk/CG92 [PubMed: 20478866]
667.: National Clinical Guideline Centre. Lower limb peripheral arterial disease: Diagnosis and management. NICE clinical guideline 147. London. National Clinical Guideline Centre, 2012. Available from: http://guidance.nice.org.uk/CG147
668.: National Clinical Guideline Centre. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NICE clinical guideline 144. London. National Clinical Guideline Centre, 2012. Available from: http://guidance.nice.org.uk/CG144
669.: National Clinical Guideline Centre. Type 1 diabetes in adults: diagnosis and management. NICE guideline 17. London. National Clinical Guideline Centre, 2015. Available from: https://www.nice.org.uk/guidance/ng17
670.: National Colloborating Centre for Acute Care. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. NICE clinical guideline CG46. London. National Institute for Health and Clinical Excellence, 2007. Available from: http://guidance.nice.org.uk/CG46
671.: National Horizon Scanning Centre. Rivaroxaban (Xarelto) for prevention of venous thromboembolism in medically ill patients. Birmingham. National Horizon Scanning Centre (NHSC), 2010. Available from: http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010001209/frame.html
672.: National Horizon Scanning Centre (NHSC). Apixaban for prevention of venous thromboembolism after joint replacement or with acute medical illness. (NHSC) NHSC, 2008. Available from: http://www.hsric.nihr.ac.uk/topics/apixaban-bms-562247-01-for-venous-thromboembolism-prevention-after-joint-replacement-and-acute-medical-illness/
673.: National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview [PubMed: 26677490]
674.: National Institute for Health and Care Excellence. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 354. London. National Institute for Health and Care Excellence, 2015. Available from: https://www.nice.org.uk/guidance/ta354/resources/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism-82602668308165
675.: National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. NICE technology appraisal guidance 157. London. National Institute for Health and Clinical Excellence, 2008. Available from: http://guidance.nice.org.uk/TA157
676.: National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd ed. London. National Institute for Health and Clinical Excellence,. 2008. Available from: https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf [PubMed: 27905706]
677.: National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of venous thromboembolism. NICE technology appraisal guidance 170. London. National Institute for Health and Clinical Excellence, 2009. Available from: http://guidance.nice.org.uk/TA170
678.: National Institute for Health and Clinical Excellence. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance 245. London. National Institute for Health and Clinical Excellence, 2012. Available from: http://guidance.nice.org.uk/TA245
679.: Navarro LM, Trufelli DC, Bonito DR, Del Giglio A, Bollmann PW. Application of Prognostic Score IPSET-thrombosis In patients with essential thrombocythemia of a brazilian public service. Revista da Associacao Medica Brasileira. 2016; 62(7):647–651 [PubMed: 27925044]
680.: Nemeth B, van Adrichem RA, van Hylckama Vlieg A, Bucciarelli P, Martinelli I, Baglin T et al. Venous thrombosis risk after cast immobilization of the lower extremity: derivation and validation of a clinical prediction score, L-TRiP(cast), in three population-based case-control studies. PLoS Medicine. 2015; 12(11):e1001899; discussion e1001899 [PMC free article: PMC4640574] [PubMed: 26554832]
681.: Nendaz MR, Bandelier P, Aujesky D, Cornuz J, Roy PM, Bounameaux H et al. Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. Thrombosis and Haemostasis. 2004; 91(6):1232–6 [PubMed: 15175812]
682.: NHS Business Services Authority. NHS electronic drug tariff June 2016. 2015. Available from: http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx Last accessed: 09/08/2017.
683.: NHS Digital. Finalised Patient Reported Outcome Measures (PROMs) in England: April 2014 to March 2015. NHS Digital, 2016. Available from: http://content.digital.nhs.uk/catalogue/PUB21189
684.: NHS Supply Chain Catalogue. Chain NS, 2015. Available from: http://www.supplychain.nhs.uk/
685.: NHS Supply Chain Catalogue. 2015. Available from: http://www.supplychain.nhs.uk/ Last accessed: 22/08/2016.
686.: Nicolaides AN, Dupont PA, Desai S, Lewis JD, Douglas JN, Dodsworth H et al. Small doses of subcutaneous sodium heparin in preventing deep venous thrombosis after major surgery. Lancet. 1972; 2(7783):890–893 [PubMed: 4116600]
687.: Nieto JA, Solano R, Trapero Iglesias N, Ruiz-Gimenez N, Fernandez-Capitan C, Valero B et al. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Thrombosis Research. 2013; 132(2):175–9 [PubMed: 23849097]
688.: Nighoghossian N, Berthezene Y, Mechtouff L, Derex L, Cho TH, Ritzenthaler T et al. Cyclosporine in acute ischemic stroke. Neurology. 2015; 84(22):2216–2223 [PubMed: 25948727]
689.: NIHR Horizon Scanning Centre (NIHR HSC). Apixaban (Eliquis) for the treatment and prevention of venous thromboembolic events. Birmingham. NIHR Horizon Scanning Centre (NIHR HSC), 2013. Available from: http://www.hsric.nihr.ac.uk/topics/apixaban-eliquis-for-the-treatment-and-long-term-prevention-of-deep-vein-thrombosis-and-pulmonary-embolism/
690.: NIHR Horizon Scanning Centre (NIHR HSC). Betrixaban for the prevention of venous thromboembolism? first line. Birmingham. NIHR Horizon Scanning Centre (NIHR HSC), 2014. Available from: file:///C:/Users/clairewallnutt/Downloads/2671.05e728c7.Betrixaban_Sept14.pdf
691.: Ning GZ, Kan SL, Chen LX, Shangguan L, Feng SQ, Zhou Y. Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials. Scientific Reports. 2016; 6:23726 [PMC free article: PMC4810418] [PubMed: 27020475]
692.: Noble S, Lewis R, Whithers J, Lewis S, Bennett P. Long-term psychological consequences of symptomatic pulmonary embolism: a qualitative study. BMJ Open. 2014; 4(4):e004561 [PMC free article: PMC3987719] [PubMed: 24694625]
693.: Noble S, Maraveyas A, Matzdorff A, Holm MV, Pisa G. Patients’ preferences for the treatment of cancer associated thrombosis. Journal of Thrombosis and Haemostasis. 2015; 13:548–549
694.: Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G. Assessing patients’ anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica. 2015; 100(11):1486–92 [PMC free article: PMC4825304] [PubMed: 26294737]
695.: Noble S, Prout H, Nelson A. Patients’ Experiences of LIving with CANcer-associated thrombosis: The PELICAN study. Patient Preference and Adherence. 2015; 9:337–345 [PMC free article: PMC4348145] [PubMed: 25750522]
696.: Noble S, Seaman S, Nelson A. Attitudes of cancer associated thrombosis patients to the novel oral anticoagulants: Insights from qualitative interviews. Thrombosis Research. 2014; 133:S219
697.: Noble S, Seaman S, Nelson A. The burden of venous thromboembolism on the cancer patient experience: A qualitative study. Thrombosis Research. 2014; 133:S212–S213
698.: Noble SIR, Nelson A, Finlay IG. Factors influencing hospice thromboprophylaxis policy: A qualitative study. Palliative Medicine. 2008; 22(7):808–813 [PubMed: 18772209]
699.: Nordenholz KE, Thompson E, Trujillo T, Misky G. Qualitative folllow up of emergency department (ED) patients discharged on rivaroxaban for low risk venous thromboembolism. Journal of Thrombosis and Haemostasis. 2015; 13:644
700.: Norgren L, S. T-L, Magyar G, Lindstrand A, Albrechtsson U. Prevention of deep vein thrombosis in knee arthroplasty. Preliminary results from a randomized controlled study of low molecular weight heparin vs foot pump compression. International Angiology. 1998; 17(2):93–96 [PubMed: 9754896]
701.: Novis SJ, Havelka GE, Ostrowski D, Levin B, Blum-Eisa L, Prystowsky JB et al. Prevention of thromboembolic events in surgical patients through the creation and implementation of a computerized risk assessment program. Journal of Vascular Surgery. 2010; 51(3):648–54 [PubMed: 20022209]
702.: Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d’Azemar P et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thrombosis and Haemostasis. 1996; 75(2):233–238 [PubMed: 8815566]
703.: Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, van Rij AM et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. American Journal of Surgery. 1995; 169(6):567–71 [PubMed: 7771617]
704.: O’Connor C, Moriarty J, Walsh J, Murray J, Coulter-Smith S, Boyd W. The application of a clinical risk stratification score may reduce unnecessary investigations for pulmonary embolism in pregnancy. Journal of Maternal-Fetal & Neonatal Medicine. 2011; 24(12):1461–4 [PubMed: 21854126]
705.: O’Sullivan EF, Renney JT. Antiplatelet drugs in the prevention of postoperative deep vein thrombosis. Proceedings of III Congress of International Society for Thrombosis and Haemostasis (Washington). 1972. p. 438.
706.: Obi AT, Alvarez R, Reames BN, Moote MJ, Thompson MA, Wakefield TW et al. A prospective evaluation of standard versus battery-powered sequential compression devices in postsurgical patients. American Journal of Surgery. 2015; 209(4):675–681 [PubMed: 25812845]
707.: Obolenskiy VN, Karpenko AV. Efficacy of electrical muscle stimulation in the treatment of patients with shin bone fractures. Wound Medicine. 2014; 5:25–28
708.: Office for National Statistics. ‘Average’ Briton highlighted on UN World Statistics Day. Office for National Statistics. Available from: https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwih1-mazv7UAhVBDMAKHcuABxQQFggpMAA&url=https%3A%2F%2Fwww.ons.gov.uk%2Fons%2Fabout-ons%2Fget-involved%2Fevents%2Fevents%2Fun-world-statictics-day%2F-average--briton-highlighted-on-un-world-statistics-day.pdf&usg=AFQjCNGiyo3NVKsSFZ8tV6sYiYtVWQPd2w
709.: Okoye O, Gelbard R, Inaba K, Esparza M, Belzberg H, Talving P et al. Dalteparin versus Enoxaparin for the prevention of venous thromboembolic events in trauma patients. European Journal of Trauma and Emergency Surgery. 2014; 40(2):183–189 [PubMed: 26815899]
710.: Okumus G, Engin Unver R, Kiyan E, Tabak L, Issever H, Arseven O. Comparison of three clinical scoring methods in patients with pulmonary thromboembolism. Tuberkuloz ve Toraks. 2009; 57(2):163–8 [PubMed: 19714507]
711.: Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011; 342:d124 [PMC free article: PMC3031123] [PubMed: 21282258]
712.: Olesen JB, Lip GY, Lane DA, Kober L, Hansen ML, Karasoy D et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. American Journal of Medicine. 2012; 125(8):826.e13–23 [PubMed: 22579139]
713.: Ollenberger GP, Worsley DF. Effect of patient location on the performance of clinical models to predict pulmonary embolism. Thrombosis Research. 2006; 118(6):685–90 [PubMed: 16380153]
714.: Ongen G, Demir M, Molinas N, Ince B, Ongen Z. Evaluation of the practice pattern of medical patients’ VTE Prophylaxis with a standard risk assessment model form: MERAM study. Clinical and Applied Thrombosis/Hemostasis. 2015; 21(5):412–9 [PubMed: 24113493]
715.: Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2012. Available from: http://www.oecd.org/std/ppp Last accessed: 09/05/2016.
716.: Orken DN, Kenangil G, Ozkurt H, Guner C, Gundogdu L, Basak M et al. Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage. Neurologist. 2009; 15(6):329–331 [PubMed: 19901711]
717.: Overcash RT, Somers AT, Lacoursiere DY. Enoxaparin dosing after cesarean delivery in morbidly obese women. Obstetrics and Gynecology. 2015; 125(6):1371–1376 [PubMed: 26000508]
718.: Oz N, Alon D, Chezar-Azerrad C, Cooper L, Levi Y, Fuchs S et al. Estimating Risk of Venous-Thromboembolic Events in Hospitalized Medical Patients: Comparison between 2008 and 2012 Guidelines. Israel Medical Association Journal: Imaj. 2016; 18(6):346–9 [PubMed: 27468528]
719.: Ozler T, Ulucay C, Onal A, Altintas F. Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement. Acta Orthopaedica et Traumatologica Turcica. 2015; 49(3):255–259 [PubMed: 26200403]
720.: Paciaroni M, Ageno W, Agnelli G. Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin. Thrombosis and Haemostasis. 2008; 99(5):978–980 [PubMed: 18449438]
721.: Pai M, Lloyd NS, Cheng J, Thabane L, Spencer FA, Cook DJ et al. Strategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial. Implementation Science. 2013; 8:1 [PMC free article: PMC3547806] [PubMed: 23279972]
722.: Paiement GD, Wessinger SJ, Walter AC, Harris WH. Low dose warfarin versus external pneumatic compression against venous thromboembolism following total hip replacement. Journal of Arthroplasty. 1987; 2(1):23–26 [PubMed: 3572408]
723.: Palareti G, Borghi B, Coccheri S, Leali N, Golfieri R, Montebugnoli M et al. Postoperative versus preoperative initiation of deep-vein thrombosis prophylaxis with a low-molecular-weight heparin (Nadroparin) in elective hip replacement. Clinical and Applied Thrombosis/Hemostasis. 1996; 2(1):18–24
724.: Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. Journal of Clinical Oncology. 2011; 29(8):986–993 [PubMed: 21282540]
725.: Pannucci C, Laird S, Campbell D, Dimick J, Henke P. Creation of a Simple VTE Risk Stratification Tool for Inpatient Surgical Procedures. Journal of Vascular Surgery. 2013; 1(1):101–2 [PubMed: 26993906]
726.: Pannucci CJ, Bailey SH, Dreszer G, Fisher Wachtman C, Zumsteg JW, Jaber RM et al. Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. Journal of the American College of Surgeons. 2011; 212(1):105–12 [PMC free article: PMC3052944] [PubMed: 21093314]
727.: Pannucci CJ, Barta RJ, Portschy PR, Dreszer G, Hoxworth RE, Kalliainen LK et al. Assessment of postoperative venous thromboembolism risk in plastic surgery patients using the 2005 and 2010 Caprini risk score. Plastic and Reconstructive Surgery. 2012; 130(2):343–53 [PMC free article: PMC4505816] [PubMed: 22495215]
728.: Pannucci CJ, Basta MN, Fischer JP, Kovach SJ. Creation and validation of a condition-specific venous thromboembolism risk assessment tool for ventral hernia repair. Surgery. 2015; 158(5):1304–13 [PubMed: 25958062]
729.: Pannucci CJ, Swistun L, MacDonald JK, Henke PK, Brooke BS. Individualized venous thromboembolism risk stratification using the 2005 Caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: a meta-analysis. Annals of Surgery. 2017; Epublication [PubMed: 28106607]
730.: Parilla BV, Fournogerakis R, Archer A, Sulo S, Laurent L, Lee P et al. Diagnosing pulmonary embolism in pregnancy: are biomarkers and clinical predictive models useful? American Journal of Perinatology Reports. 2016; 6(2):e160–4 [PMC free article: PMC4844549] [PubMed: 27119048]
731.: Parodi JC, Grandi A, Font E, Rotondaro D, Iorio J, Manrique J. EI dipiridamol y el acido acetilsalicilico en la profilaxis de las trombosis venosas postoperatorias de los miembros inferiores. Dia Medico. 1973; 45:92–93
732.: Patel AA, Nelson WW, Schein J. Impact of CHA<inf>2</inf>DS<inf>2</inf>VASc Score on Candidacy for Anticoagulation in Patients With Atrial Fibrillation: A Multi-payer Analysis. Clinical Therapeutics. 2016; 38(10):2196–2203 [PubMed: 27671867]
733.: Patel AR, Crist MK, Nemitz J, Mayerson JL. Aspirin and compression devices versus low-molecular-weight heparin and PCD for VTE prophylaxis in orthopedic oncology patients. Journal of Surgical Oncology. 2010; 102(3):276–281 [PubMed: 20740587]
734.: Patel N, Khakha R, Gibbs J. Review article: Anti-embolism stockings. Journal of Orthopaedic Surgery. 2013; 21(3):361–364 [PubMed: 24366800]
735.: Pathak R, Karmacharya P, Giri S, Poudel DR, Aryal MR, Bhatt VR et al. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients. Blood Coagulation and Fibrinolysis. 2015; 26(6):635–642 [PubMed: 26236940]
736.: Pathak R, Pandit A, Karmacharya P, Aryal MR, Ghimire S, Poudel DR et al. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. American Journal of Cardiology. 2015; 115(3):323–327 [PubMed: 25527282]
737.: Pavon JM, Williams JW, Jr., Adam SS, Razouki ZA, McDuffie JR, Lachiewicz PF et al. Effectiveness of intermittent pneumatic compression devices for venous thromboembolism prophylaxis in high-risk surgical and medical patients. Durham, NC. Evidence-based Synthesis Program (ESP) Center, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0084045/pdf/PubMedHealth_PMH0084045.pdf [PubMed: 26677487]
738.: Pebanco GD, Kaiser SA, Haines ST. New pharmacologic methods to prevent venous thromboembolism in older adults: a meta-analysis. Annals of Pharmacotherapy. 2013; 47(5):605–616 [PubMed: 23606553]
739.: Penaloza A, Melot C, Motte S. Comparison of the Wells score with the simplified revised Geneva score for assessing pretest probability of pulmonary embolism. Thrombosis Research. 2011; 127(2):81–4 [PubMed: 21094985]
740.: Pengo V, Banzato A, Bison E, Zoppellaro G, Padayattil Jose S, Denas G. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus. 2016; 25(3):301–6 [PubMed: 26466613]
741.: Perka C. Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: Safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants. Thrombosis Journal. 2011; 16(9):17 [PMC free article: PMC3228673] [PubMed: 22087515]
742.: Pettila V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thrombosis Research. 1999; 96(4):275–282 [PubMed: 10593430]
743.: Pezzuoli G, Neri-Serneri GG, Settembrini PG, Coggi G, Olivari N, Negri G et al. Effectiveness and safety of the low-molecular-weight heparin CY 216 in the prevention of fatal pulmonary embolism and thromboembolic death in general surgery. A multicentre, double-blind, randomized, controlled clinical trial versus placebo (STEP). STEP Study Group. Haemostasis. 1990; 20:(Suppl 1):193–204 [PubMed: 1964662]
744.: Pezzuoli G, Neri Serneri GG, Settembrini P, Coggi G, Olivari N, Buzzetti G et al. Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group. International Surgery. 1989; 74(4):205–210 [PubMed: 2560470]
745.: Phan M, John S, Casanegra AI, Rathbun S, Mansfield A, Stoner JA et al. Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. Journal of Thrombosis and Thrombolysis. 2014; 38(2):241–249 [PMC free article: PMC4427894] [PubMed: 24233387]
746.: Phelan HA, Wolf SE, Norwood SH, Aldy K, Brakenridge SC, Eastman AL et al. A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study. Journal of Trauma and Acute Care Surgery. 2012; 73(6):1434–1441 [PubMed: 22914079]
747.: Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D et al. Prognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrillation’ and valvular heart disease: the Loire Valley Atrial Fibrillation Project. European Heart Journal. 2015; 36(28):1822–30 [PubMed: 25994754]
748.: Phung OJ, Kahn SR, Cook DJ, Murad MH. Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest. 2011; 140(2):374–381 [PubMed: 21349929]
749.: Piazza G, Rosenbaum EJ, Pendergast W, Jacobson JO, Pendleton RC, McLaren GD et al. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation. 2009; 119(16):2196–201 [PMC free article: PMC2901546] [PubMed: 19364975]
750.: Pince J. Thromboses veineuses des membres inferieurs et embolies pulmonaires au cours des accidents vasculaires cerebraux. A propos d’un essai comparitif de traitement preventif (These pour le doctorat d’etat en medecine). 1981.
751.: Pineo GF, Gallus AS, Raskob GE, Chen D, Ramirez LM, Ramacciotti E et al. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis. 2013; 11(3):444–451 [PubMed: 23279103]
752.: Pinto DJ. Controlled trial of an anticoagulant (warfarin sodium) in the prevention of venous thrombosis following hip surgery. British Journal of Surgery. 1970; 57(5):349–352 [PubMed: 5427880]
753.: Piovella C, Dalla Valle F, Trujillo-Santos J, Pesavento R, Lopez L, Font L et al. Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry. Internal and Emergency Medicine. 2014; 9(8):847–52 [PubMed: 24839226]
754.: Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5):1093–100 [PubMed: 20299623]
755.: Pitt A, Anderson ST, Habersberger PG, Rosengarten DS. Low dose heparin in the prevention of deep-vein thromboses in patients with acute myocardial infarction. American Heart Journal. 1980; 99(5):574–578 [PubMed: 7369096]
756.: Pitto RP, Young S. Foot pumps without graduated compression stockings for prevention of deep-vein thrombosis in total joint replacement: efficacy, safety and patient compliance. A comparative, prospective clinical trial. International Orthopaedics. 2008; 32(3):331–336 [PMC free article: PMC2323417] [PubMed: 17653546]
757.: Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Compan D et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. Drugs. 1996; 52: Suppl 7:47–54 [PubMed: 9042560]
758.: Planès A, Vochelle N, Fagola M, Bellaud M, Feret J, Salzard C et al. Once-daily dosing of enoxaparin (a low molecular weight heparin) in prevention of deep vein thrombosis after total hip replacement. Acta Chirurgica Scandinavica Supplementum. 1990; 556:108–115 [PubMed: 1963015]
759.: Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thrombosis and Haemostasis. 1988; 60(3):407–410 [PubMed: 2853459]
760.: Plante J, Boneu B, Vaysse C. Dipyridamole-aspirin versus low doses of heparin in the prophylaxis of deep venous thrombosis in abdominal surgery. Thrombosis Research. 1979; 14(2–3):399–403 [PubMed: 442014]
761.: Plitt A, Giugliano RP. Edoxaban: Review of pharmacology and key phase I to III clinical trials. Journal of Cardiovascular Pharmacology and Therapeutics. 2014; 19(5):409–416 [PubMed: 24607764]
762.: Ploumis A, Ponnappan RK, Maltenfort MG, Patel RX, Bessey JT, Albert TJ et al. Thromboprophylaxis in patients with acute spinal injuries: an evidence-based analysis. Journal of Bone and Joint SurgeryAmerican Volume. 2009; 91(11):2568–2576 [PubMed: 19884429]
763.: Pohar R, Argaez C. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism: a comparative clinical and cost-effectiveness review. Toronto. Canadian Agency for Drugs and Technologies in Health (CADTH), 2008. Available from: https://www.cadth.ca/sites/default/files/pdf/htis/L0051%20%20Fondaparinux%20vs.%20Enoxaparin%20for%20Thromboembolism%20final.pdf
764.: Poller L, McKernan A, Thomson JM, Elstein M, Hirsch PJ, Jones JB. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. British Medical Journal. 1987; 295(6609):1309–1312 [PMC free article: PMC1248380] [PubMed: 3120989]
765.: Poller L, Thomson JM, MacCallum PK, Nicholson DA, Weighill FJ, Lemon JG. Minidose warfarin and failure to prevent deep vein thrombosis after joint replacement surgery despite inhibiting the postoperative rise in plasminogen activator inhibitor activity. Clinical and Applied Thrombosis/Hemostasis. 1995; 1(4):267–273
766.: Postma MJ, Kappelhoff BS, Hulst M, Brouwers JR. Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands. Journal of Medical Economics. 2012; 15(5):878–886 [PubMed: 22563715]
767.: Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs. 2012; 72(13):1739–1753 [PubMed: 22931521]
768.: Poultsides LA, Gonzalez Della Valle A, Memtsoudis SG, Ma Y, Roberts T, Sharrock N et al. Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. Journal of Bone and Joint Surgery (British Volume). 2012; 94(1):113–121 [PubMed: 22219258]
769.: Pour AE, Keshavarzi NR, Purtill JJ, Sharkey PF, Parvizi J. Is venous foot pump effective in prevention of thromboembolic disease after joint arthroplasty: a meta-analysis. Journal of Arthroplasty. 2013; 28(3):410–417 [PubMed: 23102505]
770.: Powers PJ, Gent M, Jay RM, Julian DH, Turpie AG, Levine M et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Archives of Internal Medicine. 1989; 149(4):771–774 [PubMed: 2650646]
771.: Prandoni P, Bruchi O, Sabbion P, Tanduo C, Scudeller A, Sardella C et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine. 2002; 162(17):1966–1971 [PubMed: 12230419]
772.: Prandoni P, Noventa F, Quintavalla R, Bova C, Cosmi B, Siragusa S et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood. 2012; 119(6):1561–1565 [PubMed: 22180438]
773.: Press A, Rosenberg D, Fishbein J, Batliwalla F, Spyropoulos AC. External validation of a risk assesment model for bleeding risk in medical patients: findings from the improve investigators in a tertiary health system. Blood. 2015; 126(23):748–748
774.: Prins MH, Bamber L, Cano SJ, Wang MY, Erkens P, Bauersachs R et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research. 2015; 135(2):281–288 [PubMed: 25483215]
775.: Prins MH, Lensing, Brighton TA, Lyons RM, Rehm J, Trajanovic M et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): A pooled subgroup analysis of two randomised controlled trials. Lancet Haematology. 2014; 1(1):e37–e46 [PubMed: 27030066]
776.: Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355(9212):1295–1302 [PubMed: 10776741]
777.: Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P, Physicians CGCotACo. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American college of physicians. Annals of Internal Medicine. 2011; 155(9):625–632 [PubMed: 22041951]
778.: Quinlan DJ. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. Journal of Thrombosis and Haemostasis. 2007; 5(7):1438–1443 [PubMed: 17425687]
779.: Qushmaq NA, Al-Emadi SA. Review on effectiveness of primary prophylaxis in aPLs with and without risk factors for thrombosis: efficacy and safety. ISRN Rheumatology. 2014; 2014:348726 [PMC free article: PMC4040209] [PubMed: 24944829]
780.: Rachidi S, Aldin ES, Greenberg C, Sachs B, Streiff M, Zeidan AM. The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Review of Hematology. 2013; 6(6):677–695 [PMC free article: PMC4124620] [PubMed: 24219550]
781.: Rada G, Schunemann HJ, Labedi N, El-Hachem P, Kairouz VF, Akl EA. Systematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancer. BMC Cancer. 2013; 13:76 [PMC free article: PMC3579688] [PubMed: 23406262]
782.: Rahn DD, Mamik MM, Sanses TVD, Matteson KA, Aschkenazi SO, Washington BB et al. Venous thromboembolism prophylaxis in gynecologic surgery: a systematic review. Obstetrics and Gynecology. 2011; 118(5):1111–1125 [PubMed: 22015880]
783.: Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). British Medical Journal. 1997; 314(7076):253–257 [PMC free article: PMC2125731] [PubMed: 9022487]
784.: Rajasekhar A, Lottenberg L, Lottenberg R, Feezor RJ, Armen SB, Liu H et al. A pilot study on the randomization of inferior vena cava filter placement for venous thromboembolism prophylaxis in high-risk trauma patients. Journal of Trauma. 2011; 71(2):323–9 [PubMed: 21825934]
785.: Ramos J, Perrotta C, Badariotti G, Berenstein G. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD005259. DOI: 10.1002/14651858.CD005259.pub3. [PubMed: 18843687] [CrossRef]
786.: Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC et al. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clinical and Applied Thrombosis/Hemostasis. 2016; 16:16 [PMC free article: PMC5685501] [PubMed: 27637910]
787.: Ramos R, Salem B, I, De Pawlikowski MP, Coordes C, Eisenberg S, Leidenfrost R. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest. 1996; 109(1):82–85 [PubMed: 8549224]
788.: Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. Journal of Bone and Joint Surgery (British Volume). 2012; 94(2):257–264 [PubMed: 22323697]
789.: Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thrombosis and Haemostasis. 2016; 115(6):1240–8 [PubMed: 26842902]
790.: Rasmussen MS, Jørgensen LN, Wille-Jørgensen P. Prolonged thromboprophylaxis with Low Molecular Weight heparin for abdominal or pelvic surgery. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD004318. DOI: 10.1002/14651858.CD004318.pub2. [PubMed: 19160234] [CrossRef]
791.: RE-MOBILIZE Writing Committee. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. Journal of Arthroplasty. 2009; 24(1):1–9 [PubMed: 18534438]
792.: RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. Journal of Arthroplasty. 2009; 24(1):1–9 [PubMed: 18534438]
793.: Reeves P, Cooke J, Lloyd A, Hutchings A. An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy. Pharmacy World and Science. 2004; 26(3):160–168 [PubMed: 15230364]
794.: Registry NJ. National Joint Registry for England and Wales 6th annual report. 2009. Available from: http://www-new.njrcentre.org.uk/njrcentre/Portals/0/Sixth%20annual%20NJR%20report.pdf
795.: Reilmann H, Bosch U, Creutzig H, Oetting G, Fuchs I, Tscherne H. Thromboseprophylaxe mit niedermolekularem Heparin plus Dihydroergotamin be Operationen an den unteren Extremitäten. Perfusion. 1989:230–234
796.: Renney JT, O’Sullivan EF, Burke PF. Prevention of postoperative deep vein thrombosis with dipyridamole and aspirin. British Medical Journal. 1976; 1(6016):992–994 [PMC free article: PMC1639649] [PubMed: 773495]
797.: Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. Postgraduate Medicine. 2013; 125(4):141–153 [PubMed: 23933902]
798.: Ribaudo JM, Hoellrich RG, McKinnon W-MP, Shuler SE. Evaluation of mini dose heparin administration as a prophylaxis against postoperative pulmonary embolization: a prospective double blind study. Review of Surgery. 1975; 32(4):297–299 [PubMed: 1198038]
799.: Ribaudo JM, Hoellrich RG, McKinnon WM, Shuler SE. Evaluation of mini-dose heparin administration as a prophylaxis against postoperative pulmonary embolism: a prospective double-blind study. American Surgeon. 1975; 41(5):289–295 [PubMed: 1093461]
800.: Ribic C, Lim W, Cook D, Crowther M. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. Journal of Critical Care. 2009; 24(2):197–205 [PubMed: 19327323]
801.: Riemsma R, Joore MA, Armstrong N, Misso K, Noake C. Apixaban for the prevention of venous thromboembolism in people undergoing elective knee and hip replacement surgery. Southampton. NETSCC, 2011. Available from: http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0003/96501/STAReport-09-124-01.pdf
802.: Riess H, Pelzer U, Deutschinoff G, Opitz B, Stauch M, Reitzig P et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. Journal of Clinical Oncology. 2009; 27(18 Suppl. 1):LBA4506
803.: Righini M, Jobic C, Boehlen F, Broussaud J, Becker F, Jaffrelot M et al. Predicting deep venous thrombosis in pregnancy: external validation of the LEFT clinical prediction rule. Haematologica. 2013; 98(4):545–8 [PMC free article: PMC3659985] [PubMed: 23065510]
804.: Riordan MN, Horgan R, Arya A. Pharmokinetics of low molecular weight heparins in the postpartum period. Irish Perinatal Society Annual Meetings. 2008; April(10)
805.: Riva N, Bellesini M, Di Minno MN, Mumoli N, Pomero F, Franchini M et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. Thrombosis and Haemostasis. 2014; 112(3):511–21 [PubMed: 24899092]
806.: Rivard C, Nahum R, Slagle E, Duininck M, Isaksson Vogel R, Teoh D. Evaluation of the performance of the ACS NSQIP surgical risk calculator in gynecologic oncology patients undergoing laparotomy. Gynecologic Oncology. 2016; 141(2):281–6 [PMC free article: PMC5179222] [PubMed: 26899020]
807.: Roark CD, Haines S. Pharmacological anticoagulation and mechanical compression versus mechanical compression alone for venous thromboembolism prophylaxis for post-operative neurosurgical patients. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007713. DOI: 10.1002/14651858.CD007713. [CrossRef]
808.: Robertson L, Kesteven P. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010957. DOI: 10.1002/14651858.CD010957. [PMC free article: PMC6463831] [PubMed: 26636644] [CrossRef]
809.: Robertson L, Roche A. Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD010525. DOI: 10.1002/14651858.CD010525.pub2. [PubMed: 24343728] [CrossRef]
810.: Robinson S, Zincuk A, Larsen UL, Ekstrom C, Nybo M, Rasmussen B et al. A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial. Critical Care. 2013; 17(2):R75 [PMC free article: PMC4057520] [PubMed: 23601744]
811.: Robinson S, Zincuk A, Strom T, Larsen TB, Rasmussen B, Toft P. Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Critical Care. 2010; 14(2):R41 [PMC free article: PMC2887151] [PubMed: 20298591]
812.: Rocha AT, Paiva EF, Lichtenstein A, Milani J, Cavalheiro-Filho C, Maffei FH. Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. Vascular Health and Risk Management. 2007; 3(4):533–553 [PMC free article: PMC2291339] [PubMed: 17969384]
813.: Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technology Assessment. 2005; 9(49) [PubMed: 16336844]
814.: Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014; 384(9955):1673–1683 [PubMed: 25066248]
815.: Rodger MA, Phillips P, Kahn SR, James AH, Konkle BA, PROSPER I. Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. Thrombosis and Haemostasis. 2015; 113(1):212–216 [PubMed: 25373438]
816.: Rodger MA, Ramsay T, MacKinnon M, Westphal M, Wells PS, McCormick B et al. Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial. American Journal of Kidney Diseases. 2012; 60(3):427–434 [PubMed: 22480794]
817.: Rokito SE, Schwartz MC, Neuwirth MG. Deep vein thrombosis after major reconstructive spinal surgery. Spine. 1996; 21(7):853–858 [PubMed: 8779018]
818.: Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R, Gomez AP-P, Marti-Mestre X, Bonell-Pascual A et al. Early mobilisation in patients with acute deep vein thrombosis does not increase the risk of a symptomatic pulmonary embolism. International Angiology. 2008; 27(6):494–499 [PubMed: 19078912]
819.: Rondelli F, Manina G, Agnelli G, Becattini C. Venous thromboembolism after laparoscopic cholecystectomy: clinical burden and prevention. Surgical Endoscopy. 2013; 27(6):1860–1864 [PubMed: 23389061]
820.: Rondina MT, Pendleton RC, Chaudhry SS, Freeman AF. Comparison of two weight-based enoxaparin dosing algorithms to prevent venous thromboembolism in morbidly obese medicallyill patients. Journal of Thrombosis and Thrombolysis. 2011; 31(3):391–392
821.: Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. Journal of the American Heart Association. 2014; 3(6):e001152 [PMC free article: PMC4338701] [PubMed: 25404191]
822.: Rosenberg DJ, Ansell J. Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications. Evidence-Based Medicine. 2011; 16(5):139–140 [PubMed: 21460399]
823.: Rosencher N, Albaladejo P. A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk. Expert Opinion on Pharmacotherapy. 2012; 13(2):217–226 [PubMed: 22192174]
824.: Rosengarten DS, Laird J. The effect of leg elevation on the incidence of deep-vein thrombosis after operation. British Journal of Surgery. 1971; 58(3):182–184 [PubMed: 5548159]
825.: Roth P. Prophylaxis of deepvein thrombosis in outpatients undergoingarthroscopic meniscus operationdy. Orthopdische Praxis. 1995; 5(5):3458
826.: Rothberg MB, Pekow PS, Lahti M, Lindenauer PK. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients. Journal of Hospital Medicine. 2012; 7(6):457–463 [PubMed: 22473716]
827.: Royal College of Obstetricians and Gynaecologists. Thrombosis and embolism during pregnancy and the puerperium, reducing the risk. Green-top Guideline No. 37a. London. Royal College of Obstetricians and Gynaecologists, 2015. Available from: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37a/
828.: Royal College of Physicians. National Hip Fracture Database annual report 2016. London. RCP, 2016. Available from: http://web1.crownaudit.org/Report2016/NHFD2016Report.pdf
829.: Ruiz-Gimenez N, Suarez C, Gonzalez R, Nieto JA, Todoli JA, Samperiz AL et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thrombosis and Haemostasis. 2008; 100(1):26–31 [PubMed: 18612534]
830.: Russell RD, Huo MH. Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty. Journal of Arthroplasty. 2013; 28(9):1477–1481 [PubMed: 23540535]
831.: Ruttimann S, Danner M, Glaser MG. Explicit versus implicit risk assessment for the indication of antithrombotic prophylaxis in acutely ill medical in-patients. Swiss Medical Weekly. 2005; 135(15–16):228–34 [PubMed: 15971115]
832.: Ryan MG, Westrich GH, Potter HG, Sharrock N, Maun LM, Macaulay W et al. Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography. Journal of Bone and Joint Surgery. 2002; 84-A(11):1998–2004 [PubMed: 12429761]
833.: Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Bjorholt I. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Review of Pharmacoeconomics and Outcomes Research. 2011; 11(5):601–615 [PubMed: 21958104]
834.: Sachdeva A, Dalton M, Amaragiri SV, Lees T. Graduated compression stockings for prevention of deep vein thrombosis. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No.: CD001484. DOI: 10.1002/14651858.CD001484.pub3. [PubMed: 25517473] [CrossRef]
835.: Saeed CR, Frank JB, Pravin M, Aziz RH, Serasheini M, Dominique TG. A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves. Clinical and Applied Thrombosis/Hemostasis. 2011; 17(4):313–319 [PubMed: 20547550]
836.: Sagar S. Heparin prophylaxis against fatal postoperative pulmonary embolism. British Medical Journal. 1974; 2(5911):153–155 [PMC free article: PMC1610370] [PubMed: 4825114]
837.: Sagar S, Massey J, Sanderson JM. Low-dose heparin prophylaxis against fatal pulmonary embolism. British Medical Journal. 1975; 4(5991):257–259 [PMC free article: PMC1675117] [PubMed: 1104060]
838.: Saigal S, Sharma JP, Joshi R, Singh DK. Thrombo-prophylaxis in acutely ill medical and critically ill patients. Indian Journal of Critical Care Medicine. 2014; 18(6):382–391 [PMC free article: PMC4071683] [PubMed: 24987238]
839.: Sajid MS, Desai M, Morris RW, Hamilton G. Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis in postoperative surgical patients. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD007162. DOI: 10.1002/14651858.CD007162.pub2. [PubMed: 22592717] [CrossRef]
840.: Salcuni PF, Azzarone M, Palazzini E. A new low molecular weight heparin for deep vein thrombosis prevention: effectiveness in postoperative patients. Current Therapeutic Research, Clinical and Experimental. 1988; 43:824–831
841.: Saleh HE, Pennings AL, ElMaraghy AW. Venous thromboembolism after shoulder arthroplasty: a systematic review. Journal of Shoulder and Elbow Surgery. 2013; 22(10):1440–1448 [PubMed: 23973166]
842.: Salmaggi A, Simonetti G, Trevisan E, Beecher D, Carapella CM, DiMeco F et al. Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review. Journal of Neuro-Oncology. 2013; 113(2):293–303 [PubMed: 23543244]
843.: Salvo F. Risk of major bleeding and the standard doses of dabigatran. European Journal of Internal Medicine. 2014; 25(6):e73–e75 [PubMed: 24629895]
844.: Samama CM, Clergue F, Barre J, Montefiore A, Ill P, Samii K. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar study group. British Journal of Anaesthesia. 1997; 78(6):660–665 [PubMed: 9215015]
845.: Samama CM, Vray M, Barré J, Fiessinger JN, Rosencher N, Lecompte T et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Archives of Internal Medicine. 2002; 162(19):2191–2196 [PubMed: 12390061]
846.: Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. British Journal of Surgery. 1988; 75(2):128–131 [PubMed: 2832030]
847.: Samama MM, Dahl OE, Mismetti P, Quinlan DJ, Rosencher N, Cornelis M et al. An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica. 2006; 91(1):64–70 [PubMed: 16434372]
848.: Sandercock Peter AG, Counsell C, Tseng M. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD000119. DOI: 10.1002/14651858.CD000119.pub3. [PubMed: 18646059] [CrossRef]
849.: Sant’Anna RT, Leiria TL, Nascimento T, Sant’Anna JRM, Kalil RAK, Lima GG et al. Meta-analysis of continuous oral anticoagulants versus heparin bridging in patients undergoing CIED surgery: Reappraisal after the BRUISE study. PACE - Pacing and Clinical Electrophysiology. 2015; 38(4):417–423 [PubMed: 25546244]
850.: Santori FS, Vitullo A, Stopponi M, Santori N, Ghera S. Prophylaxis against deep-vein thrombosis in total hip replacement. Comparison of heparin and foot impulse pump. Journal of Bone and Joint Surgery (British Volume). 1994; 76(4):579–583 [PubMed: 8027144]
851.: Santoro R, Iannaccaro P, Prejano S, Muleo G. Efficacy and safety of the long-term administration of low-molecular-weight heparins in pregnancy. Blood Coagulation and Fibrinolysis. 2009; 20(4):240–243 [PubMed: 19357505]
852.: Santos R, Barros VV, Igai AK, Francisco RP, Zugaib M. Maternal death and venous thromboembolism (VTE) in patients admitted in a maternity of high risk: Results pre and post application of a risk score. Journal of Thrombosis and Haemostasis. 2015; 13:679
853.: Saraiya B, Goodin S. Management of venous thromboembolism and the potential to impact overall survival in patients with cancer. Pharmacotherapy. 2009; 29(11):1344–1356 [PubMed: 19857150]
854.: Sarela AI, Dexter SP, McMahon MJ. Use of the obesity surgery mortality risk score to predict complications of laparoscopic bariatric surgery. Obesity Surgery. 2011; 21(11):1698–703 [PubMed: 21399971]
855.: Sarkar RK, Abbas M, Warreth N. A complete audit cycle of the implementation of guidelines on thromboprophylaxis in pregnancy. BJOG: An International Journal of Obstetrics and Gynaecology. 2013; 120:167–168
856.: Sasahara AA, DiSerio FJ, Singer JM. Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis. A multicenter trial. JAMA. 1984; 251(22):2960–2966 [PubMed: 6371278]
857.: Sasahara AA, Koppenhagen K, Häring R, Welzel D, Wolf H. Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis. British Journal of Surgery. 1986; 73(9):697–700 [PubMed: 3530367]
858.: Sasaki S, Miyakoshi N, Matsuura H, Saitoh H, Kudoh D, Shimada Y. Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery. Journal of Orthopaedic Science. 2009; 14(5):491–496 [PubMed: 19802659]
859.: Sasaki SM. Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery. Journal of Orthopaedic Science. 2011; 16(1):64–70 [PubMed: 21293896]
860.: Sautter RD, Koch EL, Myers WO, Ray JR, III, Mazza JJ, Larson DE et al. Aspirin-sulfinpyrazone in prophylaxis of deep venous thrombosis in total hip replacement. JAMA. 1983; 250(19):2649–2654 [PubMed: 6355542]
861.: Scherz N, Mean M, Limacher A, Righini M, Jaeger K, Beer HJ et al. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. Journal of Thrombosis and Haemostasis. 2013; 11(3):435–43 [PubMed: 23279158]
862.: Schiele F. Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies. Vascular Health and Risk Management. 2010; 6:179–187 [PMC free article: PMC2856573] [PubMed: 20407625]
863.: Schmitz-Huebner U, Bunte H, Freise G, Reers B, Ruschemeyer C, Scherer R et al. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klinische Wochenschrift. 1984; 62(8):349–353 [PubMed: 6374278]
864.: Schneider AL, Deig CR, Prasad KG, Nelson BG, Mantravadi AV, Brigance JS et al. Ability of the National Surgical Quality Improvement Program Risk Calculator to Predict Complications Following Total Laryngectomy. JAMA Otolaryngology--Head & Neck Surgery. 2016; 142(10):972–979 [PubMed: 27467967]
865.: Schoenbeck D, Nicolle A, Newbegin K, Hanley J, Loughney AD. The use of a scoring system to guide thromboprophylaxis in a high-risk pregnant population. Thrombosis. 2011; 2011:652796 [PMC free article: PMC3200277] [PubMed: 22084667]
866.: Schouten HJ, Geersing GJ, Oudega R, van Delden JJ, Moons KG, Koek HL. Accuracy of the Wells clinical prediction rule for pulmonary embolism in older ambulatory adults. Journal of the American Geriatrics Society. 2014; 62(11):2136–41 [PubMed: 25366538]
867.: Schreiber U, Hartung B. Postoperative thromboembolieprophylaxe bei patienten mit allgemeinchirurgischen operationen. Zentralblatt für Chirurgie. 1979; 104(18):1214–1220 [PubMed: 543338]
868.: Schulman S. Is the network meta-analysis (NETMA) bringing us closer to the truth? insights from recent antithrombotic drug data. Thrombosis and Haemostasis. 2012; 108(5):872–875 [PubMed: 23052242]
869.: Schulman S, Baanstra D, Eriksson H, Goldhaber S, Kakkar A, Kearon C. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis. 2011; 9:(Suppl 2):22
870.: Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis. 2015; 114(1):150–157 [PubMed: 25739680]
871.: Schweikert B, Pittrow D, Vizza CD, Pepke-Zaba J, Hoeper MM, Gabriel A et al. Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries. BMC Health Services Research. 2014; 14:246 [PMC free article: PMC4069093] [PubMed: 24912804]
872.: Scott A, Argaez C. Knee-high versus thigh-high compression devices: a review of the clinical and cost-effectiveness. Toronto. Canadian Agency for Drugs and Technologies in Health (CADTH), 2008. Available from: https://www.cadth.ca/sites/default/files/pdf/htis/may-2015/RB0861%20Knee%20Length%20Sequential%20Compression%20Devices%20Final.pdf
873.: Scurr JH, Coleridge-Smith PD, Hasty JH. Regimen for improved effectiveness of intermittent pneumatic compression in deep venous thrombosis prophylaxis. Surgery. 1987; 102(5):816–820 [PubMed: 3672322]
874.: Scurr JH, Ibrahim SZ, Faber RG, Le Quesne LP. The efficacy of graduated compression stockings in the prevention of deep vein thrombosis. British Journal of Surgery. 1977; 64(5):371–373 [PubMed: 861482]
875.: Seaman S, Nelson A, Noble S. Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Preference and Adherence. 2014; 8:453–61 [PMC free article: PMC3986276] [PubMed: 24748774]
876.: Sermsathanasawadi N, Suparatchatpun P, Pumpuang T, Hongku K, Chinsakchai K, Wongwanit C et al. Comparison of clinical prediction scores for the diagnosis of deep vein thrombosis in unselected population of outpatients and inpatients. Phlebology. 2015; 30(7):469–74 [PubMed: 24965100]
877.: Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015; 132(3):194–204 [PMC free article: PMC4765082] [PubMed: 25995317]
878.: Shea-Budgell MA, Wu CMJ, Easaw JC. Evidence-based guidance on venous thromboembolism in patients with solid tumours. Current Oncology. 2014; 21(3):e504–e514 [PMC free article: PMC4059814] [PubMed: 24940110]
879.: Sheard L, Prout H, Dowding D, Noble S, Watt I, Maraveyas A et al. The ethical decisions UK doctors make regarding advanced cancer patients at the end of life--the perceived (in) appropriateness of anticoagulation for venous thromboembolism: a qualitative study. BMC Medical Ethics. 2012; 13:22 [PMC free article: PMC3459796] [PubMed: 22947200]
880.: Sheard L, Prout H, Dowding D, Noble S, Watt I, Maraveyas A et al. Barriers to the diagnosis and treatment of venous thromboembolism in advanced cancer patients: A qualitative study. Palliative Medicine. 2013; 27(4):339–348 [PubMed: 23093572]
881.: Shelkrot M, Miraka J, Perez ME. Appropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity. Hospital Pharmacy. 2014; 49(8):740–747 [PMC free article: PMC4252202] [PubMed: 25477599]
882.: Shen JH, Chen HL, Chen JR, Xing JL, Gu P, Zhu BF. Comparison of the Wells score with the revised Geneva score for assessing suspected pulmonary embolism: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis. 2016; 41(3):482–92 [PubMed: 26178041]
883.: Shirai N. Study on prophylaxis of postoperative deep vein thrombosis. Acta Scholae Medicinalis Universitatis in Gifu. 1985; 33(6):1173–1183
884.: Shlebak A, Sandhu P, Ali V, Jones G, Baker C. The impact of the DoH Commissioning for Quality and Innovation incentive on the success of venous thromboembolism risk assessment in hospitalised patients. A single institution experience in a quality outcome improvement over a 4-year cycle. JRSM Open. 2016; 7(6):2054270416632702 [PMC free article: PMC4900198] [PubMed: 27293773]
885.: Shorr AF, Jackson WL, Sherner JH, Moores LK. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis. Chest. 2008; 133(1):149–155 [PubMed: 17925410]
886.: Shosha RI, Ibrahim OM, Setiha ME, Abdelwahab AA. The efficacy and safety of rivaroxaban as an alternative to warfarin for the prevention of thromboembolism in patients with atrial fibrillation. International Journal of Pharmaceutical Sciences Review and Research. 2017; 43(2):38–48
887.: Shukla PJ, Siddachari R, Ahire S, Arya S, Ramani S, Barreto SG et al. Postoperative deep vein thrombosis in patients with colorectal cancer. Indian Journal of Gastroenterology. 2008; 27(2):71–73 [PubMed: 18695308]
888.: Shuman AG, Hu HM, Pannucci CJ, Jackson CR, Bradford CR, Bahl V. Stratifying the risk of venous thromboembolism in otolaryngology. Otolaryngology - Head & Neck Surgery. 2012; 146(5):719–24 [PMC free article: PMC4496153] [PubMed: 22261490]
889.: Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clinic Proceedings. 2006; 81(6):758–67 [PubMed: 16770976]
890.: Silveira PC, Ip IK, Goldhaber SZ, Piazza G, Benson CB, Khorasani R. Performance of Wells score for deep vein thrombosis in the inpatient setting. JAMA Internal Medicine. 2015; 175(7):1112–7 [PubMed: 25985219]
891.: Simard JM, Aldrich EF, Schreibman D, James RF, Polifka A, Beaty N. Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment. Journal of Neurosurgery. 2013; 119(6):1611–1619 [PMC free article: PMC4350232] [PubMed: 24032706]
892.: Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014; 130(13):1062–1071 [PubMed: 25156992]
893.: Simonetti G, Trevisan E, Silvani A, Gaviani P, Botturi A, Lamperti E et al. Safety of bevacizumab in patients with malignant gliomas: a systematic review. Neurological Sciences. 2014; 35(1):83–89 [PubMed: 24281944]
894.: Singh S, Haut ER, Brotman DJ, Sharma R, Chelladurai Y, Shermock KM et al. Pharmacologic and mechanical prophylaxis of venous thrombolism among special populations: Comparative Effectiveness Review 116. Rockville, MD. Agency for Healthcare Research and Quality, 2013. [PubMed: 23844446]
895.: Singh SK, Kallhfallah A. The prevent trial-prevention of venous thromboembolism with enoxaparin vs rivaroxaban following hip and knee replacement surgeries. Internal Medicine Journal. 2012; 42(S2):21
896.: Siragusa S, Vicentini L, Carbone S, Barone M, Beltrametti C, Piovella F. Intermittent pneumatic leg compression (IPLC) and unfractionated heparin (UFH) in the prevention of post-operative deep vein thrombosis in hip surgery. Blood. 1994; 84(10 Suppl 1):70a
897.: Sjalander A, Jansson JH, Bergqvist D, Eriksson H, Carlberg B, Svensson P. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis. Journal of Internal Medicine. 2008; 263(1):52–60 [PubMed: 18088252]
898.: Skeith L, Taylor J, Lazo-Langner A, Kovacs MJ. Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study. Journal of Thrombosis and Haemostasis. 2012; 10(11):2298–2304 [PubMed: 22925003]
899.: Skillman JJ, Collins RE, Coe NP, Goldstein BS, Shapiro RM, Zervas NT et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. Surgery. 1978; 83(3):354–358 [PubMed: 628896]
900.: Slawson D. Optimal treatment of acute venous thromboembolism. American Family Physician. 2015; 91(7):492–494
901.: Smith TO, Daniell H, Hing C. Upper extremity deep vein thrombosis in orthopaedic and trauma surgery: A systematic review. European Journal of Orthopaedic Surgery & Traumatology. 2011; 21(2):79–85
902.: Snook GA, Chrisman OD, Wilson TC. Thromboembolism after surgical treatment of hip fractures. Clinical Orthopaedics and Related Research. 1981; 155:21–24 [PubMed: 7014058]
903.: Snowden S, Silus L. Oral anticoagulation with warfarin for patients with left ventricular systolic dysfunction. Cardiology in Review. 2011; 19(1):36–40 [PubMed: 21135601]
904.: Sobieraj-Teague M, Hirsh J, Yip G, Gastaldo F, Stokes T, Sloane D et al. Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patients. Journal of Thrombosis and Haemostasis. 2012; 10(2):229–235 [PubMed: 22188037]
905.: Sobieraj DM, Coleman CI, Tongbram V, Chen W, Colby J, Lee S et al. Comparative effectiveness of combined pharmacologic and mechanical thromboprophylaxis versus either method alone in major orthopedic surgery: a systematic review and meta-analysis. Pharmacotherapy. 2013; 33(3):275–283 [PubMed: 23401017]
906.: Sobieraj DM, Coleman CI, Tongbram V, Lee S, Colby J, Chen WT et al. Venous thromboembolism prophylaxis in orthopedic surgery. AHRQ Comparative Effectiveness Reviews 49. Rockville (MD). Agency for Healthcare Research and Quality (US), 2012. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0041828/ [PubMed: 22536611]
907.: Sobieraj DM, Lee S, Coleman CI, Tongbram V, Chen W, Colby J et al. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review. Annals of Internal Medicine. 2012; 156(10):720–727 [PubMed: 22412039]
908.: Soomro Q, Yousuf N, Bhutto AA, Abro HA, Memon AA. Venous thromboembolism (VTE): risk assessment in hospitalized patients. Journal of the College of Physicians & Surgeons - Pakistan. 2014; 24(7):455–8 [PubMed: 25052964]
909.: Soreff J, Johnsson H, Diener L, Goransson L. Acetylsalicylic acid in a trial to diminish thromboembolic complications after elective hip surgery. Acta Orthopaedica Scandinavica. 1975; 46(2):246–255 [PubMed: 1096521]
910.: Sourmelis S, Patoulis G, Tzortzis G. Prevention of deep vein thrombosis with low molecular weight heparin in fractures of the hip. Journal of Bone and Joint Surgery (British Volume). 1995; 77:(Suppl 2):173
911.: Specialised Commissioning Team NHS, England. A11/P/c Targeted Therapies for use in Pulmonary Hypertension in Adults. 2015.
912.: Spencer A, Cawood T, Frampton C, Jardine D. Heparin-based treatment to prevent symptomatic deep venous thrombosis, pulmonary embolism or death in general medical inpatients is not supported by best evidence. Internal Medicine Journal. 2014; 44(11):1054–1065 [PubMed: 25367724]
913.: Spyropoulos AC, Anderson FA, Jr., Fitzgerald G, Decousus H, Pini M, Chong BH et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011; 140(3):706–14 [PubMed: 21436241]
914.: Spyropoulos AC, McGinn T, Khorana AA. The use of weighted and scored risk assessment models for venous thromboembolism. Thrombosis and Haemostasis. 2012; 108(6):1072–6 [PubMed: 23138506]
915.: Stannard JP, Harris RM, Bucknell AL, Cossi A, Ward J, Arrington ED. Prophylaxis of deep venous thrombosis after total hip arthroplasty by using intermittent compression of the plantar venous plexus. American Journal of Orthopedics. 1996; 25(2):127–134 [PubMed: 8640382]
916.: Stannard JP, Riley RS, McClenney MD, Lopez-Ben RR, Volgas DA, Alonso JE. Mechanical prophylaxis against deep-vein thrombosis after pelvic and acetabular fractures. Journal of Bone and Joint Surgery. 2001; 83-A(7):1047–1051 [PubMed: 11451974]
917.: Stashenko GJ, Hargett CW, Tapson VF. Thrombolytic therapy for venous thromboembolism: Current clinical practice. Journal of Hospital Medicine. 2009; 4(5):313–316 [PubMed: 19266475]
918.: Stephenson ML, Serra AE, Neeper JM, Caballero DC, McNulty J. A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. Journal of Perinatology. 2016; 36(2):95–9 [PubMed: 26658126]
919.: Sterne J, Bodalia P, Bryden P, Davies P, Lopez-Lopez A, Okoli GN. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis [unpublished]. 2016. [PMC free article: PMC5366855] [PubMed: 28279251]
920.: Stevens SM, Douketis JD. Deep vein thrombosis prophylaxis in hospitalized medical patients: current recommendations, general rates of implementation, and initiatives for improvement. Clinics in Chest Medicine. 2010; 31(4):675–689 [PubMed: 21047575]
921.: Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technology Assessment. 2009; 13:(Suppl 3):43–48 [PubMed: 19846028]
922.: Stewart DW, Freshour JE. Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence. Annals of Pharmacotherapy. 2013; 47(1):63–74 [PubMed: 23324504]
923.: Stone MH, Limb D, Campbell P, Stead D, Culleton G. A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study. International Orthopaedics. 1996; 20(6):367–369 [PubMed: 9049766]
924.: Stranks GJ, MacKenzie NA, Grover ML, Fail T. The A-V Impulse System reduces deep-vein thrombosis and swelling after hemiarthroplasty for hip fracture. Journal of Bone and Joint Surgery (British Volume). 1992; 74(5):775–778 [PubMed: 1527133]
925.: Stroud W, Whitworth JM, Miklic M, Schneider KE, Finan MA, Scalici J et al. Validation of a venous thromboembolism risk assessment model in gynecologic oncology. Gynecologic Oncology. 2014; 134(1):160–3 [PubMed: 24796634]
926.: Stuck AK, Spirk D, Schaudt J, Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review. Thrombosis and Haemostasis. 2017; 02:02 [PubMed: 28150851]
927.: Sullivan P, Fraessdorf M, Feuring M, Schulman S, Hass B. Health-related quality of life after venous thromboembolism. Value in Health. 2011; 14(7):A384
928.: Sultan MJ, Zheng TT, Kurdy N, McCollum CN. Role of engineered compression stockings in preventing deep vein thrombosis following ankle fractures. Phlebology. 2011; 26(3):267
929.: Summers JA, Clinch J, Radhakrishnan M, Healy A, McMillan V, Morris E et al. The gekoTM electro-stimulation device for venous thromboembolism prophylaxis: a NICE medical technology guidance. Applied Health Economics and Health Policy. 2015; 13(2):135–147 [PMC free article: PMC4376951] [PubMed: 25403719]
930.: Sun Y, Chen D, Xu Z, Shi D, Dai J, Qin J et al. Deep venous thrombosis after knee arthroscopy: a systematic review and meta-analysis. Arthroscopy. 2014; 30(3):406–412 [PubMed: 24581264]
931.: Tamizifar B, Fereyduni F, Esfahani MA, Kheyri S. Comparing three clinical prediction rules for primarily predicting the 30-day mortality of patients with pulmonary embolism: The “Simplified Revised Geneva Score,” the “Original PESI,” and the “Simplified PESI”. Advanced Biomedical Research. 2016; 5:137 [PMC free article: PMC5025907] [PubMed: 27656606]
932.: Tardy B, Lafond P, Viallon A, Buchmuller A, Zeni F, Decousus H. Older people included in a venous thrombo-embolism clinical trial: A patients’ viewpoint. Age and Ageing. 2003; 32(2):149–153 [PubMed: 12615557]
933.: Ten Cate-Hoek AJ, Ten Cate H, Tordoir J, Hamulyak K, Prins MH. Individually tailored duration of elastic compression therapy in relation to incidence of the postthrombotic syndrome. Journal of Vascular Surgery. 2010; 52(1):132–138 [PubMed: 20385462]
934.: Testa S, Passamonti SM, Paoletti O, Zimmermann A, Bucciarelli P, Ronca E et al. The pregnancy health-care program: A model for the prevention of venous thromboembolism in pregnancy. Journal of Thrombosis and Haemostasis. 2013; 11:606
935.: Testroote M, Stigter WAH, Janssen L, Janzing HMJ. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD006681. DOI: 10.1002/14651858.CD006681.pub3. [PubMed: 24771319] [CrossRef]
936.: Tetri S, Hakala J, Juvela S, Saloheimo P, Pyhtinen J, Rusanen H et al. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage. Thrombosis Research. 2008; 123(2):206–212 [PubMed: 18420258]
937.: The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. Archives of Orthopaedic and Trauma Surgery. 1992; 111(2):110–120 [PubMed: 1314065]
938.: Thourani VH, Gunter RL, Hurst S, Kilgo P, Padala M, Puskas JD et al. Postoperative warfarin following mitral valve repair or bioprosthetic valve replacement. Journal of Heart Valve Disease. 2013; 22(5):716–723 [PubMed: 24383387]
939.: Tomita M, Motokawa S. Intraoperative heparin injection reduced D-dimer and TAT levels after total hip arthroplasty. Acta Medica Nagasakiensia. 2008; 53(1):9–13
940.: Tomkowski W, Kuca P, Andziak P, Dziki A, Nizankowski R, Staszkiewicz W et al. A scoring system for thromboembolic risk assessment in patients hospitalised on non-surgical wards developed by the Polish Working Group. Acta Angiologica. 2011; 17(1):77–88
941.: Tørholm C, Broeng L, Jørgensen PS, Bjerregaard P, Josephsen L, Jørgensen PK et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. Journal of Bone and Joint Surgery (British Volume). 1991; 73(3):434–438 [PubMed: 1670445]
942.: Torngren S. Low dose heparin and compression stockings in the prevention of postoperative deep venous thrombosis. British Journal of Surgery. 1980; 67(7):482–484 [PubMed: 6998538]
943.: Traby L, Kaider A, Schmid R, Kranz A, Quehenberger P, Kyrle PA et al. The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial. Thrombosis and Haemostasis. 2010; 104(1):92–99 [PubMed: 20458441]
944.: Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croatian Medical Journal. 2010; 51(2):113–123 [PMC free article: PMC2867548] [PubMed: 20401953]
945.: Tsutsumi S, Yajima R, Tabe Y, Takaaki T, Fujii F, Morita H et al. The efficacy of fondaparinux for the prophylaxis of venous thromboembolism after resection for colorectal cancer. Hepato-Gastroenterology. 2012; 59(120):2477–2479 [PubMed: 23169180]
946.: Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JPT. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Statistics in Medicine. 2015; 34(6):984–998 [PMC free article: PMC4383649] [PubMed: 25475839]
947.: Turpie AG, Delmore T, Hirsh J, Hull R, Genton E, Hiscoe C et al. Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. Thrombosis Research. 1979; 15(5–6):611–616 [PubMed: 494166]
948.: Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P et al. BAY 59–7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. Journal of Thrombosis and Haemostasis. 2005; 3(11):2479–86 [PubMed: 16241946]
949.: Turpie AG, Gallus A, Beattie WS, Hirsh J. Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology. 1977; 27(5):435–438 [PubMed: 558547]
950.: Turpie AG, Haas S, Kreutz R, Mantovani LG, Pattanayak CW, Holberg G et al. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thrombosis and Haemostasis. 2014; 111(1):94–102 [PubMed: 24154549]
951.: Turpie AG, Hirsh J, Gent M, Julian D, Johnson J. Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Archives of Internal Medicine. 1989; 149(3):679–681 [PubMed: 2645846]
952.: Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. New England Journal of Medicine. 1986; 315(15):925–929 [PubMed: 3531851]
953.: Turpie AG, Schmidt AC, Kreutz R, Lassen MR, Jamal W, Mantovani L et al. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vascular Health & Risk Management. 2012; 8:363–70 [PMC free article: PMC3373318] [PubMed: 22701330]
954.: Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002; 359(9319):1721–1726 [PubMed: 12049860]
955.: Turpie AGG, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM et al. Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study. Stroke. 2013; 44(1):249–251 [PubMed: 23117723]
956.: Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373(9676):1673–1680 [PubMed: 19411100]
957.: U.M.I.N. Randomized study of anti-coagulant therapy to prevent postoperative deep venous thrombosis/pulmonary embolism. UMIN000002444. 2009. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000002991&language=E Last accessed: 28/06/17.
958.: U.M.I.N. Phase III study of efficacy of fondaparinux on the prevention of post-operative venous thromboembolism in patients undergoing with laparoscopic colorectal cancer surgery. UMIN000008435. 2012. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000009923&language=E Last accessed: 28/06/17.
959.: U.M.I.N. The efficacy and safety of anticoagulant therapy Arixtra Injection for the prevention of the vein thromboembolism in laparoscopic colorectal surgery. UMIN000007005. 2013. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000008265&language=E Last accessed: 28/06/17.
960.: Uchino K. Review: Dabigatran increases MI and reduces mortality compared with warfarin, enoxaparin, or placebo. Annals of Internal Medicine. 2012; 156(12):JC6–JC11 [PubMed: 22711112]
961.: Valle I, Sola G, Origone A. Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep venous thrombosis. Current Medical Research and Opinion. 1988; 11(2):80–86 [PubMed: 2851413]
962.: Van der Pol LM, Mairuhu AT, Tromeur C, Couturaud F, Huisman MV, Klok FA. Use of clinical prediction rules and D-dimer tests in the diagnostic management of pregnant patients with suspected acute pulmonary embolism. Blood Reviews. 2016; 29:29 [PubMed: 27720446]
963.: van der Veen L, van Raay JJ, Gerritsma-Bleeker CLE, Veeger NJ, van Hulst M. Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA). BMJ Open. 2013; 3(1) [PMC free article: PMC3563127] [PubMed: 23355673]
964.: van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. Journal of Clinical Oncology. 2011; 29(15):2071–2076 [PubMed: 21502549]
965.: Van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: Evidence from phase 3 trials. Blood. 2014; 124(12):1968–1975 [PubMed: 24963045]
966.: van Es N, Kraaijpoel N, Klok FA, Huisman MV, Den Exter PL, Mos IC et al. The original and simplified Wells rules and age-adjusted D-dimer testing to rule out pulmonary embolism: an individual patient data meta-analysis. Journal of Thrombosis and Haemostasis. 2017; 20:20 [PubMed: 28106338]
967.: van Geloven F, Wittebol P, Sixma JJ. Comparison of postoperative coumarin, dextran 40 and subcutaneous heparin in the prevention of postoperative deep vein thrombosis. Acta Medica Scandinavica. 1977; 202(5):367–372 [PubMed: 335793]
968.: Vanassche T, Vandenbriele C, Peerlinck K, Verhamme P. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. Expert Opinion on Pharmacotherapy. 2015; 16(5):645–658 [PubMed: 25554350]
969.: Vardi M, Steinberg M, Haran M, Cohen S. Benefits versus risks of pharmacological prophylaxis to prevent symptomatic venous thromboembolism in unselected medical patients revisited. Meta-analysis of the medical literature. Journal of Thrombosis and Thrombolysis. 2012; 34(1):11–19 [PubMed: 22528330]
970.: Vazquez-Acosta JA, Ramirez-Gutierrez AE, Cerecedo-Rosendo MA, Olivera-Barrera FM, Tenorio-Sanchez SS, Nieto-Villarreal J et al. Characterization of thromboembolic risk in a Mexican population with non-valvular atrial fibrillation (AF) and its effect on the indication of anticoagulation (MAYA study). Gaceta Medica de México. 2016; 152(4):473–478 [PubMed: 27595250]
971.: Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Annals of Surgery. 2014; 259(4):665–669 [PubMed: 24253138]
972.: Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015; 147(2):475–483 [PubMed: 25211264]
973.: Velmahos GC, Petrone P, Chan LS, Hanks SE, Brown CV, Demetriades D. Electrostimulation for the prevention of deep venous thrombosis in patients with major trauma: a prospective randomized study. Surgery. 2005; 137(5):493–8 [PubMed: 15855919]
974.: Venous Thrombosis Clinical Study Group. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet. 1975; 306(7924):45–51 [PubMed: 49649]
975.: Verardi S, Cortese F, Baroni B, Boffo V, Casciani CU. (Role of low molecular weight heparin in the prevention of postoperative deep venous thrombosis. Our experience in 88 cases. Giornale di Chirurgia. 1989; 10(11):674–678 [PubMed: 2562010]
976.: Verdecchia P, Angeli F, Lip GYH, Reboldi G. Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. PloS One. 2014; 9(6) [PMC free article: PMC4067355] [PubMed: 24955573]
977.: Verdecchia P, Molini G, Bartolini C, De F, V, Valecchi F, Martone S et al. Safety of dabigatran in an elderly population: Single center experience in Italy. Current Drug Safety. 2015; 10(2):165–169 [PubMed: 25387822]
978.: Verso M, Gussoni G, Agnelli G. Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. Journal of Thrombosis and Haemostasis. 2010; 8(7):1649–1651 [PubMed: 20456756]
979.: Villa LA, Malone DC, Ross D. Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis. International Journal of Hematology. 2013; 98(4):390–397 [PubMed: 24057162]
980.: Voigt J, Hamelmann H, Hedderich J, Seifert J, Buchhammer T, Kohler A. Effectiveness and side effects of low-molecular weight heparin-dihydroergotamine in preventing thromboembolism in abdominal surgery. Zentralblatt für Chirurgie. 1986; 111(21):1269–1305 [PubMed: 3544605]
981.: Vollans S, Chaturvedi A, Sivasankaran K, Madhu T, Hadland Y, Allgar V et al. Symptomatic venous thromboembolism following circular frame treatment for tibial fractures. Injury. 2015; 46(6):1108–1111 [PubMed: 25910819]
982.: Wade R. Graduated compression stockings for prevention of deep vein thrombosis in postoperative surgical patients. HTA - 13/72/01. 2014. Available from: http://www.nets.nihr.ac.uk/projects/hta/137201 Last accessed: 28/06/17.
983.: Wade R, Paton F, Rice S, Stansby G, Millner P, Flavell H et al. Thigh length versus knee length antiembolism stockings for the prevention of deep vein thrombosis in postoperative surgical patients; a systematic review and network meta-analysis. BMJ Open. 2016; 6:009456 [PMC free article: PMC4762135] [PubMed: 26883236]
984.: Wade R, Paton F, Woolacott N. Systematic review of patient preference and adherence to the correct use of graduated compression stockings to prevent deep vein thrombosis in surgical patients. Journal of Advanced Nursing. 2017; 73(2):336–348 [PubMed: 27624587]
985.: Wade R, Sideris E, Paton F, Rice S, Palmer S, Fox D et al. Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. Health Technology Assessment. 2015; 19(98):1–220 [PMC free article: PMC4781245] [PubMed: 26613365]
986.: Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, Eddings W, Gagne JJ. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016; 353:i2607 [PMC free article: PMC4878389] [PubMed: 27221664]
987.: Wang Y, Ivany JN, Perkovic V, Gallagher MP, Woodward M, Jardine MJ. Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. Cochrane Database Syst Rev 2016, Issue 4. Art. No.: CD009631. DOI: 10.1002/14651858.CD009631.pub2. [PMC free article: PMC7097886] [PubMed: 27039404] [CrossRef]
988.: Wang Z, Anderson FA, Jr., Ward M, Bhattacharyya T. Surgical site infections and other postoperative complications following prophylactic anticoagulation in total joint arthroplasty. PloS One. 2014; 9(4):e91755 [PMC free article: PMC3981661] [PubMed: 24717837]
989.: Ward B, Pradhan S. Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery. Australian and New Zealand Journal of Obstetrics and Gynaecology. 1998; 38(1):91–92 [PubMed: 9521401]
990.: Ward DR, Moist LM, MacRae JM, Scott-Douglas N, Zhang J, Tonelli M et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. Can J Kidney Health Dis. 2014; 1:15 [PMC free article: PMC4424538] [PubMed: 25960883]
991.: Warlow C, Beattie AG, Terry G, Ogston D, Kenmure ACF, Douglas AS. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet. 1973; 302(7835):934–936 [PubMed: 4126560]
992.: Warwick D, Bannister GC, Glew D, Mitchelmore A, Thornton M, Peters TJ et al. Perioperative low-molecular-weight heparin. Is it effective and safe. Journal of Bone and Joint Surgery (British Volume). 1995; 77(5):715–719 [PubMed: 7559695]
993.: Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, Fitzgerald G et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the global orthopaedic registry. Journal of Bone and Joint SurgeryBritish Volume. 2007; 89B(6):799–807 [PubMed: 17613508]
994.: Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. Journal of Bone and Joint Surgery (American Volume). 1998; 80(8):1158–1166 [PubMed: 9730125]
995.: Warwick D, Harrison J, Whitehouse S, Mitchelmore A, Thornton M. A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. Journal of Bone and Joint Surgery (British Volume). 2002; 84(3):344–350 [PubMed: 12002490]
996.: Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. Journal of Bone and Joint SurgeryBritish Volume. 1995; 77(1):6–10 [PubMed: 7822397]
997.: Wasserlauf G, Grandi SM, Filion KB, Eisenberg MJ. Meta-analysis of rivaroxaban and bleeding risk. American Journal of Cardiology. 2013; 112(3):454–460 [PubMed: 23642380]
998.: Watson U, Hickey BA, Jones HM, Perera A. A critical evaluation of venous thromboembolism risk assessment models used in patients with lower limb cast immobilisation. Journal of Foot and Ankle Surgery. 2016; 22(3):191–5 [PubMed: 27502229]
999.: Weber C, Merminod T, Herrmann FR, Zulian GB. Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Supportive Care in Cancer. 2008; 16(7):847–852 [PubMed: 17940809]
1000.: Weill-Engerer S, Meaume S, Lahlou A, Piette F, Saint-Jean O, Sachet A et al. Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. Journal of the American Geriatrics Society. 2004; 52(8):1299–304 [PubMed: 15271117]
1001.: Weiss V, Jekiel M, Ritschard J, Bouvier CA. Prevention de la maladie thrombo-embolique post-operatoire par les anti-agregeants en chirurgie gynecologique. Médecine et Hygiène. 1977; 35:943–944
1002.: Weitz J, Michelsen J, Gold K, Owen J, Carpenter D. Effects of intermittent pneumatic calf compression on postoperative thrombin and plasmin activity. Thrombosis and Haemostasis. 1986; 56(2):198–201 [PubMed: 2949390]
1003.: Welin-Berger T, Bygdeman S, Mebius C. Deep vein thrombosis following hip surgery. Relation to activated factor X inhibitor activity: effect of heparin and dextran. Acta Orthopaedica Scandinavica. 1982; 53(6):937–945 [PubMed: 6184938]
1004.: Wells PS, Forgie MA, Simms M, Greene A, Touchie D, Lewis G et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Archives of Internal Medicine. 2003; 163(8):917–20 [PubMed: 12719200]
1005.: Welti H. Thrombo-embolytic prophylaxis using physiotherapy with and without low doses of heparin in gynecology and obstetrics. Results of a controlled and randomized mult-cancer study. Revue Médicale de la Suisse Romande. 1981; 101(11):925–934 [PubMed: 7034116]
1006.: Westrich GH, Bottner F, Windsor RE, Laskin RS, Haas SB, Sculco TP. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. Journal of Arthroplasty. 2006; 21(6 Suppl 2):139–143 [PubMed: 16950076]
1007.: Wilbur K, Lynd LD, Sadatsafavi M. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis. Clinical and Applied Thrombosis/Hemostasis. 2011; 17(5):454–465 [PubMed: 20699258]
1008.: Wild D, Murray M, Donatti C. Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. Expert Review of Pharmacoeconomics & Outcomes Research. 2009; 9(5):467–74 [PubMed: 19817530]
1009.: Wilkieson TJ, Ingram AJ, Crowther MA, Soroka SD, Nagai R, Jindal KK et al. Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology. 2011; 6(5):1018–24 [PMC free article: PMC3087766] [PubMed: 21493739]
1010.: Wille-Jorgensen P, Jorgensen LN, Crawford M. Asymptomatic postoperative deep vein thrombosis and the development of postthrombotic syndrome. A systematic review and meta-analysis. Thrombosis and Haemostasis. 2005; 93(2):236–241 [PubMed: 15711738]
1011.: Willett KC, Alsharhan M, Durand C, Cooper MR. Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients. Annals of Pharmacotherapy. 2013; 47(12):1717–1720 [PubMed: 24301685]
1012.: Williams JT, Palfrey SM. Cost effectiveness and efficacy of below knee against above knee graduated compression stockings in the prevention of deep vein thrombosis. Phlebologie. 1988; 41(4):809–811 [PubMed: 3150063]
1013.: Williams JW, Eikman EA, Greenberg SH, Hewitt JC, Lopez-Cuenca E, Jones GP et al. Failure of low dose heparin to prevent pulmonary embolism after hip surgery or above the knee amputation. Annals of Surgery. 1978; 188(4):468–474 [PMC free article: PMC1396839] [PubMed: 697431]
1014.: Wilson NV, Das SK, Kakkar VV, Maurice HD, Smibert JG, Thomas EM et al. Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V impulse system. Journal of Bone and Joint Surgery (British Volume). 1992; 74(1):50–52 [PubMed: 1732265]
1015.: Windisch C, Kolb W, Kolb K, Grutzner P, Venbrocks R, Anders J. Pneumatic compression with foot pumps facilitates early postoperative mobilisation in total knee arthroplasty. International Orthopaedics. 2011; 35(7):995–1000 [PMC free article: PMC3167399] [PubMed: 20652250]
1016.: Woller SC, Stevens SM, Jones JP, Lloyd JF, Evans RS, Aston VT et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. American Journal of Medicine. 2011; 124(10):947–954.e2 [PubMed: 21962315]
1017.: Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clinical Therapeutics. 2009; 31(1):194–212 [PubMed: 19243718]
1018.: Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thrombosis and Haemostasis. 2010; 103(2):360–371 [PubMed: 20024501]
1019.: Wong A, Kraus PS, Lau BD, Streiff MB, Haut ER, Hobson DB et al. Patient preferences regarding pharmacologic venous thromboembolism prophylaxis. Journal of Hospital Medicine. 2015; 10(2):108–11 [PubMed: 25418208]
1020.: Wong A, Streiff MB, Haut ER, Kraus PS, Lau BD, Brown VT et al. Patient perspectives on pharmacological venous thromboembolism prophylaxis at the Johns Hopkins Hospital. Journal of Thrombosis and Thrombolysis. 2013; 35 (3):416
1021.: Wood EH, Prentice CR, McGrouther DA, Sinclair J, McNicol GP. Trial of aspirin and RA233 in prevention of post-operative deep vein thrombosis. Thrombosis et Diathesis Haemorrhagica. 1973; 30(1):18–24 [PubMed: 4788747]
1022.: Woolson ST, Watt JM. Intermittent pneumatic compression to prevent proximal deep venous thrombosis during and after total hip replacement. A prospective, randomized study of compression alone, compression and aspirin, and compression and low-dose warfarin. Journal of Bone and Joint Surgery (American Volume). 1991; 73(4):507–512 [PubMed: 2013589]
1023.: Wu C, Alotaibi GS, Alsaleh K, Linkins LA, McMurtry MS. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention. Thrombosis Research. 2015; 135(2):243–248 [PubMed: 25488466]
1024.: Wu TK, Tsapogas MJ, Jordan FR. Prophylaxis of deep venous thrombosis by hydroxychloroquine sulfate and heparin. Surgery, Gynecology and Obstetrics. 1977; 145(5):714–718 [PubMed: 333643]
1025.: Xing Y, Ma Q, Ma X, Wang C, Zhang D, Sun Y. CHADS<inf>2</inf> score has a better predictive value than CHA<inf>2</inf>DS<inf>2</inf>-VASc score in elderly patients with atrial fibrillation. Clinical Interventions in Aging. 2016; 11:941–946 [PMC free article: PMC4951063] [PubMed: 27478371]
1026.: Yanar H, Kurtoglu M, Taviloglu K, Guloglu R, Ertekin C. Is intermittent pneumatic compression make low molecular weight heparin more efficent in the prophylaxis of venous thromboembolism in trauma patients. European Journal of Trauma and Emergency Surgery. 2007; 33(3 Suppl 2):79–80
1027.: Yarlagadda BB, Brook CD, Stein DJ, Jalisi S. Venous thromboembolism in otolaryngology surgical inpatients receiving chemoprophylaxis. Head and Neck. 2014; 36(8):1087–93 [PubMed: 23804491]
1028.: Yeo DXW, Junnarkar S, Balasubramaniam S, Tan YP, Low JK, Woon W et al. Incidence of venous thromboembolism and its pharmacological prophylaxis in Asian general surgery patients: a systematic review. World Journal of Surgery. 2015; 39(1):150–157 [PubMed: 25189450]
1029.: Yoo HH, Queluz TH, El Dib R. Anticoagulant treatment for subsegmental pulmonary embolism. Cochrane Database Syst Rev 2016, Issue 1. Art. No.: CD010222. DOI: 10.1002/14651858.CD010222.pub3. [PubMed: 26756331] [CrossRef]
1030.: Yoo MC, Kang CS, Kim YH, Kim SK. A prospective randomized study on the use of nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement. International Orthopaedics. 1997; 21(6):399–402 [PMC free article: PMC3619564] [PubMed: 9498151]
1031.: Yoshida RdA, Yoshida WB, Maffei FHdA, El Dib R, Nunes R, Rollo HA. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin. Annals of Vascular Surgery. 2013; 27(3):355–369 [PubMed: 23351997]
1032.: Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet. 2009; 373(9663):567–574 [PubMed: 19217991]
1033.: Young MD, Daniels AH, Evangelista PT, Reinert SE, Ritterman S, Christino MA et al. Predicting pulmonary embolus in orthopedic trauma patients using the Wells score. Orthopedics. 2013; 36(5):e642–7 [PubMed: 23672919]
1034.: Yusen RD, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM et al. Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial. Thrombosis and Haemostasis. 2013; 110(6):1152–63 [PubMed: 24085227]
1035.: Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans administration study No. 75. JAMA : the journal of the American Medical Association. 1981; 245(8):831–835 [PubMed: 6257941]
1036.: Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 1984; 53(10):2046–2052 [PubMed: 6322957]
1037.: Zaghiyan KN, Sax HC, Miraflor E, Cossman D, Wagner W, Mirocha J et al. Timing of Chemical Thromboprophylaxis and Deep Vein Thrombosis in Major Colorectal Surgery: A Randomized Clinical Trial. Annals of Surgery. 2016; 264(4):632–9 [PubMed: 27455158]
1038.: Zakai NA, Callas PW, Repp AB, Cushman M. Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. Journal of Thrombosis and Haemostasis. 2013; 11(4):634–41 [PubMed: 23336744]
1039.: Zanasi R, Fioretta G, Ciocia G, Bergonzi M. Prevention of deep venous thrombosis in orthopedic surgery: effects of defibrotide. Clinical Therapeutics. 1988; 10(4):350–357 [PubMed: 3079005]
1040.: Zareba P, Wu C, Agzarian J, Rodriguez D, Kearon C. Meta-analysis of randomized trials comparing combined compression and anticoagulation with either modality alone for prevention of venous thromboembolism after surgery. British Journal of Surgery. 2014; 101(9):1053–1062 [PubMed: 24916118]
1041.: Zekert F, Schemper M, Neumann K. Acetylsalicylic acid in combination with dihydroergotamine for preventing thromboembolism. Haemostasis. 1982; 11(3):149–153 [PubMed: 7095604]
1042.: Zhang C, Zeng W, Zhou H, Zheng BX, Cheng JC, Li XY et al. [The efficacy of intermittent pneumatic compression in the prevention of venous thromboembolism in medical critically ill patients]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue Chinese Critical Care Medicine. 2011; 23(9):563–5 [PubMed: 21944180]
1043.: Zhao JM, He ML, Xiao ZM, Li TS, Wu H, Jiang H. Different types of intermittent pneumatic compression devices for preventing venous thromboembolism in patients after total hip replacement. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No.: CD009543. DOI: 10.1002/14651858.CD009543.pub3. [PMC free article: PMC7100582] [PubMed: 25528992] [CrossRef]
1044.: Zheng X, Li DY, Wangyang Y, Zhang XC, Guo KJ, Zhao FC et al. Effect of Chemical Thromboprophylaxis on the Rate of Venous Thromboembolism After Treatment of Foot and Ankle Fractures. Foot and Ankle International. 2016; 37(11):1218–1224 [PubMed: 27521353]
1045.: Zhou H, Wang L, Wu X, Tang Y, Yang J, Wang B et al. Validation of a venous thromboembolism risk assessment model in hospitalized Chinese patients: a case-control study. Journal of Atherosclerosis & Thrombosis. 2014; 21(3):261–72 [PubMed: 24304962]
1046.: Zhou HX, Peng LQ, Yan Y, Yi Q, Tang YJ, Shen YC et al. Validation of the Caprini risk assessment model in Chinese hospitalized patients with venous thromboembolism. Thrombosis Research. 2012; 130(5):735–40 [PubMed: 22909830]
1047.: Zhou X, Varadhachary GR, Milind J, Fogelman D, Shroff R, Bueso-Ramos CE et al. Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE. Blood. 2013; 122:580–580
1048.: Zhu W, Fu L, Ding Y, Huang L, Xu Z, Hu J et al. Meta-analysis of ATRIA versus CHA<inf>2</inf>DS<inf>2</inf>-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. International Journal of Cardiology. 2017; 227:436–442 [PubMed: 27839802]
1049.: Ziemski JM, Kostrzewska E, Marchlewski S, Wieczorek K, Rudowski W, Michalski R et al. Efficacy of small doses of heparin given during 2 to 6 days in the prevention of postoperative deep vein thrombosis. Polski Tygodnik Lekarski. 1979; 34(5):161–164 [PubMed: 432128]
1050.: Zilio M, Mazzai L, Sartori MT, Barbot M, Ceccato F, Daidone V et al. A venous thromboembolism risk assessment model for patients with Cushing’s syndrome. Endocrine. 2016; 52(2):322–32 [PubMed: 26113424]
1051.: Zindel S, Stock S, Muller D, Stollenwerk B. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Services Research. 2012; 12:192(2) [PMC free article: PMC3551680] [PubMed: 22776616]
1052.: Zou Y, Tian S, Wang Y, Sun K. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coagulation and Fibrinolysis. 2014; 25(7):660–664 [PubMed: 24695091]
1053.: Zufferey P, Laporte S, Quenet S, Molliex S, Auboyer C, Decousus H et al. Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials. Thrombosis and Haemostasis. 2003; 90(4):654–661 [PubMed: 14515186]
1054.: Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). British Journal of Haematology. 2013; 160(4):530–7 [PMC free article: PMC3609903] [PubMed: 23240761]

Bookshelf ID: NBK561743

Contents

< PrevNext >

PubReader
Print View
Cite this Page
National Guideline Centre (UK). Venous thromboembolism in over 16s: Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. London: National Institute for Health and Care Excellence (NICE); 2018 Mar. (NICE Guideline, No. 89.) Appendix W, References.
PDF version of this page (816K)

References - Venous thromboembolism in over 16s
References - Venous thromboembolism in over 16s

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Venous thromboembolism in over 16s: Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism.

Appendix WReferences

Views

Other titles in this collection

Related NICE guidance and evidence

Recent Activity